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Abstract 
The research investigated: (i) potential missed opportunities for primary prevention of 
stroke and transient ischaemic attack (TIA) with pharmacotherapy through a retrospective 
case series analysis and (ii) fatigue, psychological and cognitive impairment following TIA 
through a systematic review and retrospective cohort study. The case series and cohort 
studies used electronic primary care medical records from The Health Improvement Network 
(THIN).  
The case series analysis found preventative drugs were under prescribed to people with 
clinical indications for these drugs prior to stroke or TIA. There were potential missed 
opportunities for prevention in 49% (7,836/16,028) of people with stroke or TIA who were 
eligible for lipid lowering drugs, 52% (1,647/3,194) for anticoagulant drugs and 25% 
(1,740/7,008) for antihypertensive drugs. Improving prescription of these drugs has the 
potential to reduce the incidence and subsequent burden of stroke and TIA. 
The systematic review revealed there were few high quality studies investigating residual 
impairments in people with TIA and minor stroke; however, there was limited evidence to 
suggest a relatively high prevalence of cognitive impairment and depression post-TIA and 
minor stroke. The retrospective cohort study found that TIA patients were significantly more 
likely to consult in primary care for fatigue, psychological and cognitive impairment 
compared to matched controls. This association remained when adjusted for the potential 
confounding variables and the presence of the impairment prior to TIA. These findings 
suggest that impairments exist after initial symptoms of TIA have resolved and challenge the 
 
 
‘transient’ characterisation of TIA. Residual impairments should be considered by primary 
care clinicians when treating patients following TIA. 
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Background 
The research within this thesis focuses on stroke and transient ischaemic attack (TIA); the 
studies investigate missed opportunities for primary prevention of these conditions and 
residual impairments after TIA. This chapter provides a general background and justification 
for the research. 
Definition of stroke, minor stroke and TIA 
Stroke, minor stroke and TIA are conditions caused by restricted blood supply to the brain;1-3 
definitions are summarised in Table 1. 
Stroke 
Broadly, stroke refers to an episode of neurological dysfunction, with evidence of permanent 
brain infarction, caused by focal cerebral, spinal or retinal infarction (ischaemic stroke) or 
bleeding into the subarachnoid or intracerebral space (haemorrhagic stroke).3 Symptoms of 
stroke are diverse and dependant on the type of stroke and area of the brain affected, but 
typically include disturbances in limb functioning, speech, vision or balance.4 The ‘Act 
F.A.S.T’ (Facial weakness; Arm weakness; Speech problems; Time to call 999) media 
campaign, launched in England in 2009, has been successful in improving identification of 
symptoms and emergency admissions.5 Diagnosis of stroke is facilitated by brain scans to 
determine the type of stroke (ischaemic or haemorrhagic), the location and severity.6 The 
National Institute of Health Stroke Scale (NIHSS) quantifies stroke severity through scoring 
consciousness, eye movement, vision, facial paralysis, leg and arm motor drift, coordination, 
sensory loss, language, speech and attention (Table 2).7 
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Table 1: Definitions of stroke, minor stroke and transient ischaemic attack (TIA). 
Diagnosis Definition Symptoms Permanent 
brain 
infarction? 
Stroke Disruption of blood supply to the 
brain usually caused by a blood clot 
(ischaemic stroke) or burst blood 
vessel (haemorrhagic stroke) 
Long-lasting and 
disabling 
Yes 
Minor stroke Disruption of blood supply to the 
brain with short-term functional 
recovery 
Mild and non-
disabling 
Yes 
TIA Transient disruption of blood supply 
to the brain caused by a temporary 
blood clot 
Short-lasting, 
usually less than 
one hour 
No 
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Table 2: Tests for recognition of stroke and TIA; stroke risk; and stroke severity. 
Recognition of symptoms of stroke and TIA 
FAST Face: Has their face fallen on one side? 
Arm weakness: Can they raise both arms and keep them there? 
Speech: Is speech slurred? 
ROSIER Has there been loss of consciousness or syncope? Y (-1 point) 
Has there been seizure activity?                                 Y (-1 point) 
Asymmetric facial weakness:                                       Y (1 point) 
Asymmetric arm weakness:                                         Y (1 point) 
Asymmetric leg weakness:                                           Y (1 point) 
Speech disturbance:                                                      Y (1 point) 
Visual field defect:                                                         Y (1 point) 
Stroke risk in AF patients 
CHADS2 Congestive heart failure:                   Y (1 point) 
Hypertension:                                      Y (1 point) 
Age ≥ 75:                                               Y (1 point) 
Diabetes mellitus:                                Y (1 point) 
Stroke or TIA symptoms previously: Y (2 points) 
CHA2DS2-VASc Congestive heart failure:                    Y (1 point) 
Hypertension:                                       Y (1 point) 
Age ≥ 75:                                                Y (2 points) 
Diabetes mellitus:                                 Y (1 point) 
Stroke or TIA symptoms previously:  Y (2 points) 
Vascular disease:                                   Y (1 point) 
Age 65 to 74 years:                                Y (1 point) 
Sex (female):                                           Y (1 point) 
Stroke risk in all patients 
ABCD2 Age ≥60 years:                                                                            Y (1 point) 
Blood pressure >140/90 mmHg:                                             Y (1 point) 
Clinical features: Unilateral weakness:                                  Y (2 points) 
                               Speech disturbance without weakness: Y (1 point) 
                               Other:                                                            Y (0 points) 
Duration: > 60 mins:                                                                  Y (2 points) 
                  10 – 60 mins:                                                             Y (1 point) 
                  < 10 mins:                                                                   Y (0 points) 
Diabetes:                                                                                      Y (1 point) 
  
  
Continued on next page 
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Stroke severity 
NIHSS Level of Consciousness 
Ask month and age 
'Blink eyes' and 'squeeze hands' 
Test horizontal extraocular movements 
Test visual fields 
Test facial palsy 
Test left arm motor drift 
Test right arm motor drift 
Test left leg motor drift 
Test right leg motor drift 
Test limb ataxia 
Test sensation 
Test language/aphasia 
Test dysarthria 
Test extinction/inattention 
FAST: Face Arms Speech Test; NIHSS: National Institute of Health Stroke Scale 
 
 
 
 
 
 
 
 
Table 2 continued from previous page 
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Minor stroke 
Minor stroke is also known as ‘mild stroke’ or ‘non-disabling stroke’; however, in contrast to 
stroke and TIA, there is no formal definition. Fisher et al (2010) proposed the definition to 
be: “all stroke patients with baseline NIHSS ≥3 or all stroke patients with a score 0 or 1 on 
every baseline NIHSS score item, except level of consciousness items, which must be 0”;2 
however, these are not consistently used. Broadly, minor stroke refers to an episode of 
neurological dysfunction with evidence of acute infarction whereby symptoms are non-
disabling.2 Therefore, minor stroke is differentiated from TIA by presence of brain infarction 
and from stroke by severity of symptoms and short-term recovery.  
Transient Ischaemic Attack (TIA) 
TIA is also known as ‘mini-stroke’ and was originally defined as an episode of neurological 
dysfunction with presumed vascular origin and symptoms lasting for less than 24 hours.8 
Therefore, duration of symptoms differentiated TIA from stroke. However, advances in brain 
imaging demonstrated that permanent brain infarction could result from short-lasting 
symptoms which, therefore, would not be a transient event.9 Furthermore, the time-base 
classification of TIA may promote delays in treatment because clinicians could decide to wait 
24 hours see if symptoms resolve.1 In 2002, a tissue-based definition of TIA was proposed: “a 
TIA is a brief episode of neurologic dysfunction caused by focal brain or retinal ischemia, 
with clinical symptoms typically lasting less than one hour and without evidence of acute 
infarction”.10 More recently, the American Heart Association/American Stroke Association 
(AHA/ASA) updated the tissue-based definition to remove the reference to time (symptoms 
typically lasting less than one hour) and defined TIA as: “a transient episode of neurological 
dysfunction caused by focal brain, spinal cord or retinal ischemia, without acute infarction”.1 
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The tissue-based definition differentiates TIA from stroke and minor stroke based on 
presence of permanent brain infarction; however, diagnosis requires routine brain imaging. 
Furthermore, the new definition has not been universally adopted and important 
organisations, such as the National Institute for Health and Care Excellence (NICE)6 and the 
World Health Organisation (WHO),11 still use the 24 hour criteria. Symptoms of TIA are 
similar to those of stroke; however, non-focal neurological symptoms have also been 
reported such as disconnection with surroundings, lack of awareness of deficit, visual 
displacement and impaired articulation.12 Use of brain imaging to diagnose TIA is not used 
routinely and diagnosis is predominantly based on clinical history.6 
Incidence and prevalence 
Stroke 
In the United Kingdom (UK), approximately 110,000 people have a first stroke per year, of 
which 98,000 are ischaemic strokes.13 The age-standardised incidence rate is estimated to be 
115 per 100,000 person-years. Incidence has decreased from 142 per 100,000 person-years 
in 1990;14 the greatest reduction in incidence is in people aged 70 years and over.15 
Approximately 1.1 million people have had a stroke in the UK13 and the age-adjusted 
prevalence is estimated to be 591 per 100,000.14 In contrast to incidence, prevalence has 
increased (age-standardised prevalence was 507 per 100,000 in 1990).14,15 
From a global perspective, the number of first strokes per year is estimated to be 16.9 
million, of which, 11.6 million are ischaemic strokes.16 In 2010, the worldwide age-adjusted 
incidence rate was 258 per 100,000 person-years, which had non-significantly increased 
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from 1990 (251 per 100,000 person-years).14 In terms of absolute numbers, there was a 
considerable increase in incident strokes, with a global increase of 68% between 1990 and 
2010.14 The global prevalence of stroke is estimated to be 33 million people and age-
adjusted prevalence 502 per 100,000 people.14 Absolute numbers of people surviving stroke 
increased by 84% between 1990 and 201014 and age-adjusted prevalence rates also 
increased significantly during this period.14 
Minor stroke 
The incidence and prevalence of minor stroke is not well documented and the lack of a clear 
definition hinders this. However, NICE estimates that 25% of strokes are minor strokes.17 
TIA 
In the UK, approximately 46,000 people have a first TIA per year and there are 510,000 
people with prevalent TIA.13 Both incidence and prevalence of TIA increase with age and are 
higher in women; however, this sex effect is likely to be a result of increased healthcare 
seeking behaviour in women.13 Estimating the incidence and prevalence of TIA is 
complicated by the change in definition of TIA (time vs tissue based definition) and that the 
new proposed classification has not been university adopted. The above incidence estimates 
are based on data from the Oxford Vascular study18 which used the time-based definition of 
TIA. Prevalence estimates are based on the National Stroke Audit which defined TIA using 
clinical codes (Read codes), which are used in primary care to record patients’ information 
electronically as part of routine clinical care;19 therefore, it is unclear how TIA was diagnosed 
at an individual level. Estimates of incidence and prevalence need to be considered with 
caution. There are no estimates of the global incidence and prevalence of TIA; however, it 
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has been estimated that approximately 5 million people in the United States of America 
(USA)20 and 23.9 million people in China21 have experienced a TIA. 
UK and global burden 
Stroke can cause huge burden in terms of death, disability and quality of life (QoL) (for 
patients, carers and family members) and is associated with high economic cost.16 Post-
stroke disability varies in severity and includes impairments related to: physical function 
(limb weakness or paralysis); speech (slurred speech and aphasia); mood (anxiety, 
depression, emotionalism, fatigue); cognition (impaired memory, attention, executive 
functioning).22 Furthermore, stroke patients are at high risk of recurrent stroke.23 
In the UK, strokes are attributable for 60,000 deaths and 665,000 disability-adjusted life-
years (DALYs) lost per year. However, the absolute numbers and age-adjusted estimates of 
stroke-related deaths and DALYs lost have reduced considerable since 1990.14 A North-South 
regional divide has been reported for stroke mortality in the UK with more stroke-related 
deaths in Scotland compared to the South of England.13 The UK total economic cost of stroke 
is estimated to be £9 billion, of which, almost half is health and social care costs.13 
Globally, stroke is a leading cause of death and disability in both developed and developing 
countries. The Global Burden of Disease study found stroke was the second leading cause of 
death24 and third leading cause of DALYs lost25 worldwide. The study also found that stroke 
burden varied between regions and countries,14 changed over time and differed between 
stroke sub-types.16 The estimated number of deaths and DALYs lost attributable to stroke in 
2010 were 5.9 million and 102 million, respectively.14 The age-adjusted mortality rate in 
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2010 was 88 per 100,000 person-years and DALYs lost was 1554.14 Age-adjusted stroke-
related mortality rates and DALYs lost decreased worldwide between 1990 and 2010; 
however, the absolute numbers of stroke-related deaths and DALYs lost increased by 26% 
and 12% respectively.14 Although incidence is lower, haemorrhagic strokes cause more 
burden compared to ischaemic strokes. 16 For incident strokes, in 2010, there were 3 million 
compared to 2.8 million stroke-related deaths for haemorrhagic and ischaemic stroke, 
respectively, and 62.8 million compared to 39.4 million DALYs lost for haemorrhagic and 
ischaemic stroke, respectively.16 There are geographical variations in the burden of stroke 
worldwide; most of the burden is in low- and middle-income countries including 71% of 
stroke related deaths and 78% of DALYs lost.14 Stroke is often considered a disease of the 
elderly and there was a greater increase in mortality and DALYs lost between 1990 and 2010 
in people aged 75 years and over compared to people aged less than 75 years (36% increase 
in mortality and 31% increase in DALYs lost in people ≥75 years compared to 16% increase in 
mortality and 15% increase in DALYs in people <75 years). 14 This has important implications 
given population ageing.14 However, the absolute numbers of DALYs lost is considerably 
greater in people under 75 years compared to those 75 years and over (73 million vs 28.9 
million in 2010, respectively).14 
TIA is estimated to cost the UK economy £440 million per annum, of which, 83% are health 
and social care costs.13 TIA patients are at high risk of having a full stroke; risk of stroke after 
TIA is reported to be 8% at one week, 12% at one month and 17% at three months.26 After 
minor stroke, risk of stroke is 12% at one week, 15% at one month and 19% at three months. 
Although TIA and minor stroke are characterised by short-term functional recovery, there is 
evidence to suggest that TIA and minor stroke burden may extend beyond stroke risk and 
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patients may experience residual impairments. 27 One study found that 15% of TIA and minor 
stroke patients, who were previously not disabled, had at least slight disability at 90 days 
post-TIA.27 Furthermore, anecdotally, people have reported ongoing symptoms (such as limb 
weakness, slurred speech, poor articulation, memory problems and fatigue), lack of 
confidence and emotionalism (feeling more emotional or unable to control emotions) post-
TIA and minor stroke.28 
Primary prevention of stroke and TIA 
Given the society burden and potential devastating impact of stroke and TIA on patients and 
family members, primary prevention is usually preferable to treatment. For the context of 
this thesis, primary prevention was defined as interventions to prevent stroke or TIA in 
people with no prior history of stroke. Specifically, drug therapy interventions in primary 
care were investigated.  
Stroke and TIA risk factors 
A number of risk factors for stroke and TIA have been identified, some are modifiable and 
can be targeted through pharmacotherapy and lifestyle interventions and other are non-
modifiable but are useful to determine a person’s risk of stroke. 
Modifiable risk factors 
Hypertension 
Hypertension (high blood pressure (BP)) has been proposed as the most important risk 
factor for stroke and TIA; it is attributable to over half of ischaemic strokes.29 High BP 
induces stress on blood vessels which can lead to atherosclerosis (narrowing and hardening 
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of blood vessels). In turn, this causes a blockage which results in ischaemic stroke or TIA, or 
causes a blood vessel in the brain to burst which leads to bleeding and haemorrhagic 
stroke.29 The global prevalence of hypertension in 2000 was 972 million and 26% of the adult 
population were estimated to have hypertension.30 There is a positive and continuous 
relationship between increasing BP and stroke.31,32 Hypertension is asymptomatic and 
influenced by lifestyle, including smoking, alcohol intake, inactivity and diet.33 Furthermore, 
hypertension is more prevalent with increasing age30 and people of South Asian and African-
Caribbean ethnicities are generally at higher risk compared to white people.34 
Antihypertensive drugs have been found to reduce stroke incidence and evidence for the 
effectiveness of these drugs is strong.35 
Atrial fibrillation (AF) 
Atrial fibrillation (AF) is characterised by an irregular heart rhythm and associated with a 
five-fold increase in stroke risk.36 Furthermore, strokes in people with AF are associated with 
greater mortality and disability compared to people without AF.37 Reduced blood flow from 
the irregular heart rhythm increases risk of blood clots forming in the heart which can 
migrate to the brain and cause stroke.38 The global prevalence of AF is 33.5 million and 
prevalence increases with age.39 Independent stroke risk factors have been identified for 
people with AF, including older age (≥65 years), female sex, history of stroke or TIA, 
congestive heart failure (CHF), hypertension, vascular disease and diabetes.40 Aspirin was 
found to reduce stroke risk in AF patients; however, anticoagulant drugs have now been 
shown to be more effective.41 Furthermore, the reduction of stroke risk through 
anticoagulation with warfarin is very high42 (particularly compared to lipid lowering and 
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antihypertensive drugs) and novel anticoagulant drugs are now available which are 
potentially safer based on current evidence.43 
Dyslipidaemia 
Dyslipidaemia, abnormal amount of lipids in the blood, is defined as high levels of total or 
low-density lipoprotein (LDL) cholesterol or low levels of high-density lipoprotein (HDL) 
cholesterol.44 The association between cholesterol levels and stroke is complex; high levels 
of total cholesterol have been found to increase the risk of ischaemic stroke,45 but protect 
against haemorrhagic stroke.46 There are inconsistencies from epidemiological studies 
regarding the association between lipid levels and stroke risk;47,48 however, lipid lowering 
drugs have been found to be effective at reducing stroke incidence.49 In addition to lifestyle 
factors, particularly diet, high cholesterol can be caused by familial hypercholesterolemia, a 
genetic condition with a UK prevalence of 1 in 500.50 
Other modifiable risk factors 
Risk of stroke is at least doubled by smoking,51 consuming large amounts of alcohol52 and 
having diabetes.53 Other lifestyle factors, including diet (high in saturated fat or salt), obesity 
and physical inactivity, contribute to increase stroke risk through raising cholesterol levels, 
BP and risk of diabetes.54 
Non-modifiable risk factors 
Non-modifiable risk factors for stroke and TIA are important to determine a person’s risk of 
stroke. Age is the most important non-modifiable risk factor; the incidence and prevalence 
of stroke and TIA increases with age13 and risk of stroke doubles every decade after age 55 
years.55 Male sex is considered a risk factor for stroke; men have a higher incidence of stroke 
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and their mean age of first stroke is approximately five years younger compared to 
women.56 In the UK, people of South Asian and African-Caribbean ethnicities have been 
found to have increased stroke risk compared to the national average.57 In addition, having a 
family history of stroke is associated with increased stoke risk.58 
Evidence-based guidelines for the prevention of stroke and TIA 
Evidence-based guidelines which identify people who are at high risk of stroke and TIA and 
recommend appropriate pharmacotherapy and lifestyle interventions have been developed 
for use in primary care. NICE guidelines relevant to the research within this thesis are 
discussed below and include hypertension, AF and lipid modification guidelines.43,59,60 
Hypertension guidelines recommend that antihypertensive drug prescribing is considered in 
the context of cardiovascular disease (CVD) and CVD risk, not solely BP measurements.59 
Antihypertensive drugs should be prescribed to people with sustained high BP (≥160/100 
mmHg) or moderately high BP (≥140/90 mmHg) and established CVD or high CVD risk.59 
Lifestyle advice regarding smoking, alcohol intake, diet and exercise should also be 
administered. People with sustained moderately high BP (≥140/90 mmHg) but no other risk 
factors should receive lifestyle advice and be reviewed annually. 
AF guidelines take into consideration the independent stroke risk factors for people with AF 
and recommend that patients’ stroke risk is estimated using a risk algorithm (Table 2).60 The 
2006 NICE AF guideline61 recommended that patients at low risk of stroke are prescribed 
aspirin for stroke prevention, at moderate risk are prescribed aspirin or anticoagulant drugs 
and at high risk are prescribed anticoagulant drugs. However, the guideline was updated in 
the 201460 to recommend anticoagulation, using warfarin or new oral anticoagulants, in high 
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risk patients (defined as CHA2DS2-VASc score ≥2) and specifies that aspirin monotherapy 
should not be used for stroke prevention. Anticoagulant drugs should be considered for 
males with a CHA2DS2-VASc score of 1, but stroke prevention drugs should not be prescribed 
to females with a CHA2DS2-VASc score of 1, (one point is given for female sex) or males with 
a score of 0.60  
Lipid modification guidelines recommend prescription of lipid lowering drugs based on CVD 
risk as opposed to blood cholesterol levels. 43 The guidelines advise that lipid lowering drugs 
are prescribed and lifestyle advice administered to people with existing CVD or at high risk of 
CVD. For calculated CVD risk, the 2008 lipid modification guidelines62 used a threshold of a 
10-year CVD risk of ≥20%; however, this was lowered to ≥10% in the updated 2014 
guidelines.43  
Potential barriers to stroke and TIA prevention in primary care 
The decrease in the incidence of stroke and TIA is associated with an increase in prescribing 
trends of primary prevention drugs.15 However, evidence suggests prescribing remains 
suboptimal and there are barriers to guideline adherence.63-65 Cabana et al (1999) identified 
multiple and diverse barriers to physicians’ adherence to guidelines which included factors 
related to physicians’ knowledge of the guidelines (lack of awareness or familiarity), 
physicians’ attitudes towards the guidelines (lack of agreement, self-belief, outcome 
expectancy) and external barriers (time or resource constrains, organisational barriers, 
patient factors).66  
Barriers for adherence to guidelines relevant for stroke prevention have been demonstrated 
and impact on prevention drug prescribing. For antihypertensive prescribing, barriers 
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identified were: lack of agreement with guidelines;67 accepting higher BP thresholds than 
guideline recommendations; belief that benefits for the patient does not outweigh the 
potential harms or there were side effects; and knowledge of patients’ non-adherence to 
medication.67,68 For anticoagulant prescribing, a systematic review reported that the main 
barriers were associated with clinicians’ attitude towards the guidelines and external factors, 
including those related to  patients’ age, comorbidities and risk of bleeding or falls.69 In 
relation to lipid modification guidelines, a qualitative study reported barriers to statin 
prescribing included: interpretation of risk tools, concerns about medicalisation of patients, 
patients’ non-adherence to medication and organisational issues.65 Studies have reported 
under-prescribing of stroke prevention drugs to patients with clinical indications for these 
drugs63,64,70-72 and over-prescribing to patients without clinical indications.73,74 
Management of stroke, minor stroke and TIA 
Treatment pathways are summarised in Figure 1. Rapid response to stroke and TIA reduces 
death, disability and recurrent events.75 Therefore, fast diagnosis and referral to specialist 
stroke services is essential. Recognition of stroke or TIA symptoms are important; the Face 
Arms and Speech Test (FAST)76 is a validated tool which can be used by members of the 
public or healthcare professionals and the Recognition of Stroke in the Emergency Room 
(ROSIER) score77 is a more detailed tool used in emergency departments (Table 2). People 
with suspect TIA and stroke should have blood sugar checked by first responders to exclude 
hypoglycaemia, which can cause stroke and TIA-like symptoms, and be transferred to a 
specialist stroke unit within one hour of symptoms onset.6 The pathways for management of 
stroke and TIA are differentiated by whether symptoms have resolved at the time of 
assessment and there is not a distinct pathway for the management of minor stroke.6 
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Figure 1: Summary of treatment pathways for stroke and transient ischaemic attack (TIA). 
Adapted from National Institute for Health and Care Excellence (NICE) pathways.79 
Recognition of symptoms: FAST or ROSIER screening tools 
Have neurological symptoms resolved at time of assessment? 
TIA pathway Stroke pathway 
Initial management: Aspirin 300 mg, 
blood tests, ECG 
Exclude hypoglycaemia stroke mimic 
Assess stroke risk: ABCD2 score 
Low risk (ABCD2 
score <4 or >1 week 
since symptoms): 
Specialist 
assessment within 1 
week 
 
High risk (ABCD2 
score ≥4 or ≥ TIAs 
in 1 week): 
Specialist 
assessment within 
24 hours 
Specialist assessment: 
Confirm diagnosis, management of 
risk factors, administer initial stroke 
prevention pharmacotherapy and 
lifestyle advice 
Brain or carotid imaging if appropriate 
Carotid endarterectomy 
if significant carotid 
stenosis 
Follow-up in primary care: stroke 
prevention pharmacotherapy and 
lifestyle advice 
Brain imaging 
Thrombolysis if 
indicated 
Pharmacotherapy: Antiplatelet if 
ischaemic stroke, reverse 
anticoagulation if haemorrhagic 
stroke 
Specialist assessment and care: 
swallowing, blood pressure, blood 
sugar, nutrition, mobilisation 
Rehabilitation with multidisciplinary 
team in rehabilitation unit 
Early supported discharge from 
hospital 
Continued care and rehabilitation 
with community stroke team 
(reviewed at 6 and 12 months) 
Yes No 
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Stroke  
If neurological symptoms persist, a patient is considered to have a stroke during the initial 
assessment.6 Brain imaging should be performed within one hour if indicated (such as 
known bleeding tendency or thrombolysis indicated) or 24 hours if no indications.6 For 
ischaemic strokes, thrombolysis with alteplase should be administered within four and a half 
hours, if indicated from the brain imaging.75 Acute treatment in the specialist stroke unit 
comprises of antiplatelet therapy for ischaemic stroke and reversal of anticoagulation for 
haemorrhagic stroke if indicated. Further specialist assessments and care includes: 
electrocardiogram (ECG), early mobilisation, assessment of swallowing function, continence 
assessment, nutritional supplements, BP and blood sugar control, surgery for intracerebral 
haemorrhage (if deemed appropriate) and anticoagulant and statin therapy.78 
Following acute treatment, stroke patients are assessed to determine the extent of 
impairments and disability and may be transferred to a rehabilitation unit.78 Stroke can 
cause a wide range of impairments which vary in severity and can affect cognition, emotion, 
speech, function, vision, hearing and balance.78 Patients should be screened and goals set by 
a multidisciplinary rehabilitation team including: clinicians, nurses, physiotherapists, 
occupational therapists, speech and language therapists and social workers.6 Before hospital 
discharge, an early support discharge plan is developed whereby patients’ health and social 
care needs are assessed, including support and training requirements for carers and family 
members.6 Following discharge, rehabilitation is continued in primary care and with 
community stroke teams. A patient tailored health and social care plan is developed to 
support patients and carers, including return to work, and is reviewed at six months and 
then annually.6 
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TIA 
According to the NICE guidelines, a diagnosis of TIA should be considered if neurological 
symptoms resolved within a few hours. 6 Initial management comprises of administration of 
aspirin (300 mg) and/or modified-release dipyridamole to prevent occlusive vascular events; 
blood tests, including fasting blood glucose and lipids, platelets and renal function; and an 
ECG test to exclude AF.76 A validated tool should be used to assess stroke risk, such as the 
ABCD2 score (Age, Blood pressure, Clinical features of TIA, Duration of symptoms, 
Diabetes).80 People should be considered at high risk of stroke if they have an ABCD2 score 
≥4 or present with two or more TIAs in one week.76 High risk patients receive specialist 
assessment within 24 hours.76 People with an ABCD2 score <4 or who present more than a 
week after symptoms have resolved should be considered at low risk of stroke and receive 
specialist assessed within one week.76 Specialist assessment should confirm the diagnosis, 
assess risk factors, administer initial pharmacotherapy and lifestyle advice and, if 
appropriate, refer for brain and carotid imaging. People should undergo brain imaging if the 
vascular territory or pathology is uncertain or haemorrhage needs to be excluded.6 Carotid 
imaging should be completed within one week if carotid endarterectomy is considered. If 
carotid imaging shows evidence of significant carotid stenosis, carotid endarterectomy 
should be performed within two weeks.6 People with a confirmed diagnosis of TIA are 
followed-up at one month in primary or secondary care and then annually in primary care.81 
Follow-up comprises of review of drug therapy and lifestyle advice for stroke and TIA 
prevention.81 
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Justification for research 
Missed opportunities for primary stroke and TIA prevention 
The burden of stroke and TIA to patients and society is substantial;16 therefore, primary 
prevention is important to reduce their incidence and subsequent burden. Hypertension, AF 
and dyslipidaemia are important modifiable risk factors for stroke and TIA. There is a strong 
evidence-base for the effectiveness of primary prevention drugs which target these risk 
factors and reduce stroke incidence; comprehensive primary care guidelines identify people 
at high stroke risk and are eligible for prevention drugs.43,59,60 There is evidence of 
improvement in the prescribing of primary prevention drugs between 1999 and 2008;15 
however, literature suggests that prescribing remains suboptimal.63,64,70-72 Therefore, it is 
important to quantify missed opportunities for prevention prior to stroke or TIA to 
determine if primary prevention in primary care is inadequate. 
Residual impairments after TIA 
The care pathway for TIA patients is focused on prevention of subsequent TIA or stroke. 
Symptoms of TIA are short-lasting; however, there is anecdotal evidence to suggest that 
these patients may experience ongoing impairments.28 If TIA causes ongoing impairments, 
these impairments may impact on patients’ health and wellbeing. Therefore, it is important 
to understand the holistic consequences of TIA to ensure patents receive adequate health 
care. 
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Aims 
The research within this thesis aimed to determine: (i) the extent to which people that had a 
stroke or TIA had prior missed opportunities for prevention with pharmacotherapy and (ii) if 
TIA patients experience ongoing residual impairments after initial symptoms have resolved. 
Objectives 
1. To quantify missed opportunities for primary stroke and TIA prevention with lipid 
lowering, anticoagulant and antihypertensive drugs through analysis of electronic 
primary care records. 
2. To identify patient characteristics associated with missed opportunities for primary 
prevention of stroke and TIA. 
3. To establish the prevalence of fatigue, cognitive and psychological impairment post-
TIA and minor stroke through a systematic review of the literature. 
4. To investigate if TIA is associated with consultation for fatigue, psychological or 
cognitive impairment in primary care in an age and gender matched population from 
an electronic primary care database. 
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General methods 
This thesis is comprised of three studies: a case series analysis, a systematic review and a 
retrospective cohort study. The case series analysis and retrospective cohort study used 
electronic primary care medical records extracted from The Health Improvement Network 
(THIN). This chapter provides a general overview of the methods used and justifies the 
approach taken. Detailed protocols are presented in Chapters 3, 6 and 8. 
Primary care database studies 
Two studies (Chapters 3-5 and 8-9) used anonymised electronic primary care medical 
records extracted from the THIN database. The first investigated missed opportunities for 
primary prevention of stroke and TIA (case series analysis). The second explored if TIA was 
associated with consultation for fatigue, psychological or cognitive impairment in primary 
care (retrospective cohort study). The full protocols for these studies are presented in 
Chapters 3 and 8. 
The Health Improvement Network (THIN) database 
THIN is a database that contains anonymised electronic patient records from over 580 
general practices from the UK.1 The THIN database covers approximately 6% of the UK 
population and includes data on 12 million patients, of which, 3.6 million are active and the 
remainder are former (left the practice) or deceased patients.1 Data can be extracted from 
THIN and used for epidemiological research.2  
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Data collection and extraction 
The data collection process is summarised in Figure 1. General practitioners (GPs) record 
clinically relevant information from consultations using Vision patient records software as 
part of routine clinical care.2 Additional administrative data and lab results are also recorded  
in Vision and demographic data (such as age and sex) are collected when a patient joins the 
general practice. 2 Anonymised data is collected from contributing general practices through 
software developed by In Practice Systems (INPS).2 General practices receive financial 
incentives to contribute data to THIN.3 A full collection of retrospective data is completed 
when a general practice first joins THIN and subsequent data are automatically downloaded 
on a monthly basis. Intercontinental Marketing Services (IMS) Health, the company which 
owns THIN, combines data from different general practices within THIN, completes quality 
checks and provides access to the data for research.4 The University of Birmingham holds a 
sub-licence for THIN whereby the entire database is accessible and updated three times a 
year.5 Study specific data required for each of the two THIN database studies were extracted 
by Doctor Ronan Ryan. 
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Figure 1: Summary of how data is collected for The Health Improvement Network (THIN) 
from general practices and made available for research. 
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Structure of the THIN database 
The structure of the THIN database is summarised in Figure 2. Data is organised by general 
practice then patient and linked by practice ID and patient ID. There are practice files, four 
main files (patient, therapy, medical and additional health data (AHD) files) and three linked 
files (postcode variable indicators (PVI), staff and consult files), which are described below. 
Practice file 
The practice file is a separate file for each general practice which includes date of 
computerisation, acceptable mortality reporting (AMR) date (when the practice mortality 
rate is similar to the UK mortality rate),6 date of last data collection and country. This file is 
linked to the four main files below. 
Main files 
1. Patient file: Demographic information (including sex and year of birth) and 
registration information (such as registration date and date patient left the practice). 
2. Therapy file: Data on prescriptions (including strength and formulation) which is 
automatically recorded when a GP or nurse issues a prescription. 
3. Medical file: Diagnoses and symptoms which are recorded at consultations and 
information provided from secondary care discharge notes. 
4. AHD file: Other information including lifestyle factors (such as smoking and alcohol), 
information for preventive healthcare (such as height, weight and cholesterol) and 
lab test results. 
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Linked files 
1. PVI file: Socioeconomic and environmental data at an area level to maintain 
anonymity (linked to the patient file). 
2. Staff file: Data on the sex and roles of general practice staff (linked to the therapy, 
medical and AHD files). 
3. Consult file: Information on consultations including date, time and duration (linked 
to the therapy, medical and AHD files). 
Data within THIN are presented in the form of coded information, with the exception of free 
text.7 Clinical data, including diagnoses, procedures, investigations, signs and symptoms, are 
coded using Read codes (version 2).8 Read codes are hierarchical, organised in chapters and 
categories, and comprise of seven characters (e.g. G64z200: left sided cerebral infarction). 
Read codes for diagnoses also map to International Classification of Diseases-9 (ICD-9) 
codes.8 Additional clinical information, such as clinical measurements, are coded using AHD 
codes. The therapy file contains drug codes which correspond to specific drug formulations 
and British National Formulary (BNF) codes which are based on BNF chapters.9 Anonymised 
free text comments are contained in the medical and AHD files.7 
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Figure 2: Structure of The Health Improvement Network (THIN) database. 
AHD: Additional Health Data; AMR: Acceptable Mortality Rate; BNF: British National 
Formulary; PVI: Postcode Variable Indicators; YOB: Year of Birth 
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Defining variables 
Prior to data extraction, comprehensive lists of Read and drug codes were developed which 
defined the population, outcomes, exposures and variables for each study. The Read and 
drug codes which define these can affect results or interpretation of a study; therefore, it is 
important that comprehensive search strategies are employed to identify all relevant codes 
and there is transparency in the reporting of codes. Read code and drug code dictionaries 
detail the individual codes and corresponding description.7 A systematic approach was used 
to identify all relevant Read codes which comprised of: (i) identifying Quality and Outcomes 
Framework (QOF) Read codes (GPs are incentivised to use QOF Read codes), (ii) searching 
the Read code dictionary for key words, (iii) conducting hierarchical searches of Read codes 
identified in the first two steps, (iv) reviewing the literature and (v) consulting a clinician 
(Professor Tom Marshall). Drug codes were identified through searching the drug code 
dictionary for relevant BNF chapters. Drug codes corresponding to relevant BNF chapters 
were reviewed for relevance and checked by clinician Professor Tom Marshall. The selection 
of AHD codes was more straightforward as individual clinical measurements, such as BP, are 
identified using a single AHD code.7 Free text was not used for either of the THIN database 
studies within this thesis. 
Ethical approval 
Research which involves National Health Service (NHS) patients requires Research Ethics 
Committee approval; data collection for THIN was approved by the South East Multicentre 
Research Ethics Committee (MREC) in 2003.3 Individual studies using THIN data do not 
require separate ethical approval if only anonymised THIN data is used. However, these 
studies must be reviewed by an independent Scientific Review Committee (SRC) to ensure 
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data is analysed and interpreted appropriately.10 The two studies within this thesis that used 
THIN data received SRC approval in May 2013 (reference: 13-023) and February 2014 
(reference: 14-008, Appendix 1.2 and 6.2). THIN studies that use non-anonymised patient 
data, such as patient questionnaires, require additional MREC and local Research and 
Development (R and D) approval;10 however, this was not required for the studies within this 
thesis. 
Strengths 
One of the main strengths is that the THIN database is representative of usual primary care 
practice because data are routinely collected and, therefore, non-interventional. The 
database has geographical spread across the UK, allowing regional sub-analyses, and is 
broadly representative of the UK population.11 Over 580 general practices contribute data to 
THIN; therefore, large sample sizes can be obtained from this database.1 The data are 
continuously updated and the database at the University of Birmingham is updated three 
times a year. Therefore, current data was extracted for each study. Consultations for an 
individual patient are linked which allows knowledge of patients’ medical history and follow-
up over time. Furthermore, the data includes people who are often excluded from research, 
such as pregnant women or the very elderly.  
The THIN database contains rich clinical and prescribing data. Vision software is used to print 
prescriptions and these are automatically retained in the patients’ electronic record; 
therefore, prescribing data is comprehensive and accurate.2 The quality of clinical data is 
improved by validation checks within Vision which prevent implausible values being entered, 
such as height,7 and the UK pay-for-performance scheme, QOF, which incentivises the 
36 
 
recording and management of patients with common chronic comorbidities.12 Furthermore, 
quality checks of THIN data are completed by IMS Health and AMR dates calculated which 
identify when the practice mortality rate is similar to UK mortality rate.4 THIN data is 
amenable to epidemiological study designs and case patients and controls can be extracted 
from the same source population. A major advantage of the database is the accessibility and 
relatively minimal time and cost required compared to traditional prospective 
epidemiological studies that recruit patients. It would not have been feasible to complete 
the two studies presented in this thesis within the time and financial constraints of the PhD 
if patients had been prospectively recruited and followed-up. 
Limitations 
The THIN database has limitations which have implications for research. Importantly, 
accuracy of the research is dependent on quality of the data recorded by GPs. A key 
characteristic of electronic primary care patient records is that they are routinely collected 
for clinical management, not for research purposes. Therefore, GPs may not record 
information that is not considered important for patients’ health care but may be important 
for research. There is a hierarchy of data accuracy in THIN and, while prescribing and 
demographic (age and sex) data are comprehensive,2 lifestyle, socio-economic data and over 
the counter medication is less accurate and ethnicity is poorly recorded.7 Furthermore, 
prescription of a medication does not necessarily mean that it was collected or the drugs 
were taken by the patient; however, does reflect the behaviour of the GP.  
The introduction of QOF improved recording of common long term conditions;12 however, 
other conditions not included in QOF may be underreported. QOF was introduced in 2004; 
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therefore, recoding of QOF conditions before 2004 may be less reliable. Furthermore, 
changes in QOF may affect the recording of different conditions and associated clinical 
variables over time.13 Consideration of QOF changes must be taken into account when 
looking at time trends. QOF incentives may also introduce a bias in the recording of clinical 
variables which are incentivised under QOF.12 Disease severity may not be recorded within 
primary care databases like THIN if this information is not present in the Read codes.8 This 
had implications for the studies within this thesis because minor stroke could not be 
distinguished from full stroke. In addition, it is not always possible to differentiate between 
subtypes of stroke (such as ischaemic or haemorrhagic stroke). There will inevitably be 
missing and incomplete data within general practices and data are not always missing at 
random.14 It is possible to infer diagnoses from other data recorded, such as depression from 
antidepressant drug prescriptions, but this is not feasible for many diagnoses.  
General practices are likely to vary in the information they record and how information is 
coded.15 Furthermore, data entry is subject to human error and data which requires manual 
input, such as information from hospital letters, may be less accurate or missing.16 There are 
some validation checks within Vision and implausible values can be excluded from the 
analysis;7 however, values which are incorrect but plausible are difficult to identify. 
Furthermore, there is only information available for people who are registered in primary 
care and timing of data collection can be sporadic, as opposed to planned follow-up time 
points in a prospective cohort study. Finally, although the size of the THIN database is a 
major advantage, this may also create a problem of having too much power which may 
cause statistical significance in all analyses. Therefore, clinical significance should be 
considered when interpreting results. 
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Alternative methods and primary care databases 
An alternative method to the use of a primary care database for epidemiological studies is to 
recruit participants to an observational study, such as a prospective cohort study. The 
advantage of this method is that there is greater control over the data collected and the 
timing of collection, which may allow more accurate measurement, as opposed to reliance 
on what information is routinely collected during consultations. In addition, outcomes 
measured may be more representative of community incidence rather than being reliant on 
patients consulting in primary care; however, this depends on sampling strategies. The main 
limitations of conducting a prospective observational study are the high cost and length of 
follow-up required; two full prospective observational studies would not have been feasible 
within the time and financial constraints of this PhD. It would also not have been achievable 
to recruit a large, UK wide sample size which was obtained by use of THIN data. In addition 
to time and financial burden, prospective observational studies also impose burden on 
participants. Other methodological limitations of observational studies include those related 
to recruitment, retention and introduction of bias.17 
The aims of the thesis could have been explored using qualitative studies. The advantage of 
qualitative research is that ‘why’ questions can be asked, such as why clinicians do not 
prescribe prevention medication to eligible patients. This method also allows context to be 
explored, such as how residual impairments post-TIA impact on people’s lives. However, the 
objectives of the thesis (such as, quantifying missed opportunities for stroke and TIA 
prevention and investigating the association between TIA and residual impairments) could 
not be delivered through qualitative methods. 
39 
 
In addition to THIN, there are other UK primary care databases including Clinical Practice 
Research Datalink (CPRD; formerly GPRD)18 and QResearch19. CPRD collects primary care 
data through Vision and Educational Management Information System (EMIS) software and 
there is an approximate 50% overlap between the general practices which contribute data to 
THIN and CPRD.18 In addition, CPRD has links to secondary care data.18 QResearch also 
contains electronic primary care patient records and collects data using EMIS software.19 The 
THIN database was chosen for the research conducted within this thesis because of 
accessibility to the data through the sub-licence at the University of Birmingham.  
Systematic review 
A systematic review, which investigated fatigue, psychological and cognitive impairment 
after TIA and minor stroke, was completed to identify and synthesise existing literature. 
Scoping search 
Prior to the systematic review, a scoping search was completed to: (i) determine if there 
were any existing reviews related to the topic; (ii) obtain an insight into the extent and 
quality of existing literature; and (iii) inform the search strategy and inclusion criteria for the 
systematic review. 
The scoping searches found one unpublished systematic review which explored functional, 
emotional and cognitive outcomes after TIA (Brittle 2012).20 The review included cohort and 
case-control studies, between 1991 and 2012, which compared TIA patients with no history 
of stroke to controls free of stroke and TIA. The outcomes were measures of cognition, 
emotion or physical function. Twelve studies met the inclusion criteria: nine measured 
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cognition, four depression, two QoL and one activities of daily living. The studies were 
heterogeneous in the study designs, populations recruited, outcome measures and 
statistical analyses. Furthermore, the strength of evidence was judged as low or medium in 
seven out of 12 of studies. Significant differences between TIA patients and controls were 
reported in five out nine studies which measured cognition, two out of four studies which 
measured depression and the two studies which measured QoL. A non-significant difference 
was reported by the study that measured activities of daily living. The main limitations of the 
review were that non-English papers were excluded and there was a lack of clarity for the 
outcomes reported. It was unclear how the outcome measures for TIA patients and controls 
were compared (for example, were difference in mean or total scores compared) and 
summary measures were not reported for the outcomes. Furthermore, it was unclear if 
functional, emotional and cognitive outcomes were clinically relevant, which is often 
identified by a pre-defined cut-off score on validated measurement tools. 
The findings of the Brittle (2012)20 systematic review demonstrated there were few high 
quality studies which measured residual impairments after TIA. However, further scoping 
searches found studies relevant to the aims of this thesis which had not met the eligibility 
criteria for the Brittle (2012)20 systematic review. Therefore, there was a need to complete a 
broader systematic review of the literature which was not restricted by study design or 
English language and was reported in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement.21 Furthermore, minor stroke 
patients should be included because, by definition, these strokes are non-disabling22 and, 
therefore, follow-up care is likely to focus on secondary stroke prevention similar to TIA 
patients.23 To obtain a comprehensive understanding of the literature, inclusion criteria for 
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my systematic review were kept broad in terms of study design and publication status. 
Based on scoping searches and anecdotal evidence, the residual impairments included were: 
fatigue, anxiety, depression, post-traumatic stress disorder (PTSD) and cognitive impairment. 
Frequency of these impairments post-TIA and minor stroke was selected as the primary 
outcome to determine the prevalence of impairments post-TIA and minor stroke. The full 
protocol for the systematic review is presented in chapter 6. 
Strengths and limitations 
Systematic reviews are generally considered the highest level of information in evidence 
hierarchies for health care research and the gold standard to synthesise existing evidence.24 
The strengths of conducting a systematic review are that a clearly formulated research 
question is answered through methods that adhere to a pre-defined protocol, which is 
explicit and reproducible. A comprehensive and systematic search aims to identify all 
relevant studies, regardless of publication status, using pre-defined inclusion criteria.25 The 
reporting of study characteristics and findings is systematic and transparent. If appropriate, 
quantitative data can be pooled using statistical techniques in a meta-analysis. Furthermore, 
quality of the studies and generalisability and reliability of findings are assessed.  However, 
systematic reviews are very time consuming and, despite best efforts, some studies may be 
missed. Furthermore, the strength of evidence for the findings of the review is dependent on 
the quality of the studies included. 
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Alternative methods  
Other methods which could have been used to synthesise literature instead of a systematic 
review include a literature review or rapid review and are discussed below. 
Literature review 
A literature review attempts to summarise evidence and usually covers a general topic or 
broad question rather than a focused research question. The methods are not usually 
described explicitly or pre-specified. Searches of the literature may or may not be 
systematic, but are limited and usually restricted to published studies. Inclusion criteria and 
excluded studies are not reported or justified. The included studies are generally not 
critically appraised and results are synthesised narratively. The advantage of a literature 
review is that less time and resources are required compared to a systematic review. 
However, bias may be introduced (for example, publication or authors’ bias), it is unlikely 
that all relevant literature is included and findings may not be reproducible. 
Rapid review 
Rapid reviews can be a quick and efficient method of evidence synthesis.26 Specific research 
questions are answered but these may be broader than those of a systematic review. 
Systematic review methods are usually employed; however, not as robustly as a systematic 
review, for example, fewer electronic databases searched. The definition and methodology 
of rapid reviews are not standardised and vary in which components of a systematic review 
are included (searching, screening, quality assessment, data extraction, synthesis methods, 
report structure and number of reviewers).27 Synthesis of results are usually narrative. The 
advantage of a rapid review is that less time and resources are required compared to a 
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systematic review. Rapid reviews are valuable when rapid decision making is required and 
are often used in commissioning. However, caution is required when interpreting findings 
because they are not as evidence-based as those of a systematic review. 
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Retrospective case review of missed 
opportunities for primary prevention of 
stroke and TIA in primary care: 
protocol paper 
The absolute numbers of first strokes and stroke-related deaths and disability has increased 
worldwide.1 Primary prevention of stroke and TIA is important to reduce the incidence and 
subsequent burden of these conditions. Lipid lowering, anticoagulant and antihypertensive 
drugs are effective at reducing incidence of stroke and TIA;2-5 however, may be underused in 
primary care.6-8 The extent of missed opportunities for primary prevention prior to stroke or 
TIA in the UK is unknown. This chapter presents the protocol for a study which aims to 
quantify the proportion of strokes and TIAs with prior missed opportunities for prevention 
with lipid lowering, anticoagulant and antihypertensive drugs. The protocol describes the 
use of primary care electronic medical records extracted from the THIN database to conduct 
a retrospective analysis to identify people who had stroke and TIA prevention drugs clinically 
indicated at the time of their stroke or TIA but were not prescribed them. The findings of this 
study are presented in Chapter 4 (missed opportunities for lipid lowering drugs) and Chapter 
5 (missed opportunities for anticoagulant and antihypertensive drugs). Multiple missed 
opportunities for prevention with all three drugs are presented in Chapter 5. 
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ABSTRACT
Introduction: Stroke is a major health problem and
transient ischaemic attack (TIA) is an important risk factor
for stroke. Primary prevention of stroke and TIA will have
the greatest impact on reducing the burden of these
conditions. Evidence-based guidelines for stroke/TIA
prevention identify individuals eligible for preventative
interventions in primary care. This study will investigate:
(1) the proportion of strokes/TIAs with prior missed
opportunities for prevention in primary care; (2) the
influence of patient characteristics on missed prevention
opportunities and (3) how the proportion of missed
prevention opportunities has changed over time.
Methods and analysis: A retrospective case review will
identify first-ever stroke and patients with TIA between
2000 and 2013 using anonymised electronic medical
records extracted from the health improvement network
(THIN) database. Four categories of missed opportunities
for stroke/TIA prevention will be sought: untreated high
blood pressure in patients eligible for treatment (either
blood pressure ≥160/100 or ≥140/90 mm Hg in patients
at high cardiovascular disease (CVD) risk); patients with
atrial fibrillation with high stroke risk and no anticoagulant
therapy; no lipid modifying drug therapy prescribed in
patients at high CVD risk or with familial
hypercholesterolaemia. The proportion of patients with
each missed opportunity and multiple missed
opportunities will be calculated. Mixed effect logistic
regression will model the relationship between
demographic and patient characteristics and missed
opportunities for care; practice will be included as a
random effect.
Ethics and dissemination: THIN data collection was
approved by the NHS South East Multi-centre Research
Ethics Committee (MREC) in 2003. This study was
approved by the independent scientific review committee
in May 2013. Dissemination of findings has the potential
to change practice, improve the quality of care provided to
patients and ultimately reduce the incidence of strokes and
TIAs. Findings will be published in a peer-reviewed journal
and disseminated at national and international
conferences.
INTRODUCTION
Stroke is one of the leading causes of mortal-
ity and disability in the UK.1 Transient
ischaemic attack (TIA) is characterised by
transient stroke-like symptoms and is an
important risk factor for stroke. Given there
are approximately 110 000 ﬁrst strokes and
46 000 ﬁrst TIAs a year reported in the
UK,1 2 primary prevention is important to
reduce the burden of stroke and TIA.3
Understanding risk factors for stroke and
TIA is important to identify people at high risk
and implement preventative intervention.
Hypertension is arguably the most well-
documented risk factor; a positive and con-
tinuous relationship has been shown between
increasing blood pressure and stroke.4 5 Atrial
ﬁbrillation is associated with a ﬁvefold increase
in stroke risk.6 In addition, evidence suggests
strokes in patients with atrial ﬁbrillation are
associated with greater disability and higher
mortality rates.6 Cholesterol has been identi-
ﬁed as risk factor for stroke; however, the rela-
tionship is not well characterised and is likely
to be complex. Epidemiological studies have
observed an association between lipid levels
and stroke7 but ﬁndings are inconsistent across
studies.8 On the other hand, a systematic
review of 26 studies found a 20% reduction in
strokes with statin therapy compared with
placebo or usual care.9 Other conditions
found to increase stroke risk include diabetes
and cardiovascular disease (CVD).10 In add-
ition, lifestyle factors related to diet, obesity,
physical inactivity, smoking and alcohol intake
have been identiﬁed as risk factors for stroke
and, moreover, have been shown to interact
with other risk factors to exacerbate the risk.
For example, obesity is associated with hyper-
tension and high cholesterol.11
Age is an important risk factor; incidence
and prevalence of stroke and TIA increases
with age2 and stroke risk doubles every
decade over 55 years.12 Male sex has also
been identiﬁed as a risk factor with men
having a higher incidence of stroke com-
pared with women.13 Although the mechan-
ism is not fully understood, increased stroke
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incidence has been observed in south Asian and
Afro-Caribbean ethnic groups.14
A person’s stroke and CVD risk is determined by the
combination of different risk factors. Multivariable CVD
risk equations have been developed to identify high-risk
patients and express risk as a probability over a period of
time.15 Multiple risk equations exist, although they differ
slightly in the risk factors included, the majority include
age, sex, blood pressure, cholesterol, smoking and dia-
betes.16 Patients with atrial ﬁbrillation stroke risk is
increased by independent risk factors.17 Stroke risk algo-
rithms for these patients include the risk factors: age,
congestive heart failure, hypertension, diabetes and pre-
vious stroke or TIA.6
Primary care offers the best opportunity to identify
people at high risk of stroke and TIA and administer
preventative action. Studies have shown that pharmaco-
logical treatments reduce risk by a constant propor-
tion.18 Evidence-based guidelines relevant to stroke
prevention have been developed for hypertension, atrial
ﬁbrillation and lipid modiﬁcation. Hypertension guide-
lines advise antihypertensive drug therapy is initiated in
people with sustained blood pressure ≥160/100 mm Hg
or a lower threshold of ≥140/90 mm Hg for people with
established CVD, diabetes or an estimated CVD risk of
≥20% over 10 years.19 Atrial ﬁbrillation guidelines rec-
ommend patients’ stroke risk is assessed using an algo-
rithm and high-risk patients should be prescribed
anticoagulant therapy.6 Lipid modiﬁcation guidelines
advise lipid lowering drug therapy should be initiated in
people considered high risk as opposed to measuring
blood cholesterol levels. Guidelines regard high risk as
people with established CVD, diabetes or an estimated
CVD risk of ≥20% over 10 years and endorse prescrip-
tion of statins.16
Despite the extensive evidence-based guidelines to
reduce stroke risk, patients who present at hospital with
ﬁrst stroke have been found to have multiple untreated
or undertreated risk factors.20 Furthermore, it has been
found that some general practitioners (GPs) accept
higher blood pressure thresholds than recommended by
the guidelines21 and overestimate the proportion of
their patients with controlled blood pressure.22 Existing
studies of adherence to stroke prevention guidelines are
limited as they use hypothetical questionnaires or retro-
spective interviews, where responses may differ from
actual practice, and often focus on only one risk factor.
Considering the complexity of the risk factors for ﬁrst-
time stroke and TIA, a large-scale UK study using real-
life primary care data to examine the administration of
primary prevention is an important and necessary step
to reduce the burden of strokes and TIAs on the
National Health Service (NHS) and society.
AIMS
The study aims to investigate: (1) the proportion of ﬁrst
strokes and TIAs with prior missed opportunities for
prevention in primary care; (2) the inﬂuence of patient
characteristics on missed prevention opportunities and
(3) how proportions of missed prevention opportunities
have changed over time.
METHODS AND ANALYSIS
Study design
A retrospective case review of patients with a ﬁrst-ever
stroke or TIA.
Data source
Relevant data will be extracted from the health improve-
ment network (THIN), a large database of anonymised
UK electronic primary care records. Data are comprised
of over 500 general practices, include 11.9 million
patients and cover 6% of the UK population.23 The infor-
mation recorded within THIN is comprehensive and
includes demographics, diagnoses, prescriptions, add-
itional health information (eg, lifestyle factors), socio-
economic data and free-text comments. Data are coded
using drug codes which correspond to British National
Formulary (BNF) chapters24 and Read codes (V.2).25
THIN data collection was approved by the NHS South
East Multi-centre Research Ethics Committee (MREC) in
2003.26
Population
Patients with stroke and TIA between 2000 and 2013 will
be identiﬁed and relevant data extracted from the THIN
database. This study will investigate primary prevention
of stroke and TIA; therefore, will comprise of patients
with ﬁrst-ever stroke and TIA. However, as TIA is a risk
factor for stroke, patients will be categorised into three
groups: stroke only, TIA only, stroke with a history of
TIA. To exclude childhood stroke, only patients with a
diagnosis of stroke or TIA over 18 years will be included
in the study. Date of stroke or TIA will be taken as the
index date, and patients must be registered for at least
1 year prior to the index date to allow sufﬁcient time for
risk factor data to be recorded. To ensure data quality,
the index date must occur at least 1 year after the prac-
tice had begun using Vision software, and after the prac-
tice date of acceptable mortality recording, the year
mortality rates for the practice correspond to expected
regional mortality rates.27
Outcomes
Four missed opportunities for primary stroke and TIA
prevention have been deﬁned through consulting rele-
vant guidelines6 16 19 and encompass the risk factors
hypertension, atrial ﬁbrillation and dyslipidaemia. The
missed opportunities will be deﬁned as:
1. Untreated high blood pressure: Patients with an average
of three blood pressure recordings ≥160 mm Hg for
systolic or ≥100 mm Hg for diastolic but no antihy-
pertensive medication has been prescribed.
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2. Untreated moderately high blood pressure and at high CVD
risk: Patients with an average of three blood pressure
recordings ≥140 mm Hg for systolic or ≥90 mm Hg
for diastolic and have a history of coronary heart
disease (CHD), peripheral arterial disease (PAD),
chronic kidney disease (CKD), diabetes mellitus and
over 40 years or an estimated CVD risk of ≥20% over
10 years but no antihypertensive medication has been
prescribed.
3. Atrial ﬁbrillation and at high risk of stroke with no anti-
coagulant therapy prescribed: Patients with atrial ﬁbrilla-
tion and a CHADS2 score ≥1 but no anticoagulant
medication prescribed.
4. Patients at high CVD risk or with familial hypercholesterol-
aemia and no lipid-modifying drug therapy prescribed:
High CVD risk will be deﬁned as having a history of
CHD, PAD, CKD, diabetes mellitus and over 40 years
or an estimated CVD risk of ≥20% over 10 years.
Definition of outcomes and variables
Stroke/TIA
A comprehensive list of stroke and TIA Read codes has
been developed to identify the eligible population (see
online supplementary appendix 1). A systematic search
strategy was conducted to ensure all relevant Read codes
were included:
1. Quality Outcomes Framework (QOF)28 stroke and
TIA Read codes were reviewed for relevance to the
study’s eligibility criteria. To capture ﬁrst stroke and
TIA, Read codes relating to history of stroke or TIA
were removed.
2. To identify additional Read codes not included in
QOF, we conducted a hierarchy screening of QOF
stroke and TIA Read codes and key word searches
using STATAV.12 (College Station, Texas, USA).
3. Literature was searched for additional Read codes
and a clinician was consulted.
Missed opportunities variables
To identify patients with blood pressure ≥160/100 or
≥140/90 mm Hg, the average of the three most recent
systolic and diastolic blood pressure recordings within
3 years prior to the index date will be used. Diagnoses of
atrial ﬁbrillation, CHD, CKD, diabetes mellitus and PAD
will be identiﬁed using QOF Read codes (V.27).28 In
addition, where present, Read codes indicating history
of diagnosis will be used. Similarly, where available, we
have identiﬁed ‘resolved’ Read codes (eg, 212H.00 dia-
betes resolved), which will be used to indicate if the con-
dition resolved before the index date (see online
supplementary appendix 2). Familial hypercholesterol-
aemia is poorly coded in primary care but is associated
with total cholesterol of ≥9 mmol/L.29 Therefore, in
addition to Read codes for familial hypercholesterol-
aemia, total cholesterol of ≥9 mmol/L (most recent
record prior to index date) will be used to indicate
familial hypercholesterolaemia.
A missed opportunity will be identiﬁed if a patient was
eligible for primary prevention drug therapy but was not
on relevant treatment at the time of stroke or TIA. To
determine if patients were on antihypertensive, anti-
coagulant or lipid-modifying drug therapies before their
stroke or TIA, the most recent prescriptions for these
drugs prior to the index date will be extracted.
Prescriptions will be identiﬁed using drug codes corre-
sponding to relevant BNF chapters (V.67) and relevant
Read codes (eg, 66Q..11, anticoagulant monitoring; see
online supplementary appendix 3). In primary care,
90 days is the maximum prescribing length for any treat-
ment. Therefore, a missed opportunity will be recorded
when patients were eligible for treatment but their most
recent prescription was over 90 days from the index date
and consequently were not on treatment at the time of
stroke or TIA. However, prescribing anticoagulant
therapy usually involves referral to an anticoagulant
clinic; to account for this, an additional lag period of
30 days will be allowed for anticoagulant prescribing (ie,
120 days from the index date). The length of the lag
period was determined though consultation with eight
practising GPs.
The Framingham risk equation will be used to calcu-
late CVD risk over 10 years (table 1). This risk equation
was chosen as it can be incorporated within Vision, the
electronic system used by general practices that contrib-
ute to the THIN database. In addition, it was the risk
score recommended by the guidelines during the major-
ity of the study period16 and the equation is freely avail-
able. For consistency, the Framingham CVD risk will be
calculated at the index date for all eligible patients and
in accordance with Vision calculations.30 As recom-
mended by the guidelines, the Framingham CVD risk
will be adjusted for South Asian ethnicity and family
history of premature CHD.16 The CHADS2 score will be
used to determine stroke risk for patients with atrial
Table 1 Variables required for the Framingham
cardiovascular disease risk equation
Variable Criteria
Default
value
Age* 30–74 †
Sex Male/female †
Systolic blood
pressure
Most recent record prior
to index date
†
Total cholesterol Most recent record prior
to index date
6.0
HDL cholesterol Most recent record prior
to index date
Female:
1.4
Male: 1.15
Smoking Yes/no
Diabetes mellitus Yes/no
ECG-LVH Yes/no
*Age at index date.
†Mandatory field.
HDL, high-density lipoprotein; LVH, left ventricular hypertrophy.
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ﬁbrillation (table 2). Similar to the Framingham risk
equation, CHADS2 will be used because it can be incor-
porated within Vision and it will be calculated at the
index date in compliance with Vision calculations.
Predictor variables
Sociodemographic variables will be extracted including
Townsend deprivation quintiles,31 urban rural scores,31
strategic health authority32 and ethnicity. Comorbidities
will be identiﬁed and deﬁned by QOF Read codes
(QOF business rules V.27; see online supplementary
appendix 2).33 To document patients’ contact with
primary care before their stroke or TIA, the number of
consultations in the year prior to the index date and
length of registration will be extracted for each patient.
In addition, Read codes indicating exceptions for initiat-
ing stroke prevention drug therapy will be extracted
including white coat hypertension and contraindications
to prescribing antihypertensive, anticoagulant or lipid-
modifying drugs (eg, 8I3N.00, hypertension treatment
refused; see online supplementary appendix 4).
Predictor variables encompassing modiﬁable and non-
modiﬁable risk factors for stroke and TIA will be
extracted. Non-modiﬁable risk factors include sex and
age at index date, whereas modiﬁable risk factors relate
to lifestyle: body mass index (BMI), smoking and
alcohol intake. GPs initiating lifestyle interventions has
been reported to delay initiation of antihypertensive
drug therapy by up to 12 months;21 therefore, we have
also identiﬁed Read codes indicating lifestyle interven-
tions related to smoking, alcohol intake, diet, exercise
and weight (see online supplementary appendix 5).
Quality checks, missing data and extreme values
Absence of a diagnosis code will be taken to indicate the
diagnosis is not present. For categorical variables (eg,
smoking status), a separate ‘missing’ category will be
created. Extreme values for blood pressure, total and high-
density lipoprotein cholesterol, height and BMI will be
identiﬁed using the ranges seen in the Health Survey for
England statistics as a guide34 and excluded. Incidence of
stroke and TIA diagnoses will be investigated over time to
check for indication of unusual variation which might indi-
cate incorrect clinical coding. If appropriate, a cut-off date
will be introduced for quality of reporting.
Analysis
The primary analysis will calculate the proportion of
strokes and TIAs with missed opportunities for primary
prevention drug therapy. Proportions will be calculated
for each missed opportunity: untreated high blood pres-
sure; untreated moderately high blood pressure and
high CVD risk; atrial ﬁbrillation and high risk of
stroke with no anticoagulant therapy prescribed; high
CVD risk or with familial hypercholesterolaemia and no
lipid-modifying drug therapy prescribed. In addition,
the proportion of patients with two, three or four
missed opportunities will be calculated.
Secondary analysis will comprise of multivariable
logistic regression modelling to predict the effect of
demographic and patient characteristics on missed
opportunities. The logistic regression model will be
mixed effect and include practice as a random effect.
Year of stroke will be included to investigate how missed
opportunities have changed over time. We aim to
develop a model that ﬁts the data well, is biologically
meaningful and can be meaningfully interpreted. To
achieve this, explanatory variables will be entered into
the logistic regression model which have been prespeci-
ﬁed and informed through literature searches and clin-
ical input (table 3). There is compelling evidence from
the literature that age and sex are important predictors
of non-adherence to guidelines in primary care;21 35 36
therefore, these variables will be included in the model
regardless of statistical contribution. Although the other
prespeciﬁed variables have been informed through the
literature and clinical advice, the evidence is limited; for
that reason, a backwards elimination approach will be
adopted to inform model selection. Backwards elimin-
ation will be used as it is favourable over forwards or
stepwise selection.37 Traditionally, a p value of >0.1–0.2 is
used as a criteria to eliminate variables. However, our
sample size is expected to be large and consequently we
will use a p-to-eliminate value of >0.05. Exploratory ana-
lysis will be conducted to explore the relationship of the
effect of consultation frequency in the year prior to the
index date and duration of registration on missed oppor-
tunities for stroke and TIA prevention.
DISCUSSION
This study will quantify the proportion of patients in
whom opportunities to prevent strokes and TIAs were
missed. In addition, it will identify the risk factors with the
highest proportion of untreated patients. The results of
the regression model will be important to provide insight
into patient characteristics that predict missed prevention
opportunities. Dissemination of these ﬁndings to GPs will
raise awareness of patients who are vulnerable to not being
prescribed relevant stroke and TIA prevention pharmaco-
therapy when eligible. Furthermore, the ﬁndings have the
potential to change practice and improve patient care.
The strength of this study is that data are available from
over 500 general practices and reﬂect actual practice.
Table 2 Variables required for the CHADS2 stroke risk
equation for patients with atrial fibrillation
Variable Points
C Congestive heart failure 1
H Hypertension 1
A Age ≥75 years 1
D Diabetes mellitus 1
S2 Prior stroke or TIA 2
TIA, transient ischaemic attack.
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However, the data will be extracted from routinely col-
lected electronic medical records and, therefore, does
not capture the decision-making process which occurs
during a consultation. For instance, patients’ preferences
and GPs knowledge of patient’s adherence to medica-
tion.38 Although our study will include comorbidities in
the regression model and report Read codes which indi-
cate contraindications for medications, there may be
other legitimate reasons for not prescribing stroke pre-
vention drug therapy and patients might decline antihy-
pertensive, anticoagulant or lipid-lowering drug therapy.
Inevitably, there will be missing data and errors in data
entry; however, this is expected to be a small proportion
of the population and we will exclude extreme values and
incorporate missing data as a category in the analysis.
The use of QOF Read codes to identify comorbidities is
likely to result in missing diagnoses that have been
recorded using alternative Read codes. However, the use
of QOF Read codes provides a consistent method to iden-
tify diagnoses and, since being introduced, GPs are incen-
tivised to use QOF Read codes.
In conclusion, this study will offer an insight into
whether stroke and TIA risk factors are being managed
adequately in UK primary care. Primary prevention of
stroke and TIA is important to reduce the burden of
these conditions on the NHS and society. If optimal
rates of prevention are not being delivered in primary
care, dissemination of our ﬁndings will be important
and further research should be conducted to identify
barriers to guideline adherence and intervention(s) to
overcome these.
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Missed opportunities for prevention of 
stroke or TIA with lipid lowering drugs 
Dyslipidaemia is an important modifiable risk factor for stroke and TIA,1 but can be targeted 
through intervention with lipid lowering drugs to reduce the incidence of stroke and TIA.2 
This chapter presents the findings of the retrospective analysis of primary care electronic 
medical records described in Chapter 3 for the lipid lowering drugs analysis. The aims were 
to determine: (i) the proportion of strokes and TIAs with prior missed opportunities for 
prevention with lipid lowering drugs; (ii) the relationship between patient and demographic 
characteristics and the probability of having a missed opportunity; and (iii) how the 
proportion of missed opportunities for prevention with lipid lowering drugs has changed 
over time. 
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Abstract 
Importance 
There are estimated to be 16.9 million strokes annually worldwide, making it a leading cause 
of death and disability. Lipid lowering therapy in eligible patients can prevent strokes, but 
these drugs may be underused. The scale of missed opportunities for prevention with lipid 
lowering drugs prior to stroke is unknown. 
Objective 
To determine the proportion of patients with a missed opportunity for prevention with lipid 
lowering drugs prior to a stroke or TIA. 
Design 
Analysis of anonymised electronic primary care records from the United Kingdom (UK) 
between 2009 and 2013. 
Setting 
556 general practices in the UK providing data to The Health Improvement Network (THIN), 
a primary care database which includes 3.6 million current patients and 8.8 million former or 
deceased patients and covers approximately 6% of the UK population. 
Participants 
29,043 patients with a diagnosis of first-stroke and/or TIA between 1st January 2009 and 31st 
December 2013 who were aged ≥18 years at the time of the event. 
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Main outcome 
The proportion of strokes/TIAs with a prior missed opportunity for prevention with lipid 
lowering drugs. A missed opportunity was when lipid lowering drugs were clinically indicated 
but not prescribed at the time of stroke/TIA.  
Results 
Of the 29,043 stroke/TIA patients included, 16,028 of these were eligible for lipid lowering 
drugs. However, 49% (7,836/16,028) of eligible patients were not prescribed lipid lowering 
drugs at the time of stroke/TIA. 
Conclusions and relevance 
Almost half of eligible patients were not prescribed lipid lowering drugs prior to stroke/TIA in 
this population where coverage of primary care is nearly complete. Extrapolating our results 
to the UK stroke incidence in people ≥35 years, we estimate that at least 9,300 first strokes 
could potentially be prevented annually by prescribing all eligible patients lipid lowering 
drugs. Improving prescription of these drugs is important to reduce the burden of 
stroke/TIA. 
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Introduction 
Stroke is a leading cause of death and disability worldwide with an estimated annual 
incidence of 16.9 million first-strokes and 6 million stroke-related deaths.1 Although the age-
standardised incidence rates have decreased over the past two decades, the absolute 
numbers of strokes and stroke-related deaths and disability have increased due to the 
ageing population.1 Transient ischaemic attack (TIA) is an important risk factor for stroke.2 
Primary prevention through targeted intervention of modifiable risk factors3-5 can reduce the 
global burden of stroke and TIA. 
Dyslipidaemia is one of the leading contributors to stroke and TIA worldwide6 and lipid 
lowering drugs significantly reduce stroke incidence.7,8 Evidence-based guidelines 
recommend lipid lowering drugs for people with existing cardiovascular disease (CVD) or 
those at high CVD risk.4,9,10  
Despite evidence-based guidelines, research suggests that prescribing of primary prevention 
lipid lowering drugs is suboptimal in primary care;11-13 however, there is no quantitative 
estimate of the size of missed opportunities prior to stroke or TIA. Our objectives were to 
determine in a large database covering approximately 6% of the United Kingdom (UK) 
population: (i) the proportion of patients with a missed opportunity for lipid lowering drug 
prevention therapy prior to a stroke or TIA; (ii) the relationship between 
patient/demographic characteristics and the probability of a stroke or TIA patient having a 
prior missed opportunity; and (iii) how the proportion of missed opportunities for 
prevention with lipid lowering drugs has changed over time. 
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Methods 
The full protocol for this study has been published elsewhere,14 methods are summarised in 
brief below. 
Study design and data source 
The study analysed routine electronic primary care medical records from The Health 
Improvement Network (THIN) database.15 This is a large database of anonymised UK 
electronic primary care records extracted from general practices using Vision patient records 
software. The database covers approximately 6% of the UK population, including 3.6 million 
current patients and 8.8 million former or deceased patients.16 Analysis of the THIN 
database has ethical approval from the National Health Service (NHS) South-East Multi-
centre Research Ethics Committee subject to independent scientific review.17 This study was 
approved by a Scientific Review Committee (SRC) (reference: 13-023). 
Population 
The study population comprised of patients with a diagnosis of first-stroke and/or TIA 
between 1st January 2009 and 31st December 2013 who were aged 18 years and over at the 
time of the event. Patients were categorised with a diagnosis of: (i) stroke only, (ii) TIA only, 
or (iii) stroke with previous TIA. The date of first stroke or TIA was taken as the index date. 
To ensure data quality and that important patient outcomes were being recorded 
consistently, the index dates had to occur at least one year after the practice began using 
Vision patient record software and after the practice date of acceptable mortality 
recording.18 Only patients registered at a practice for at least one year were included to 
allow sufficient time for risk factor data to be recorded. 
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Outcomes 
Patients were categorised as eligible or ineligible for lipid lowering drugs using the most 
recent risk factor data prior to their stroke or TIA. A missed opportunity for prevention was 
recorded when eligible patients had not received a prescription for lipid lowering drugs up to 
90 days before their stroke or TIA (the usual maximum prescription length in the UK) or had 
no clinical code indicating the patient was on lipid lowering drugs. Patients were eligible for 
lipid lowering medication if they had a history of coronary heart disease (CHD); chronic 
kidney disease (CKD); peripheral arterial disease (PAD); TIA (in stroke patients with prior 
TIA); diabetes mellitus and aged over 40 years;  a 10-year CVD risk of ≥20% estimated by the 
adjusted Framingham risk equation; or familial hypercholesterolemia. These eligibility 
criteria were based on UK national guidelines used during the study period.19,20 A sensitivity 
analysis explored the effect of using the QRISK2-2014 equation instead of the Framingham 
equation to reflect updated recommendations of the 2014 UK guidlines.4 Familial 
hypercholesterolemia was defined as having a clinical code for the diagnosis or total 
cholesterol of ≥9mmol/L.21 
Definition of outcomes and variables 
A comprehensive list of clinical codes (Read codes)22 for stroke and TIA was used to identify 
the study cohort. Comorbidities were defined by the standard list of clinical codes used to 
identify chronic diseases for the UK chronic disease monitoring programme (Quality and 
Outcomes Framework (QOF) business rules version 2723) and, where present, ‘history of’ or 
‘resolved’ clinical codes were extracted. Patients with a clinical code indicating history of 
stroke or TIA recorded before a clinical code for stroke or TIA were excluded as their true 
index date could not be identified. Socio-demographic and patient characteristics were also 
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extracted.14 Drug prescriptions corresponding to British National Formulary (BNF) chapter 
2.12 (v67)24 for lipid lowering drugs and clinical codes indicating that the patient was on lipid 
lowering drugs were extracted to identify treated patients. 
Quality checks, missing data and extreme values 
Absence of a clinical code for an individual diagnosis prior to the index date was taken to 
indicate the diagnosis was not present at the index date. Missing data were not imputed; 
however, a separate ‘missing’ category was created for categorical predictor variables if 
there was no value recorded prior to the index date because patients with variables 
recorded systematically differ from those with missing data.25 Clinically implausible values 
were excluded for blood pressure, height, weight, body mass index (BMI), total cholesterol, 
and high density lipoprotein (HDL) cholesterol based on pre-specified cut-off values (eTable 
1 in the Supplement). If no clinically plausible values were recorded at any time prior to the 
index date, the variable was categorised as missing. Data were initially extracted between 
2000 and 2013; however, crude incidence of recorded stroke and TIA before 2008 was less 
than 15% of recorded stroke and TIA incidence after 2009 (eFigure 1 in the Supplement). 
After 2009, recorded incidence was more stable; therefore, only strokes and TIAs which 
occurred from the 1st January 2009 were included. 
Analysis 
All analysis was conducted using STATA version 12 (StataCorp, College Station, Texas). 
Patients were categorised as having a stroke, TIA, or stroke with previous TIA. The 
proportion of patients with a missed opportunity for lipid lowering drug therapy was 
calculated for each group and the difference between groups tested using Pearson’s Chi 
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squared. The relationship between patient/demographic characteristics (eTable 2 in the 
Supplement) and having a missed opportunity was evaluated using mixed-effects logistic 
regression, with general practice as a random effect and odds ratio (OR) reported. Age and 
sex were forced into the model because they were pre-identified as important predictors of 
undertreatment.26-28 Year of stroke/TIA was included as a covariate in the regression model 
to investigate change over time. Backwards elimination with a p-to-eliminate value of >0.05 
was used to select variables to be included in the final model. Exploratory analyses were 
conducted (see the online Supplement). 
Results 
During the study period, 29,043 stroke and TIA patients met the inclusion criteria; of these, 
55% (16,028/29,043) were eligible for lipid modification therapy at the time of their stroke 
or TIA. Their median age was 75 years (IQR 67,83) and 56% were male (Table 1). Fifty-three 
percent of patients had experienced a stroke, 32% a TIA, and 15% a stroke with previous TIA. 
Only 5% (869/16,028) of patients eligible for lipid lowering drugs had a clinical code 
indicating these drugs were declined, contraindicated or there was an adverse reaction. 
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Table 1: Descriptive characteristics of patients eligible (n=16,028) and ineligible (n=13,015) 
for lipid lowering prevention drugs prior to stroke or transient ischaemic attack (TIA). 
     Eligible   
   Patients 
  Ineligible  
  Patients 
  Frequency (%) Frequency (%) 
Total  16,028  (100) 13,015 (100) 
Age (years) <45      115   (0.7)    997   (7.7) 
 45-49      221   (1.4)    723   (5.6) 
 50-54      494   (3.0)    919   (7.0) 
 55-59      811   (5.1)    954   (7.3) 
 60-64   1,489   (9.3)      1,097   (8.4) 
 65-69   2,049 (12.8) 1,193   (9.2) 
 70-74   2,638 (16.5) 1,083   (8.3) 
 75-79   2,329 (14.5) 2,069 (15.9) 
 80-84   2,514 (15.7) 1,791 (13.8) 
 85-89   2,068 (12.9) 1,293   (9.9) 
 90-94   1,012   (6.3)    665   (5.1) 
 ≥95      288   (1.8)    231   (1.8) 
Sex Male   8,941 (55.8) 5,263 (40.4) 
 Female   7,087 (44.2) 7,752 (59.6) 
BMI Healthy (18.5-25.9 kg/m2)   4,655 (29.1) 4,548 (34.9) 
 Underweight (<18.5 kg/m2)      339   (2.1)    373   (2.9) 
 Overweight (26-30 kg/m2)   5,995 (37.4) 4,293 (33.0) 
 Obese (>30 kg/m2)   4,172 (26.0) 2,442 (18.8) 
 Missing      867   (5.4) 1,359 (10.4) 
Smoking 
status 
Non   3,927 (24.5) 2,410 (18.5) 
Ex   7,910 (49.0) 7,180 (55.2) 
 Current   3,716 (23.3) 2,521 (19.4) 
 Missing      475   (3.2)    904   (6.9) 
Rurality Urban   5,997 (37.4) 4,881 (37.5) 
 Rural 10,021 (62.5) 8,128 (62.5) 
 Missing         10   (0.1)         6   (0.0) 
Deprivation 1 (least deprived)   3,709 (23.2) 3,242 (24.9) 
 2   3,497 (21.8) 3,085 (23.7) 
 3   3,210 (20.0) 2,685 (20.6) 
 4   3,047 (19.0) 2,201 (16.9) 
 5 (most deprived)   2,187 (13.6) 1,486 (11.4) 
 Missing      378   (2.4)    316   (2.5) 
Continued on next page 
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Table 1 continued from previous page   
     Eligible   
   Patients 
  Ineligible  
  Patients 
Comorbidity Atrial fibrillation   2,392 (14.9) 1,152   (8.9) 
 Asthma   1,724 (10.8) 1,338 (10.3) 
 Cancer   1,911 (11.9) 1,328 (10.2) 
 CHD   5,543 (34.6)         0   (0.0) 
 CKD   5,774 (36.0)         0   (0.0) 
 COPD   1,470   (9.2)     728   (5.6) 
 Dementia      737   (4.6)     533   (4.1) 
 Depression   3,420 (21.3) 2,754 (21.2) 
 Diabetes   4,486 (28.0)       26   (0.2) 
 Epilepsy      287   (1.8)     327   (2.5) 
 Familial 
hypercholesterolemia 
        95  (0.6)         0   (0.0) 
 Heart failure   1,338   (8.3)     287   (2.2) 
 Hypertension   9,666 (60.3) 4,980 (38.3) 
 Hypothyroidism   1,724 (10.8) 1,166   (9.0) 
 Learning disability         54   (0.3)       76   (0.6) 
 Osteoporosis   1,265   (7.9) 1,053   (8.1) 
 PAD   1,431   (8.9)         0   (0.0) 
 Palliative care      223   (1.4)     136   (1.0) 
 Psychosis      262   (1.6)     177   (1.4) 
 Rheumatoid arthritis      394   (2.5)     261   (2.0) 
CVD Risk  ≥20% over 10 years   3,902 (24.3)         0   (0.0) 
BMI: Body Mass Index, CHD: Coronary Heart Disease, CKD: Chronic Kidney Disease, 
COPD: Chronic Obstructive Pulmonary Disease, CVD: Cardiovascular Disease, PAD: 
Peripheral Artery Disease 
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Proportion of missed opportunities 
The proportion of stroke and TIA patients with a missed opportunity for lipid lowering drug 
prevention therapy was 49% (7,836/16,028). There were statistically significant differences 
(p=<0.01) in the proportions of missed opportunities in patients with stroke (51%), TIA 
(46%), and stroke with previous TIA (50%) (Table 2). 
 
Table 2: Proportion of stroke and transient ischaemic attack (TIA) patients with a missed 
opportunity for prevention with lipid lowering drugs. 
Diagnosis 
Missed opportunities 
Frequency (%) 
Stroke only (n=8,464) 4,276 (50.5) 
TIA only (n=5,212) 2,387 (45.8) 
Stroke with previous TIA (n=2,352) 1,173 (49.9) 
Total (n=16,028) 7,836 (48.9) 
 
 
Demographic and patient characteristics associated with having a missed 
opportunity 
The results of the multivariable logistic regression model are presented in Table 3. With age 
75-79 years (median age) as the reference category, there was a J-shaped relationship 
between age and proportion of missed opportunities, which were markedly more frequent 
in both older and younger age groups (Figure 1). Sex was not significantly associated with 
having a missed opportunity but remained in the model as pre-specified. 
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The odds of having a missed opportunity were more than halved in stroke and TIA patients 
with a diagnosis of CHD or diabetes and significantly reduced in patients with a diagnosis of 
PAD, CKD, or hypertension. Stroke and TIA patients receiving palliative care had more than 
twice the odds of having a missed opportunity. With healthy BMI (18.5-25.9 kg/m2) as the 
reference category, both BMI <18.5 kg/m2 (underweight) and missing BMI were associated 
with increased odds of having a missed opportunity, whereas BMI 26-30 kg/m2 (overweight) 
and BMI >30 kg/m2 (obese) were associated with decreased odds. Being a current smoker 
and having no record of smoking status were associated with increased odds of having a 
missed opportunity. There was no association between area deprivation score and the odds 
of having a missed opportunity; however, there were statistically significant regional 
differences with stroke and TIA patients in Wales and Northern Ireland less likely to have a 
missed opportunity (West Midlands region of England as reference). Administration of 
lifestyle interventions for smoking or weight was associated with reduced odds of having a 
missed opportunity. There was no statistically significant change in the proportion of missed 
opportunities between 2009 and 2013, and the remaining predictor variables were non-
significant and excluded from the model (eTable 2 in the Supplement). Results for 
exploratory analyses are presented in the online Supplement. 
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Figure 1: Adjusted odds ratios for effect of age on having a missed opportunity for 
prescription of lipid lowering drugs, in eligible patients, prior to stroke or transient 
ischaemic attack (TIA), with age 75-79 years as the reference category. 
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Table 3: Adjusted* odds ratios for effects of patient and demographic characteristics on 
having a missed opportunity for prescription of lipid lowering drugs, in eligible patients, 
prior to stroke or transient ischaemic attack (TIA). 
  Odds 
Ratio 
95% CI P value 
Age (years) <45 2.34 1.46, 3.74 <0.01 
 45-49 1.11 0.83, 1.47   0.48 
 50-54 1.50 1.21, 1.86 <0.01 
 55-59 1.36 1.13, 1.64 <0.01 
 60-64 1.28 1.10, 1.50 <0.01 
 65-69 1.27 1.10, 1.47 <0.01 
 70-74 1.08 0.94, 1.24   0.26 
 75-79 1.00  
 80-84 1.30 1.13, 1.48 <0.01 
 85-89 1.63 1.42, 1.86 <0.01 
 90-94 3.14 2.61, 3.78 <0.01 
 ≥95 7.11 4.93, 10.26 <0.01 
Sex Male 1.00   
 Female 0.96 0.89, 1.04   0.28 
Comorbidity CHD 0.21 0.19, 0.22 <0.01 
 CKD 0.86 0.79, 0.94 <0.01 
 PAD 0.52 0.45, 0.60 <0.01 
 Diabetes 0.31 0.28, 0.33 <0.01 
 Hypertension 0.69 0.64, 0.75 <0.01 
 Palliative care 2.48 1.83, 3.34 <0.01 
BMI Healthy (18.5-25.9 kg/m2) 1.00   
 Underweight (<18.5 kg/m2) 1.93 1.45, 2.57 <0.01 
 Overweight (26-30 kg/m2) 0.89 0.81, 0.97   0.01 
 Obese (>30 kg/m2) 0.79 0.72, 0.88 <0.01 
 Missing 1.58 1.32, 1.88 <0.01 
Smoking Non-smoker 1.00   
 Current 1.40 1.21, 1.61 <0.01 
 Ex 1.08 0.98, 1.19   0.12 
 Missing 1.65 1.31, 2.07 <0.01 
Region West Midlands 1.00   
 Yorkshire & Humber 0.95 0.72, 1.25   0.72 
 North West 0.85 0.70, 1.05   0.13 
 East Midlands 1.01 0.81, 1.25   0.93 
 North East 0.85 0.65, 1.13   0.26 
Continued on next page 
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  Odds 
Ratio 
95% CI P value 
Region East of England 0.94 0.75, 1.18   0.59 
 London 0.84 0.70, 1.02   0.07 
 South East Coast 0.87 0.73, 1.05   0.16 
 South Central 1.01 0.86, 1.20   0.87 
 South West 1.00 0.96, 1.18   0.96 
 Northern Ireland 0.72 0.59, 0.88 <0.01 
 Scotland 0.92 0.78, 1.09   0.34 
 Wales 0.72 0.59, 0.89 <0.01 
 Missing 0.80 0.47, 1.37   0.42 
Lifestyle 
intervention 
Smoking 0.76 0.68, 0.84 <0.01 
Weight 0.78 0.67, 0.91 <0.01 
*Each odds ratio is adjusted for the other variables in the table. 
BMI: Body Mass Index, CHD: Coronary Heart Disease, CI: Confidence Intervals, CKD: 
Chronic Kidney Disease, PAD: Peripheral Artery Disease 
 
 
 
 
 
 
 
 
 
 
Table 3 continued from previous page 
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Discussion 
Half of eligible patients were not prescribed lipid lowering drugs prior to first-stroke or TIA. 
There was no association between missed opportunities for prevention with lipid lowering 
drugs and sex, but there was a J-shaped relationship with age. Missed opportunities were 
more common in people who were underweight, smokers, were receiving palliative care or 
lived in Wales or Northern Ireland (compared to the West Midlands in England). In contrast, 
missed opportunities were less common in people who were overweight or obese or had a 
diagnosis of CHD, CKD, diabetes, PAD or hypertension. There was no change in the 
proportion of missed opportunities between 2009 and 2013.  
Stroke is a global issue; the most recent Global Burden of Disease study29 found stroke was 
the third leading cause of years of life lost (YLL) worldwide. Furthermore, the absolute 
number of first-strokes, stroke related deaths and disability-adjusted life-years (DALYs) has 
increased worldwide over the last two decades.30 Primary prevention of stroke and TIA is, 
therefore, important to reduce the burden of these conditions. We extrapolated our findings 
using estimates of UK population,31 stroke incidence32 and relative risk reduction of statins8 
to determine the potential impact of improving prescribing of lipid lowering drugs on stroke 
prevention in the UK. We estimate that in people aged 35 years and over, approximately 
9,300 strokes could be prevented in the UK each year by prescribing lipid lowering drugs to 
all eligible patients (eTable 5 in the Supplement). Lipid lowering drugs are often more 
commonly associated with CHD prevention; however, these estimates demonstrate the 
potential impact of improving prescription of lipid lowering drugs in the context of stroke 
prevention. UK primary care aims to provide universal access, free at the point of delivery 
and, in international comparisons, financial barriers to care are very low.33 Missed 
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opportunities are likely to be lower in such a system compared to countries with restricted 
access or barriers to primary health care. Stroke incidence rates and burden are higher in 
low- and middle-income countries compared to high-income countries,34 which may reflect 
disparities in prevention therapy. Therefore, the potential of improving the prescribing of 
stroke prevention drugs is likely to be even greater in these countries compared to the UK. 
We found that a diagnosis of CHD, CKD, PAD, diabetes, or hypertension was associated with 
reduced odds of having a missed opportunity. In the UK, there are incentives to include such 
patients on a chronic disease register which might promote better management in terms of 
stroke prevention. Furthermore, exploratory analysis found patients with high CVD risk but 
without comorbid CVD had a 3-fold increase in odds of having a missed opportunity (see the 
online Supplement). This suggests that inclusion on a disease register was more strongly 
associated with lipid lowering drug prescribing rather than calculated CVD risk. Underweight 
patients were also less likely to be treated, whereas, overweight, or obese patients were 
more likely. This finding is more consistent with lay epidemiology (the concept of lay 
perception of health risk) than clinical epidemiology.35 
Lipid lowering drugs are second to antihypertensive drugs as the most common drugs 
prescribed for CVD prevention;36 in 2013 there were 78.8 million prescriptions for lipid 
lowering drugs in the UK.37 Statin drugs account for the majority of lipid lowering drugs 
prescribed38 and prescription of statins has increased over the past decade.39 Despite this, 
there is controversy regarding administration of statins for primary stroke prevention. Fears 
about side effects and polypharmacy, particularly in the elderly, have been highlighted as 
reasons for GPs not prescribing statins.40 Medicalisation of “healthy” patients and concerns 
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that pharmacotherapy would discourage patients from participating in lifestyle interventions 
have also been identified as barriers for GPs prescribing statins.41 In addition, there is a lack 
of evidence for the benefits of statin prescribing in the very elderly.42 However, statins have 
been found to be effective at reducing incidence of stroke8 and statin-induced side effects 
are likely to be less frequent than originally thought.43 The most recent updated lipid 
guideline recommendations4,10 increase the number of people eligible for statin drug 
therapy, which has further fuelled concerns regarding medicalisation of the population. On 
the other hand, Wu et al (2013) found that over half of their sample who were prescribed 
lipid lowering drugs were ineligible.44 Therefore, improving lipid lowering drug prescribing in 
eligible people may reduce the number of unnecessary prescriptions without substantially 
increasing the number of people taking lipid lowering drugs. 
The strengths of this study are that the dataset is representative of UK general practice and 
the data are recent. Prescribing data are comprehensively recorded and the sample size is 
very large. Stroke and the main comorbidities are likely to be accurately recorded as they are 
clinically significant and, in the UK, GPs are incentivised to keep a register of patients with 
these conditions; however, TIA may be misclassified.45 Furthermore, restricting the 
definition of comorbidities to QOF clinical codes may result in diagnoses being missed if they 
were recorded using alternative clinical codes. Patients with a clinical code indicating lipid 
lowering drugs were declined, contraindicated, or there was an adverse reaction were not 
excluded from the analysis; however, we reported this descriptively. The Framingham 
equation was used in our primary analysis because this was in use during the early part of 
the period of interest. In more recent years the Framingham equation has been superseded 
by QRISK2; therefore, in a sensitivity analysis we explored impact of using QRISK2-2014 over 
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the Framingham equation to calculate 10-year CVD risk. In addition to non-prescribing, 
patients’ non-adherence to prevention drugs is an important consideration in the context of 
stroke prevention. A limitation of the dataset is that information on adherence is not 
available and prescription of lipid lowering drugs may not reflect patients’ medication taking 
behaviour. 
Future research could go beyond stroke and investigate missed opportunities for CVD 
prevention. Additional research should also investigate ineligible patients prescribed lipid 
lowering drugs to identify the patient/demographic characteristics associated with 
unnecessary prescribing. Furthermore, we found that inclusion on a disease register with 
active monitoring of performance was associated with greatly improved prevention. 
Therefore, the effects of creating a register of high CVD risk patients for primary prevention 
should be investigated. 
In conclusion, almost half of eligible patients were not prescribed lipid lowering drugs for 
primary prevention prior to stroke or TIA. Furthermore, the proportion of missed 
opportunities is likely to increase following the updated UK guideline recommendations 
where the threshold for lipid lowering therapy was reduced from a 10-year CVD risk of 20% 
to 10%.4,10 Substantial numbers of strokes and TIAs could potentially be prevented through 
improving prescription of lipid lowering drug in primary care.  
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Missed opportunities for prevention of 
stroke or TIA with anticoagulant and 
antihypertensive drugs 
In addition to dyslipidaemia, AF and hypertension are also important modifiable risk factors 
for stroke and TIA.1,2 Similar to dyslipidaemia, these risk factors can be targeted through 
intervention with anticoagulant and antihypertensive drugs, respectively, to reduce the 
incidence of stroke and TIA.3-5 This chapter presents the findings of the retrospective 
analysis of primary care electronic medical records, described in Chapter 3, for the 
anticoagulant and antihypertensive drug analysis. The aims were to determine: (i) the 
proportion of strokes and TIAs with prior missed opportunities for prevention with 
anticoagulant and antihypertensive drugs; (ii) the relationship between patient and 
demographic characteristics and the probability of having a missed opportunity; and (iii) how 
the proportion of missed opportunities for prevention with anticoagulant and 
antihypertensive drugs has changed over time. Multiple missed opportunities for prevention 
with all three drugs are presented at the end of the chapter (page 113). 
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Abstract 
Background 
Stroke is a leading cause of death and disability worldwide. Anticoagulant and 
antihypertensive drugs are effective in preventing stroke/TIA in patients with atrial 
fibrillation (AF) and hypertension, respectively; however, their use in primary care may be 
suboptimal. The objective of this study was to quantify the size of missed opportunities for 
prevention with these drugs prior to stroke/TIA. 
Methods 
Analysis of anonymised electronic primary care records from the United Kingdom (UK), 
extracted from The Health Improvement Network (THIN) database which covers 
approximately 6% of the UK population. The study included first-ever stroke/TIA patients, 
with a diagnosis between 2009 and 2013, aged ≥18 years. A missed opportunity for 
prevention was when anticoagulant or antihypertensive drugs were indicated but not 
prescribed at the time of stroke/TIA. The proportions and predictors of strokes/TIAs with a 
missed opportunity for prevention were calculated. 
Results 
29,043 stroke/TIA patients met the inclusion criteria; 3,194 patients were eligible for 
anticoagulant drugs and 7,008 for antihypertensive drugs. Missed opportunities for 
prevention were identified in 52% (1,647/3,194) of the patients eligible for anticoagulants 
and 25% (1,740/7,008) of patients eligible for antihypertensive drugs. 
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Conclusions 
Anticoagulant and antihypertensive drugs are underused for primary prevention prior to 
stroke/TIA. We estimate that, in people aged >35 years, approximately 2,900 and 3,100 first 
strokes could potentially be prevented a year in the UK through optimal prescribing of 
anticoagulant and antihypertensive drugs, respectively. Improving prescription of 
anticoagulant and antihypertensive drugs is important to reduce the incidence and burden 
of stroke and TIA. 
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Introduction 
Stroke is a leading cause of death and disability worldwide.1 The global annual incidence of 
first-ever strokes is 16.9 million and the absolute number of strokes has increased over the 
past two decades.2 Transient ischaemic attack (TIA) is characterised by short-lasting stroke-
like symptoms and is a risk factor for stroke.3 Targeting common modifiable risk factors is 
important to reduce the global burden of stroke and TIA. 
Atrial fibrillation (AF) and hypertension are two of the most important risk factors for stroke 
and TIA and have a high global prevalence of 33.5 million4 and 978 million5, respectively. 
Absolute numbers of people with each risk factor has increased over the past two 
decades.4,5 AF is associated with a five-fold increase in stroke risk and strokes in these 
patients are correlated with greater post-stroke disability and mortality.6,7 Hypertension is 
one of the most well documented risk factors for stroke and TIA and there is a positive and 
continuous relationship between blood pressure (BP) and stroke.8 Anticoagulant and 
antihypertensive drugs have been shown to be effective at reducing stroke incidence in 
patients with AF and hypertension respectively.9-11 Evidence-based guidelines recommend 
prescription of anticoagulant drugs for AF patients at high stroke risk.12,13 Antihypertensive 
drugs are recommended for people with stage 2 hypertension (BP ≥160/100 mmHg) or with 
stage 1 hypertension (BP ≥140/90 mmHg) and existing cardiovascular disease (CVD) or at 
high CVD risk.14 
Despite guideline recommendations and the evidence for the effectiveness of anticoagulant 
and antihypertensive drugs for stroke and TIA prevention, prescription of these drugs may 
be suboptimal in primary care. A systematic review (1997-2008), found non-prescribing of 
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anticoagulant drugs ranged between 19% and 81% in patients with previous stroke or TIA 
(n=29 studies) and 39% to 92% in patients with a CHADS2 score ≥2 (n=9 studies).15 
Treatment of hypertension has also been found to be variable; survey data found 
percentages of treated hypertensive patients were 51% in England, 74% in the United States 
and 80% in Canada.16 Furthermore, a systematic review identified multiple physician and 
patient barriers to hypertension treatment including those related to knowledge and 
agreement with guidelines and health system barriers, such as time and resource 
constraints.17 However, there is a lack of studies which focus on primary stroke and TIA 
prevention and quantify missed opportunities for anticoagulant and antihypertensive drug 
prescribing prior to stroke or TIA using a large sample size and recent data.  
Our objectives were to determine in a large database covering approximately 6% of the UK 
population: (i) the proportion of patients with a missed opportunity for prevention with 
anticoagulant and antihypertensive drugs prior to a stroke or TIA; (ii) the relationship 
between patient/demographic characteristics and the probability of a stroke or TIA patient 
having a prior missed opportunity; and (iii) how proportions of missed opportunities have 
changed over time. 
Methods 
The full protocol for this study has been published elsewhere,18 methods are summarised in 
brief below. 
Study design and data source 
The study analysed United Kingdom (UK) primary care data from The Health Improvement 
Network (THIN) database.19 This is a large database of anonymised, electronic primary care 
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records extracted from general practices using Vision patient records software. The database 
covers approximately 6% of the UK population, including 3.6 million current patients and 8.8 
million former or deceased patients.20 Analysis of the THIN database has ethical approval 
from the National Health Service (NHS) South-East Multi-centre Research Ethics Committee 
subject to independent scientific review.21 This study was approved by a Scientific Review 
Committee in May 2013 (reference: 13-023). 
Population 
The study population comprised of patients with a diagnosis of first-stroke and/or TIA 
between 1st January 2009 and 31st December 2013 who were aged 18 years and over at the 
time of the event. Patients were categorised with a diagnosis of: (i) stroke only, (ii) TIA only, 
or (iii) stroke with previous TIA. The date of first stroke or TIA was taken as the index date. 
To ensure data quality and that important patient outcomes were being recorded 
consistently, the index dates had to occur least one year after the practice began using 
Vision patient record software and after the practice date of acceptable mortality 
recording.22 Only patients registered at a practice for at least one year were included to 
allow sufficient time for risk factor data to be recorded. 
Outcomes 
Patients were categorised as eligible or ineligible for prevention drugs using the most recent 
risk factor data prior to their stroke or TIA. A missed opportunity for prevention was 
recorded when eligible patients had not received a prescription for antihypertensive drugs 
up to 90 days before their stroke or TIA (the usual maximum prescription length in the UK) 
or up to 120 days for anticoagulant drugs (to allow for referral to an anticoagulation clinic), 
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and had no clinical code indicating the patient was on these drugs. Patients were eligible for 
anticoagulant drugs if they had a diagnosis of AF and were at high risk of stroke (CHADS2 
score ≥1). Patients were eligible for antihypertensive medication if they had high BP 
(≥160/100 mmHg) or moderately high BP (≥140/90 mmHg) with existing CVD or high risk of 
CVD. Patients with a clinical code to indicate a diagnosis of hypertension but whose average 
BP recordings were lower than these thresholds were excluded from the analysis; therefore, 
the analysis for antihypertensive drugs focused on uncontrolled hypertension. Exiting CVD 
was defined as having a history of coronary heart disease (CHD); chronic kidney disease 
(CKD); peripheral arterial disease (PAD); TIA (in stroke patients with prior TIA); or diabetes 
mellitus and aged over 40 years. High risk of CVD was defined as having a 10-year CVD risk of 
≥20% estimated by the adjusted Framingham risk equation. These eligibility criteria were 
based on UK national guidelines used during the study period.12,14  
Definition of outcomes and variables 
A comprehensive list of clinical codes (Read codes)23 for stroke and TIA was used to identify 
the study cohort. Comorbidities were defined by the standard list of clinical codes used to 
identify chronic diseases for the UK chronic disease monitoring programme (Quality and 
Outcomes Framework (QOF) business rules version 2724) and, where present, disease-
specific ‘history of’ or ‘resolved’ clinical codes were extracted. Patients with a clinical code 
indicating history of stroke or TIA recorded before a clinical code for stroke or TIA were 
excluded as their true index date could not be identified. Socio-demographic and other non-
clinical patient characteristics were also extracted.18 Drug prescriptions corresponding to 
British National Formulary chapters (v67)25 for anticoagulant and antihypertensive drugs and 
clinical codes indicating that the patient was on one of these drugs were extracted to 
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identify treated patients. Clinical codes indicating that prevention drugs were declined or 
contraindicated, a patient had white coat hypertension or there was an adverse reaction 
were also extracted. 
Quality checks, missing data and extreme values 
Absence of a clinical code for a comorbidity diagnosis prior to the index date was taken to 
indicate that the diagnosis was not present at the index date. Missing data were not 
imputed; however, separate ‘missing’ category was created for categorical predictor 
variables if there was no value recorded prior to the index date because patients with 
variables recorded systematically differ from those with missing data.26 Clinically implausible 
values were excluded for BP, height, weight, body mass index (BMI), total cholesterol, and 
high density lipoprotein (HDL) cholesterol based on pre-specified cut-off values (Table S1 in 
the Supplementary Appendix). If no clinically plausible values were recorded at any time 
prior to the index date, the variable was categorised as missing. Data were initially extracted 
between 2000 and 2013; however, the number of incident stroke and TIA events before 
2008 was less than 15% of recorded stroke and TIA incidence after 2009 (Figure S1 in the 
Supplementary Appendix). After 2009, this was more stable; therefore, only strokes and TIAs 
which occurred from the 1st January 2009 were included. 
Analysis 
All analysis was conducted using STATA version 12 (StataCorp, College Station, Texas). 
Patients were categorised as having a stroke, TIA, or stroke with previous TIA. The 
proportions of patients with a missed opportunity for stroke and TIA prevention with 
anticoagulant or antihypertensive drugs were calculated for each group and the difference 
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between groups tested using Pearson’s Chi squared. The relationship between 
patient/demographic characteristics (Table S2 in the Supplementary Appendix) and having a 
missed opportunity was evaluated using mixed-effects logistic regression models, with 
general practice as a random effect and odds ratio (OR) reported. Age and sex were forced 
into the model because they were pre-identified as important predictors of 
undertreatment.27-29 Year of stroke/TIA was included as a covariate in the regression model 
to investigate change over time. Backwards elimination with a p-to-eliminate value of >0.05 
was used to select variables to be included in the final model. Exploratory analyses were 
conducted (see the Supplementary Appendix). 
Results 
During the study period, 29,043 stroke and TIA patients met the inclusion criteria; 3,194 
patients were eligible for anticoagulant drugs and 7,008 for antihypertensive drugs. Of the 
patients eligible for antihypertensive drugs, 2,038 had high BP (≥160/100 mmHg) and 6,272 
had moderately high BP (≥140/90 mmHg) with high CVD risk (groups not mutually exclusive). 
Descriptive characteristics of patients eligible for each prevention drug are presented in 
Table 1. Patients eligible for anticoagulant drugs had a median age of 82 years [IQR 77, 87] 
and 54% were female. For patients eligible for antihypertensive drugs, the median age was 
76 years [IQR 68, 84] and 51% were female. Seven percent (244/3,194) of patients eligible 
for anticoagulants and 0.7% (47/7,008) of patients eligible for antihypertensive drugs had a 
clinical code indicating these drugs were declined, contraindicated, there was an adverse 
reaction, or had a record of white coat hypertension (for hypertensive patients).
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Table 1: Descriptive characteristics of patients eligible and ineligible for antihypertensive and anticoagulant drugs prior to stroke or 
transient ischaemic attack (TIA). 
  Anticoagulant drugs Antihypertensive drugs 
  Eligible Ineligible                Eligible Ineligible 
  Frequency (%) Frequency (%) Frequency (%) Frequency (%) 
Diagnosis Stroke only 1,881    (58.9) 14,364    (55.6) 3,843    (54.8) 12,402    (56.3) 
 TIA only 958    (30.0) 9,488    (36.7) 2,253    (32.2) 8,193    (37.2) 
 Stroke with previous TIA 355    (11.1) 1,997      (7.7) 912    (13.0) 1,440      (6.5) 
 Total 3,194  (100.0) 25,849  (100.0) 7,008  (100.0) 22,035  (100.0) 
Age (years) <45 6      (0.2) 1,106      (4.3) 69      (1.0) 1,043      (4.7) 
 45-49 9      (0.3) 935      (3.6) 109      (1.5) 835      (3.8) 
 50-54 15      (0.5) 1,398      (5.4) 190      (2.7) 1,223      (5.6) 
 55-59 39      (1.2) 1,726      (6.7) 311      (4.4) 1,454      (6.6) 
 60-64 70      (2.2) 2,516      (9.7) 556      (7.9) 2,030      (9.2) 
 65-69 170      (5.3) 3,072    (11.9) 832    (11.9) 2,410    (10.9) 
 70-74 291      (9.1) 3,430    (13.3) 1,091    (15.6)  2,630    (11.9) 
 75-79 604    (18.9) 3,794    (14.7) 1,133    (16.2) 3,265    (14.8) 
 80-84 760    (23.8) 3,545    (13.7) 1,179    (16.8) 3,126    (14.2) 
 85-89 719    (22.5) 2,642    (10.2) 974    (13.9) 2,387    (10.8) 
 90-94 399    (12.5) 1,278      (4.9) 453      (6.5) 1,224      (5.6) 
 ≥95 112      (3.5) 407      (1.6) 111      (1.6) 408      (1.9) 
Sex Male 1,469    (46.0) 12,735    (49.3) 3,440    (49.1) 10,764    (48.8) 
 Female 1,725    (54.0) 13,114    (50.7) 3,568    (50.9) 11,271    (51.2) 
    Continued on next page 
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Table 1 continued from previous page     
  Anticoagulant drugs Antihypertensive drugs 
  Eligible Ineligible                Eligible Ineligible 
BMI* Healthy  1,108    (34.7) 8,095    (31.3) 1,953    (27.9) 7,250    (32.9) 
 Underweight  98      (3.1) 614      (2.4) 135      (1.9) 577      (2.6) 
 Overweight  1,141    (35.7) 9,147    (35. 4) 2,599    (37.1) 7,689    (34.9) 
 Obese  651    (20.4) 5,963    (23.0) 2,010    (28.7) 4,604    (20.9) 
 Missing 196      (6.1) 2,030      (7.9) 311      (4.4) 1,915      (8.7) 
Smoking 
status 
Non 886    (27.7) 5,452    (21.1) 1,626    (23.2)  4,712    (21.4) 
Ex 1,865    (58.4) 13,173    (51.0) 3,702    (52.8) 11,336    (51.4) 
 Current 335    (10.5) 5,916    (22.9) 1,487    (21.2) 4,764    (21.6) 
 Missing 108      (3.4) 1,308      (5.1) 193      (2.8) 1,223      (5.6) 
Rurality Urban 1,236    (38.7) 9,642    (37.3) 2,555    (36.5) 8,323    (37.8) 
 Rural 1,957    (61.3) 16,192    (62.6) 4,451    (63.5) 13,698    (62.1) 
 Missing 1      (0. 0) 15      (0.1) 2      (0.0) 14      (0.1) 
Deprivation 1 (least deprived) 815    (25.5) 6,136    (23.7) 1,630    (23.3) 5,321    (24.1) 
 2 763    (23.9) 5,819    (22.5) 1,582    (22.6) 5,000    (22.7) 
 3 670    (21.0) 5,225    (20.2) 1,405    (20.0) 4,490    (20.4) 
 4 528    (16.5) 4,720    (18.3) 1,323    (18.9) 3,925    (17.8) 
 5 (most deprived) 347    (10.9) 3,326    (12.9) 900    (12.8) 2,773    (12.6) 
 Missing 71      (2.2) 623      (2.4) 168      (2.4) 526      (2.4) 
Comorbidity AF 3,194 (100. 0) 350      (1.4) 923    (13.2) 2,621    (11.9) 
 Asthma 320    (10.0) 2,742    (10.6) 736    (10.5) 2,326    (10.6) 
 Cancer 420    (13.1) 2,819    (10.9) 796    (11.4) 2,443    (11.1) 
 CHD 1,083    (33.9) 4,460    (17.3) 2,023    (28.9) 3,520    (16.0) 
    Continued on next page 
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Table 1 continued from previous page     
  Anticoagulant drugs Antihypertensive drugs 
  Eligible Ineligible                Eligible Ineligible 
 CKD 1,157    (36.2) 4,617    (17.9) 2,343    (33.4) 3,431    (15.6) 
 COPD 309      (9.7) 1,889      (7.3) 547      (7.8) 1,651      (7.5) 
 Dementia 213      (6.7) 1,057      (4.1) 226      (3.2) 1,044      (4.7) 
 Depression 613    (19.2) 5,561    (21.5) 1,413    (20.2) 4,761    (21.6) 
 Diabetes 658    (20.6) 3,854    (14.9) 1,796    (25.6) 2,716    (12.3) 
 Epilepsy 47      (1.5) 567      (2.2) 117      (1.7) 497      (2.3) 
 Heart failure 651    (20.4) 974      (3.8) 437      (6.2) 1,188      (5.4) 
 Hypertension 2,297    (71.9) 12,349    (47.8) 5,241    (74.8) 9,405    (42.7) 
 Hypothyroidism 440    (13.8) 2,450      (9.5) 755    (10.8) 2,135      (9.7) 
 Learning disability 6      (0.2) 124      (0.5) 16      (0.2) 114      (0.5) 
 Osteoporosis 372    (11.6) 1,946      (7.5) 578      (8.2) 1,740      (7.9) 
 PAD 216      (6.8) 1,215      (4.7) 576      (8.2) 855      (3.9) 
Comorbidity Palliative care 52      (1.6) 307      (1.2) 67      (1.0) 292      (1.3) 
 Psychosis 30      (0.9) 409      (1.6) 96      (1.4) 343      (1.6) 
 Rheumatoid arthritis 80      (2.5) 575      (2.2) 170      (2.4) 485      (2.2) 
*BMI: Healthy (18.5-25.9 kg/m2), Underweight (<18.5 kg/m2), Overweight (26-30 kg/m2), Obese (>30 kg/m2) 
AF: Atrial Fibrillation; BMI: Body Mass Index, CHD: Coronary Heart Disease, CKD: Chronic Kidney Disease, COPD: Chronic 
Obstructive Pulmonary Disease, PAD: Peripheral Artery Disease, TIA: Transient Ischaemic Attack 
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Proportion of missed opportunities 
A missed opportunity for primary prevention was found in half of patients eligible for 
anticoagulant drugs (52%; 1,647/3,194) and a quarter of patients eligible for 
antihypertensive drugs (25%; 1,740/7,008). Of those eligible for antihypertensive drugs, 
there were missed opportunities in 27% (540/2,038) of patients with high BP (≥160/100 
mmHg) and 24% (1,484/6,272) in patients with moderately high BP (≥140/90 mmHg) and 
high CVD risk (groups not mutually exclusive). There were significantly more missed 
opportunities for anticoagulant drug prescribing in patients with stroke only or TIA only 
compared to patients who had stroke with previous TIA (p=0.02; Table 2). This was not the 
case for antihypertensive drug prescribing (p=0.21; Table 2). 
 
 
Table 2: Proportion of stroke and transient ischaemic attack (TIA) patients with a prior 
missed opportunity for antihypertensive or anticoagulant drug prevention therapy. 
 Proportion of missed opportunities  
(% (frequency)) 
 Anticoagulant drugs Antihypertensive drugs 
Stroke 52.3  (983/1,881) 25.3  (971/3,843) 
TIA 52.8  (506/958) 23.6  (531/2,253) 
Stroke with previous TIA 44.5  (158/355) 26.1  (238/912) 
Total 51.6  (1,647/3,194) 24.8  (1,740/7,008) 
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Demographic and patient characteristics associated with having a missed 
opportunity 
Anticoagulant drug prescribing 
Variables associated with having a missed opportunity for anticoagulant drug prescribing are 
presented in Table 3. With age 75-79 years (median age of total sample) as the reference 
category, younger age (55-59 years) was associated with reduced odds of having a missed 
opportunity, whereas age over 85 years was associated with increased odds (Figure 1). A sex 
effect was observed with females having increased odds of having a missed opportunity 
compared to males. The odds of having a missed opportunity for anticoagulant drug 
prescribing was reduced in patients with a diagnosis of heart failure or diabetes, but 
increased in people with a diagnosis of dementia. With non-smoker as the reference 
category, current smokers and patients with a missing smoking status had increased odds of 
having a missed opportunity. Being underweight, overweight, obese and having a missing 
BMI were all associated with increased odds of having a missed opportunity compared to 
patients with a healthy BMI (18.5-25.9 kg/m2). There was a marked decrease in the 
proportion of missed opportunities between 2009 and 2013 (Figure 2). Exploratory analyses 
are presented in the Supplementary Appendix. 
Antihypertensive drug prescribing 
Variables associated with having a missed opportunity for antihypertensive drug prescribing 
are presented in Table 4. With age 75-79 years as the reference category, both younger age 
(50-59 and 65-69 years) and very old age (≥90 years) were associated with increased the 
odds of having a missed opportunity (Figure 1). In contrast to anticoagulant prescribing, 
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female sex was associated with decreased odds of having a missed opportunity for 
antihypertensive prescribing. The odds of having a missed opportunity were more than 
halved in patients with a diagnosis of hypertension, CHD, AF, diabetes, heart failure and CKD. 
In addition, patients with a diagnosis of PAD, cancer, hypothyroidism, asthma and dementia 
had significantly reduced odds. However, dementia and multimorbidity were associated with 
increased odds of having a missed opportunity. Administration of lifestyle advice for weight 
was protective against having a missed opportunity. In comparison to anticoagulant drugs, 
no change in the odds of having a missed opportunity for antihypertensive drugs was 
observed between 2009 and 2013 (Figure 2). Exploratory analyses are presented in the 
Supplementary Appendix. 
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Table 3: Adjusted* odds ratios for effects of patient and demographic characteristics on 
having a missed opportunity for prescription of anticoagulant drugs, in eligible patients, 
prior to stroke or transient ischaemic attack (TIA). 
  Odds Ratio 95% CI P value 
Age (years) <55 0.72 0.33, 1.57   0.41 
 55-59 0.36 0.17, 0.77   0.01 
 60-64 1.01 0.62, 1.66   0.97 
 65-69 0.98 0.68, 1.40   0.90 
 70-74 0.89 0.66, 1.20   0.43 
 75-79 1.00   
 80-84 1.01 0.81, 1.26   0.94 
 85-89 1.27 1.02, 1.57   0.03 
 90-94 1.74 1.32, 2.30 <0.01 
 ≥95 4.54 2.60, 7.94 <0.01 
Sex Male 1.00   
 Female 1.37 1.18, 1.58 <0.01 
Comorbidity Heart failure 0.53 0.44, 0.63 <0.01 
 Diabetes 0.82 0.69, 0.98   0.03 
 Dementia 1.51 1.11, 2.06   0.01 
Smoking Non 1.00   
 Ex 1.08 0.91, 1.29   0.36 
 Current 1.41 1.08, 1.84   0.01 
 Missing 1.67 1.07, 2.62   0.03 
BMI Healthy (18.5-25.9 kg/m2) 1.00   
 Underweight (<18.5 kg/m2) 1.51 1.01, 2.26   0.04 
 Overweight (26-30 kg/m2) 1.24 1.04, 1.48   0.02 
 Obese (>30 kg/m2) 1.23 1.01, 1.51   0.04 
 Missing 1.60 1.13, 2.27   0.01 
Year of event 2009 1.00   
 2010 0.95 0.73, 1.22   0.67 
 2011 0.78 0.61, 0.99   0.04   
 2012 0.70 0.55, 0.89 <0.01 
 2013 0.59 0.47, 0.75 <0.01 
*Each odds ratio is adjusted for the other variables in the table. 
BMI: Body Mass Index, CI: Confidence Intervals 
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Table 4: Adjusted* odds ratios for effects of patient and demographic characteristics on 
having a missed opportunity for prescription of antihypertensive drugs, in eligible patients, 
prior to stroke or transient ischaemic attack (TIA). 
  Odds Ratio 95% CI P value 
Age (years) <45 1.64 0.87, 3.10   0.13 
 45-49 1.50 0.93, 2.40   0.10 
 50-54 1.55 1.07, 2.24   0.02 
 55-59 1.54 1.11, 2.12   0.01 
 60-64 1.12 0.84, 1.49   0.45 
 65-69 1.30 1.00, 1.68   0.05 
 70-74 1.16 0.92, 1.46   0.21 
 75-79 1.00   
 80-84 0.96 0.76, 1.22   0.74 
 85-89 1.26 0.98, 1.62   0.08 
 90-94 1.70 1.26, 2.29 <0.01 
 ≥95 3.61 2.18, 5.99 <0.01 
Sex Male 1.00   
 Female 0.85 0.74, 0.97   0.02 
Comorbidity Hypertension 0.09 0.07, 0.11 <0.01 
 CHD 0.26 0.21, 0.33 <0.01 
 AF 0.35 0.27, 0.47 <0.01 
 Diabetes 0.43 0.35, 0.52 <0.01 
 Heart failure 0.49 0.33, 0.73 <0.01 
 CKD 0.50 0.41, 0.60 <0.01 
 PAD 0.62 0.47, 0.81 <0.01 
 Cancer 0.78 0.62, 0.98   0.03 
 Hypothyroidism 0.79 0.63, 1.00   0.05 
 Asthma 0.79 0.62, 1.00   0.05 
 Dementia 1.78 1.26, 2.51 <0.01 
Multimorbidity One unit increase 1.28 1.16, 1.42 <0.01 
Lifestyle intervention Weight 0.63 0.48, 0.83 <0.01 
*Each odds ratio is adjusted for the other variables in the table. 
AF: Atrial Fibrillation; CHD: Coronary Heart Disease, CI: Confidence Intervals, CKD: 
Chronic Kidney Disease: PAD: Peripheral Artery Disease 
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Figure 1: Adjusted odds ratios for effects of age on having a missed opportunity for 
prescription of anticoagulant and antihypertensive drugs, in eligible patients, prior to 
stroke or transient ischaemic attack (TIA), with age 75-79 years as the reference category. 
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Figure 2: Proportion of missed opportunities for anticoagulant and antihypertensive drug 
prescribing, in eligible patients, prior to stroke or transient ischaemic attack (TIA) between 
2009 and 2013. 
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Discussion 
Half of patients eligible for anticoagulant drugs and a quarter eligible for antihypertensive 
drugs had a missed opportunity for primary prevention prior to stroke or TIA. Missed 
opportunities for anticoagulant drug prescribing were more common in females, the very 
elderly (≥85 years), smokers, patients underweight, overweight or obese or with a diagnosis 
of dementia; but, declined markedly from 2009 to 2013. In contrast, missed opportunities 
for antihypertensive drug prescribing did not change between 2009 and 2013 and were 
more common in patients aged 50-59/65-69 years or over 85 years, males, patients with a 
diagnosis of dementia or with multimorbidities. 
Using estimates of the UK population,30 stroke incidence31 and effectiveness of anticoagulant 
and antihypertensive drugs,9-11 we determined the potential impact of improving prescribing 
of anticoagulant and antihypertensive drugs on stroke prevention in the UK. We estimate 
that, in people aged 35 years and over, 2,900 and 3,100 first strokes could potentially be 
prevented each year in the UK by prescribing all eligible patients anticoagulant and 
antihypertensive drugs, respectively (Tables S9 and S10 in the Supplementary Appendix). 
These estimates demonstrate the potential impact of improving prescription of these drugs 
for stroke prevention in the UK. Furthermore, stroke is a global issue; the Global Burden of 
Disease study found stroke was the second leading cause of death and third leading cause of 
disability-adjusted life-years (DALYs) lost worldwide.32,33 The absolute numbers of first 
strokes, stroke-related death and DALYs lost has increased worldwide over the last two 
decades.34 UK primary care aims to provide universal access, free at the point of delivery 
and, in international comparisons, financial barriers to care are very low.35 Therefore, missed 
opportunities in the UK are likely to be lower than in countries with restricted access or 
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barriers to primary health care. Given that the incidence and prevalence of AF has 
worldwide over the past two decades4 and hypertension is attributable for over half of 
strokes globally,36 improving primary prevention in these patients is key to reduce the global 
burden of stroke and TIA. 
Consistent with the literature we found underuse of anticoagulants for stroke prevention in 
AF patients.15,37-42 Our findings support studies which found an association between non-
prescribing of anticoagulants and being very elderly (≥85 years),37,40,43-46 female,37,47 or 
having a diagnosis of dementia.44,48-50 Older age has been reported by clinicians as one of the 
main reasons for not prescribing anticoagulants.51 Bleeding risk, falls risk and polypharmacy, 
particularly in those with a reduced life expectancy are likely to be reasons for reduced 
prescribing in the elderly.51 However, under-prescribing in the elderly is particularly relevant 
because prevalence of AF and stroke risk is increased in the elderly;52 therefore, given 
population ageing, underuse of anticoagulants in these high risk patients has important 
implications for stroke prevention; 39% of patients eligible for anticoagulants in our study 
were aged 85 years and over. Furthermore, the benefits of anticoagulation in the elderly 
have been shown to outweigh the risk and the net benefit of anticoagulation is actually 
greatest in the elderly.53 Under-prescribing of anticoagulants in females will also contribute 
to the burden of stroke because female sex is an independent risk factor for stroke in AF 
patients. Furthermore, strokes in women with AF are associated with increased mortality 
and disability.6,7 Therefore, it is counterintuitive and unclear why female AF patients are 
more likely to have a missed opportunity.  
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Our study found a relationship between comorbidities and anticoagulant drug prescribing. 
Having a diagnosis of dementia was associated with increased odds of having a missed 
opportunity. This finding is supported by other studies44,48-50 and patients’ cognitive ability 
has been identified as a reason for not prescribing anticoagulant drugs.51 The relationship 
between dementia and non-prescribing is important because AF has been identified as a risk 
factor for dementia54 and an association between cognitive impairment and poor 
anticoagulation control observed.55 On the other hand, we found having a diagnosis of heart 
failure or diabetes was associated with reduced odds of having a missed opportunity. In 
addition, stroke patients with a previous TIA had fewer missed opportunities for 
anticoagulant drug prescribing compared to stroke only or TIA only patients (p=0.02). Heart 
failure, diabetes, and TIA are independent risk factors for stroke in AFs patients and are 
included in the CHADS2 stroke risk score. This finding could suggest that GPs consider 
patients’ stroke risk when prescribing anticoagulants. Scowcroft et al (2012) found higher 
CHADS2 score was associated with increased warfarin prescribing.56 However, Gallagher et al 
(2008) found no association between CHADS2 score44 and warfarin prescribing and Lip et al 
(2015) reported overuse of anticoagulant drugs in patients at low stroke risk.57 
To a lesser extent, we found underuse of antihypertensive drugs for primary stroke 
prevention. The lower proportion of missed opportunities for antihypertensive drugs could 
be a result of the strong evidence base, safely profile and low cost of these drugs.14 
However, the absolute number of strokes/TIAs with a prior missed opportunity for 
prevention with antihypertensive drugs was higher than anticoagulant drugs (1,647 vs 1,740 
for anticoagulant and antihypertensive drugs, respectively). The management of 
hypertension has substantially improved over the past two decades58 and the evidence base 
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is strong;14 however, our findings demonstrate that antihypertensive drug prescribing 
remains suboptimal and is likely to affect a large number of people. This is important 
because the hypertension is a common comorbidity and is attributable for over half of 
strokes globally.36 However, our study focused on uncontrolled hypertension and, therefore, 
the proportion of missed opportunities does not represent the entire hypertensive 
population. Similar to anticoagulant drugs, the very elderly (≥90 years) had increased odds of 
having a missed opportunity for prevention with antihypertensive drugs. However, in 
contrast to anticoagulants, younger patients (50-59/65-69 years) were also more likely to 
have a missed opportunity. A UK study which investigated primary CVD prevention also 
found younger patients were less likely to be prescribed antihypertensive drugs and 
prescribing increased with age.59 Contrary to anticoagulant drugs, we found females were 
less likely to have a missed opportunity for antihypertensive drug prescribing. It is unclear 
why females are more likely to be prescribed antihypertensive drugs, but this finding is 
supported by other studies.45,59-61 
A clear relationship was observed between having a diagnosis of a chronic comorbidity and 
reduced odds of having a missed opportunity, with the exception of a diagnosis of dementia 
where the opposite was found. In the UK GPs are incentivised to keep a register and actively 
review people with chronic diseases;24 our finding could suggest that hypertension is more 
often treated in patients on an incentivised register. Other studies have found that 
hypertension patients with existing CVD are more likely to be prescribed antihypertensive 
drugs compared to those without CVD.62,63 The guidelines recommend a lower BP treatment 
threshold for patients with existing CVD or high CVD risk; however, Falaschetti et al (2014) 
reported that patients with a 10-year CVD risk ≥20% were less likely to be prescribed 
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antihypertensive drugs compared to people with existing CVD or diabetes.58 Similarly, our 
exploratory analysis found that hypertensive patients with a 10-year CVD risk ≥20% were 
more likely to have a missed opportunity for antihypertensive prescribing (OR 1.5; 
Supplementary Appendix). On the other hand, multimorbidity was associated with increased 
odds of having a missed opportunity which could reflect the influence of polypharmacy or 
lack of guidelines for antihypertensive prescribing in complex patients. People with a 
diagnosis of dementia were more likely to have a missed opportunity for antihypertensive 
drug prescribing. This is an important finding because, similar to AF, hypertension has been 
associated with increased risk of dementia.64 Dementia patients are underrepresented in 
clinical trials and cognitive ability may affect patients’ adherence to medication. 
The proportion of missed opportunities for anticoagulant drug prescribing significantly 
reduced during the relatively short time period of our study (58% in 2009 to 45% in 2013). 
However, the underuse of these drugs remains substantial and there is a need for future 
research to accelerate the reduction in missed opportunities. Females and the very elderly 
have increased risk of stroke and are under-prescribed anticoagulants despite these risk 
factors being incorporated into the CHA2DS2-VASc stroke risk score.
13 Future research should 
particularly aim to improve anticoagulant prescribing in these patient group. However, 
increased side effects of prevention drugs and lack of evidence for the effectiveness of these 
drugs in the very elderly should be taken into consideration. Exploratory analysis found the 
majority of patients with missed opportunities were prescribed aspirin (Supplementary 
Appendix). However, the most recent guidelines13 and UK QOF incentives24 recommend that 
aspirin is not used for stroke prevention in AF patients. AF patients currently taking aspirin 
should be identified and subsequently be prescribed anticoagulant drugs. An intervention 
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comprised of education and behavioural change targeted at both patients and GPs could 
optimise this process and improve future prescribing practice. Inadequate stroke prevention 
in AF patients is further complicated by the fact that approximately 474,000 people in the UK 
are estimated to have undiagnosed AF which exacerbates the scale of missed 
opportunities.65 Therefore, improving detection and diagnosis of AF through a systematic 
approach and appropriate prescribing of anticoagulant drugs could substantially reduce the 
incidence and burden of stroke and TIA. Although there is a strong evidence base for 
antihypertensive drugs, future research should aim to improve prescribing of these drugs in 
people without existing CVD but with high calculated CVD risk. The majority of patients who 
were eligible for antihypertensive drugs in our sample had a lower BP threshold of 140/90 
mmHg which emphasises the importance of consideration of CVD risk when prescribing 
antihypertensive drugs in primary care, which could be promoted through an intervention. 
Furthermore, our finding that multimorbidity increased the likelihood of having a missed 
opportunity for antihypertensive drugs is important because the majority of the patients in 
our sample had two or more chronic conditions. Patients with multimorbidity are likely to be 
underrepresented in trials and there is a need for guidelines to more comprehensively 
address multimorbidity. 
The strengths of our study are that the sample size was large, the data are recent, broadly 
representative of the UK population, and reflects actual primary care practice. In addition, 
stroke and the main comorbidities are likely to be accurately recorded as they are clinically 
significant and, in the UK, GPs are incentivised to keep a register of patients with these 
conditions. However, TIA may be misclassified66 and, through restricting the definition of 
comorbidities to QOF clinical codes, comorbidity diagnoses may be missed if they were 
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recorded using alternative clinical codes. We did not exclude patients with a clinical code 
indicating anticoagulant or antihypertensive drugs were declined, contraindicated, or there 
was an adverse reaction because it is unclear if these were historic or current codes; 
however, this number in our sample was small (7% and 0.7%  for anticoagulant and 
antihypertensive drugs). Furthermore, there may be other legitimate reasons for GPs not 
prescribing stroke/TIA prevention drugs which are not available in our dataset, such as 
bleeding risk when prescribing anticoagulant drugs or knowledge of a patient’s adherence to 
medication. We defined a missed opportunity for anticoagulants as no prescription of these 
drugs to AF patients with a CHADS2 score of ≥1 prior to stroke/TIA. The 2006 AF guidelines 
allow a prescription of aspirin in patients with a CHADS2 score of 1.12 However, during the 
study period, important studies had been published which showed aspirin to be ineffective 
for stroke prevention10,53 and this recommendation was superseded in the 2014 guidelines.13 
Therefore, missed opportunities for anticoagulants were based on adherence to best 
evidence rather than guideline recommendations. Missed opportunities defined by a 
CHADS2 score ≥2 were explored in a sensitivity analysis (Supplementary Appendices). 
Exploratory analysis also investigated the impact of updated guidelines regarding use of the 
CHA2DS2-VASc and QRISK2-2014 risk scores (Supplementary Appendices). In addition to non-
prescribing, patients’ non-adherence to prevention drugs is an important consideration in 
the context of stroke prevention. A limitation of the dataset is that information on 
adherence is not available and prescription of anticoagulant or antihypertensive drugs may 
not reflect patients’ medication taking behaviour. 
Our study demonstrates the underuse of antihypertensive and anticoagulant drugs for 
primary stroke/TIA prevention. This is important because strokes in AF patients are 
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associated with increased disability and mortality compared to strokes in people without AF. 
Furthermore, hypertension is one of the most prevalent comorbidities worldwide and 
subsequently missed opportunities for prevention affect a large number of people. 
Improving prescription of anticoagulant and antihypertensive drugs has the potential to 
prevent a substantial number of strokes worldwide and reduce the global burden of stroke 
and TIA. 
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Multiple missed opportunities for prevention of stroke and TIA with 
lipid lowering, anticoagulant and antihypertensive drugs 
Methods 
The proportion of strokes and TIAs with clinical indications and missed opportunities for 
more than one stroke and TIA prevention drugs were calculated. In addition, for people 
eligible for multiple drugs and with missed opportunities for multiple drugs, the 
combinations of different prevention drugs were explored. 
 
Results 
At the time of their stroke or TIA 17,680 (61%) people were eligible for one or more stroke 
prevention drug: 9,953 (56%) were eligible for one prevention drug, 6,904 (39%) for two and 
823 for three (5%). Fifty four percent (9,579/17,680) of people eligible for one or more 
prevention drug prior to stoke or TIA had a missed opportunity for primary prevention; the 
majority of these had one missed opportunity (83%: 7,969/9,579), 16% (1,576/9,579) had 
two missed opportunities and 0.4% (34/9,579) had three. Combinations of different missed 
opportunities are presented in Appendix 3. 
Using estimates of the UK population,1 stroke incidence2 and effectiveness of statins, 
anticoagulant and antihypertensive drugs,3-7 the number of strokes that could potentially be 
prevented through prescribing prevention drugs to all people eligible for these drugs was 
determined (Tables 5 and 6). In people aged 35 years and over, 41,400 first stroke patients 
would be estimated to have had one or more missed opportunity for prescription of lipid 
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lowering, anticoagulant or antihypertensive drugs. Based on the relative risk reduction of 
these drugs, 12,000 strokes could potentially be prevented each year in the UK by optimal 
prescribing of stroke prevention drugs. Restricting the age range to between 35 and 84 
years, 29,000 strokes would have had a prior missed opportunity and 8,000 strokes could 
have been prevented. 
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           Table 5: Combinations of missed opportunities for prevention of stroke and TIA. 
Age band 
Number of 
strokes in the 
THIN sample 
Number of missed 
opportunities for one or 
more prevention drug in 
the THIN sample  
Proportion of 
missed 
opportunities in 
THIN (%) 
Number of strokes 
per year in UK 
Estimated number 
of missed 
opportunities in UK 
  Male Female Male Female Male Female Male Female Male Female 
<35 115 124 7 7 6% 6% 0 0 0 0 
35-44 301 258 35 33 12% 13% 1,469 896 171 115 
45-54 841 652 234 102 28% 16% 2,453 1,097 683 172 
55-64 1,669 1,034 736 222 44% 21% 6,712 4,413 2,960 947 
65-74 2,462 1,903 1,191 567 48% 30% 18,817 12,744 9,103 3,797 
75-84 2,613 2,925 805 955 31% 33% 14,656 20,001 4,515 6,530 
≥85 1,232 2,468 509 1,241 41% 50% 9,747 16,677 4,027 8,386 
All ages         18,597          6,644            35.7%   109,682         41,405 
<85          14,658          4,880            33.3%    83,258         28,992 
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              Table 6: Estimated number of strokes prevented in the UK with statin, anticoagulant and antihypertensive drugs. 
Age band 
Number of 
strokes in the 
THIN sample 
Estimated number of 
strokes that could be 
prevented in the 
THIN sample 
Proportion of strokes 
that could be 
prevented in the 
THIN sample (%) 
Number of 
strokes per year 
in UK 
Estimated number 
of strokes that 
could be 
prevented in UK 
  Male Female Male Female Male Female Male Female Male Female 
<35 115 124 2 2 1% 1% 0 0 0 0 
35-44 301 258 10 9 3% 3% 1,469 896 50 30 
45-54 841 652 63 27 7% 4% 2,453 1,097 184 46 
55-64 1,669 1,034 195 60 12% 6% 6,712 4,413 784 256 
65-74 2,462 1,903 317 159 13% 8% 18,817 12,744 2,426 1,063 
75-84 2,613 2,925 230 282 9% 10% 14,656 20,001 1,288 1,931 
≥85 1,232 2,468 156 374 13% 15% 9,747 16,677 1,237 2,529 
All ages 18,597       1,886          10.1%   109,682          11,823 
<85 14,658       1,352            9.2%    83,258           8,057 
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Discussion 
Six out of ten patients who had a first stroke or TIA were previously eligible for at least one 
prevention drug and over half of these had at least one missed opportunity for prevention. 
In effect, one third of all strokes or TIAs occur in patients who had missed opportunities for 
prevention. Our findings indicate underuse of lipid lowering, anticoagulant and 
antihypertensive drugs in primary care in patients whom these drugs are clinically indicated 
for prevention of stroke or TIA. 
Forty-four percent of people eligible for stroke or TIA prevention drugs had clinical 
indications for two or three prevention drugs. However, the vast majority (83%) of missed 
opportunities were for just one prevention drug. Future research should investigate why 
some prevention drugs but not others are prescribed to patients. Improving prescribing of 
lipid lowering, anticoagulant and antihypertensive drugs has the potential to reduce a 
substantial number of strokes annually in the UK. 
 
 
 
 
 
 
119 
 
References 
1. Office for National Statistics (ONS) Population Estimates.  
http://data.london.gov.uk/dataset/office-national-statistics-ons-population-estimates-
borough. Accessed October, 2015. 
2. Rothwell PM, Coull AJ, Silver LE, et al. Population-based study of event-rate, incidence, case 
fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular 
Study). The Lancet. 2005;366(9499):1773-1783. 
3. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular 
atrial fibrillation and no previous history of stroke or transient ischemic attacks. The 
Cochrane Database of Systematic Reviews. 2005(3):Cd001927. 
4. Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing 
stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient 
ischemic attacks. The Cochrane Database of Systematic Reviews. 2007(3):Cd006186. 
5. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various 
antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 
2003;289(19):2534-2544. 
6. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular 
disease. The Cochrane Database of Systematic Reviews. 2013;1:Cd004816. 
7. Wang W, Zhang B. Statins for the prevention of stroke: a meta-analysis of randomized 
controlled trials. PLoS ONE. 2014;9(3):e92388. 
 
 
 
 
 
 
 
 
120 
 
Appendices for Chapter 5 
Appendix 3  Page 
A3.1 
Supplementary 
material 
Table S1: Values outside clinically plausible ranges which were 
excluded. 
237 
Figure S1: Crude incidence of stroke and TIA recorded in the 
THIN database. 
238 
 Table S2: Summary of logistic regression predictor variables. 239 
 Exploratory analysis: Methods 245 
 Table S3: Comparison between the CHADS2 and CHA2DS2-VASc 
stroke risk scores. 
246 
 Table S4: Variables included in Framingham and QRISK2-2014 
equations. 
247 
 Exploratory analysis: Results 248 
 Table S5: CHADS2 score and the proportion of AF patients with 
a missed opportunity for prescription of anticoagulant drugs 
prior to stroke or TIA. 
249 
 Table S6: Proportion of stroke and TIA patients with a prior 
missed opportunity for antihypertensive drug prescribing in 
eligible patients  
250 
 Table S7: Adjusted odds ratios for effects of patient and 
demographic characteristics on having a missed opportunity for 
prescription of antihypertensive drugs prior to stroke or TIA in 
patients with high BP (≥160/100mmHg). 
251 
 Table S8: Adjusted odds ratios for effects of patient and 
demographic characteristics on having a missed opportunity for 
prescription of antihypertensive drugs prior to stroke or TIA in 
patients with moderately high BP (≥140/90mmHg) and high 
CVD risk. 
252 
 Table S9: Number of strokes that potentially could be 
prevented through prescribing anticoagulant drugs. 
254 
 Table S10: Number of strokes that potentially could be 
prevented through prescribing antihypertensive drugs. 
255 
 Table S11: Combinations of stroke and TIA prevention drugs 
clinically indicated. 
256 
 Table S12: Combinations of missed opportunities for different 
stroke and TIA prevention drugs. 
257 
 
121 
 
 
 
 
 
 
 
 
Chapter 6: Residual impairments 
after TIA 
 
Systematic review: Protocol 
 
 
 
 
 
 
 
 
122 
 
A systematic review investigating 
fatigue, psychological and cognitive 
impairment following TIA and minor 
stroke: protocol paper 
Primary prevention of stroke and TIA is important to reduce the incidence and burden of 
these conditions. However, for people who do experience a stroke or TIA, it is important that 
stroke or TIA-related impairments are identified and patients receive appropriate health 
care. Impairments post-stroke are well characterised;1 however, TIA is not currently 
acknowledged to cause any ongoing impairments.2 Follow-up care after TIA is focused on 
prevention of stoke and further TIA.2 Guidelines describe the acute and follow-up care 
pathways for stroke and TIA, but recommendations for the management of minor stroke are 
not explicit.3 However, the pathway is determined by whether a patient’s symptoms have 
resolved at the time of assessment; therefore, minor stroke patients may receive similar 
care to TIA patients.3 Anecdotal evidence suggests that TIA and minor stroke patients may 
experience ongoing residual impairments.4 This chapter presents the protocol for a 
systematic review which aimed to establish the prevalence of fatigue, psychological and 
cognitive impairment after TIA and minor stroke. 
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Background: Approximately 20,000 people have a transient ischemic attack (TIA) and 23,375 have a minor stroke in
England each year. Fatigue, psychological and cognitive impairments are well documented post-stroke. Evidence
suggests that TIA and minor stroke patients also experience these impairments; however, they are not routinely
offered relevant treatment. This systematic review aims to: (1) establish the prevalence of fatigue, anxiety,
depression, post-traumatic stress disorder (PTSD) and cognitive impairment following TIA and minor stroke and to
investigate the temporal course of these impairments; (2) explore impact on quality of life (QoL), change in
emotions and return to work; (3) identify where further research is required and to potentially inform an
intervention study.
Methods/Design: A systematic review of MEDLINE, EMBASE, PsycINFO, CINAHL, Cochrane libraries and grey
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results, study selection, data extraction and quality assessment. Studies of adult TIA and minor stroke participants
containing any of the outcomes of interest; fatigue, anxiety, depression, PTSD or cognitive impairment will be
included. Studies at any time period after TIA/minor stroke, including those with any length of follow-up, will be
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be documented. The proportion of TIA or minor stroke participants experiencing each outcome will be reported.
If appropriate, a meta-analysis will pool results of individual outcomes. Studies will be grouped and analyzed
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months) and long term (> 12 months). Sub-analysis of studies with a suitable control group will be conducted.
Exploratory sub-analysis of memory and attention domains of cognitive impairment will be conducted.
Discussion: The current treatment goal for TIA and minor stroke patients is secondary stroke prevention. If these
patients do experience fatigue, psychological or cognitive impairments then this treatment alone is unlikely to be
sufficient. The results of this comprehensive review will increase understanding of treatment needs for this patient
group, identify where further research is required and potentially inform an intervention trial.
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Stroke is caused by an impaired supply of blood to the
brain resulting in loss of brain function, and is one of
the major causes of mortality and functional disability in
the United Kingdom (UK) [1,2]. The severity of strokes
differ between patients and can be classified as major
stroke, minor stroke and transient ischemic attack (TIA),
also known as mini-stroke. The term major stroke broadly
refers to strokes that result in long-term or permanent
neurological symptoms and may result in disability. Minor
stroke is a term that is widely used in research but has not
been formally defined, however, it refers to strokes with
symptoms lasting longer than 24 hours but where symp-
toms are mild and non-disabling [3]. TIA is defined by
stroke-like symptoms typically lasting less than one hour
and no evidence of acute infarction [4]. TIA and minor
stroke also create a substantial burden on society and
affect a huge proportion of the population. In England, ap-
proximately 20,000 people have a TIA and 23,375 people
have a minor stroke every year [5].
Fatigue, cognitive and psychological problems after stroke
In addition to functional disability, sequelae following
stroke include fatigue, cognitive impairments and psycho-
logical impairments, such as anxiety, depression and post-
traumatic stress disorder (PTSD) [6]. These impairments
are documented in the literature and have a detrimental
impact on people’s lives [7-10]. Fatigue is multidimen-
sional and comprises physical, emotional and cognitive el-
ements [11]. Fatigue has been shown to impact on stroke
survivors’ rehabilitation and quality of life (QoL) [12] and
is associated with depression [13], inability to return to
work [14] and increased fatality post-stroke [15]. The bur-
den of fatigue should not be underestimated, for instance
one study found 40% of stroke patients reported fatigue as
their worst symptom [16].
Anxiety is universally the most common mental health
disorder and is coupled with physical, behavioral and cog-
nitive symptoms [17]. Anxiety and depression frequently
occur simultaneously and, in this circumstance, depres-
sion is more severe and patients experience higher levels
of functional and cognitive impairment [17]. Both major
and minor depression have been documented post-stroke
and can occur at any time point from the acute stage up
to five years post-stroke with an estimated prevalence of
33% [18]. In addition, Ayerbe et al. reported that a high
proportion of patients with depression post-stroke at one
time point remained depressed [19]. Depression is associ-
ated with a poor prognosis, decreased QoL and increased
mortality [20].
PTSD can develop after exposure to a life-threatening
medical event and has been documented post-stroke [21].
Research has shown that occurrence of post-stroke PTSD is
independent of physical disability [8]. PTSD has detrimentalimplications and patients with PTSD have been shown to
have an increased risk for a worse physical and mental
health prognosis and have greater suicidal intention [8]. It
is speculated that a poor health prognosis related to PTSD
is associated with both biological mechanisms, such as
high blood pressure, and behavioral factors, such as non-
adherence to medication [22]. Resultant non-adherence to
medication may impact on stroke and TIA survivors as this
is essential for secondary prevention of stroke. PTSD also
adversely affects people’s QoL and normal functioning [23].
Conversely, life-threatening events can also produce a posi-
tive psychological change known as post-traumatic growth.
McGrath and Linley [24] reported evidence of sustained
positive psychological change after acquired brain injury.
However the sample size for this study was small. Further-
more post-traumatic growth following stroke is reported to
be inversely correlated with anxiety and depression [25].
This concept is relatively new to stroke research and there
is only a small amount of literature available, which to our
knowledge has not yet been extended to TIA and minor
stroke. Therefore this review will be limited to PTSD.
Cognitive impairment is well documented following
stroke and exhibits a wide-range of symptoms including
difficulty with memory, reading, writing and number skills,
visual impairment and difficulty planning and problem
solving. A relationship between cognitive and functional
impairment has been reported along with a negative im-
pact on rehabilitative outcomes [26]. Cognitive impairment
is associated with depression but the directional relation-
ship is unclear [27]. For the purpose of this review, cogni-
tive impairment will encompass impairments of attention,
memory, spatial awareness, perception, apraxia and execu-
tive functioning as in accordance with the Royal College of
Physicians National Clinical Guidelines for Stroke [28].
Impairment after TIA and minor stroke
Fatigue, psychological and cognitive impairment have been
shown to occur post-stroke in the absence of functional im-
pairment and independent of stroke severity [29]. Although
TIA and minor stroke are characterized by short-lasting
symptoms, evidence suggests that this cohort experience
residual problems. Coutts et al. [30] found that 15% of a
sample of TIA and minor stroke patients were disabled at
90 days as defined by a modified Rankin Scale score ≥ 2.
Another study reported TIA patients to have comparable
QoL scores to stroke patients in all domains with the ex-
ception of social isolation [31]. However, results of this
study may be unrepresentative of the true stroke population
as stroke patients in rehabilitation hospitals and care homes
were excluded. Significant fatigue has been reported in a
community population of TIA and minor stroke patients
with a prevalence, at six months, of 29% and 56% respec-
tively [32]. Qualitative research of people’s experiences fol-
lowing TIA or minor stroke revealed that people reported a
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tional impairments, such as limb weakness and numbness;
cognitive impairments, such as memory difficulties; slurred
speech; emotional issues, such as feeling depressed, con-
fused and more emotional [34].
Current treatment guidelines relevant to TIA and minor
stroke focus on secondary prevention of stroke [5]. How-
ever, no consideration is given to psychological or cogni-
tive impacts of TIA or minor stroke and patients are not
routinely offered additional rehabilitative support. Un-
treated fatigue, psychological or cognitive impairment will
result in a reduced QoL and affect people’s ability to re-
turn to work and social activities.
Aims
Considering the diversity and complexity of residual im-
pairments anecdotally described by people following
TIA and minor stroke, it is important to conduct a com-
prehensive systematic review of the literature. This is a
necessary step to develop future intervention studies that
will inform treatment recommendations and guidelines.
This systematic review therefore aims to:
 Establish the prevalence of fatigue, anxiety,
depression, PTSD and cognitive impairment
following a TIA or minor stroke and investigate if
this prevalence changes over time.
 Explore the impact of TIA and minor stroke on
people’s QoL, change in emotions and return to work.
 Identify where there are gaps in the understanding
of residual problems after TIA and minor stroke.
Methods
Our search strategy, selection of studies, assessment of risk
of bias and reporting of results for the review will be
conducted in accordance with the Preferred Reporting
Items for Systematic Reviews and Meta-analyses (PRISMA)
statement [35]. This protocol is not registered with Pro-
spective Registering of Systematic Reviews (PROSPERO)
as the scope of the research does not meet their current in-
clusion criteria.
Eligibility criteria
The inclusion of studies in the systematic review will be de-
termined by participants, comparators, outcomes and study
designs used by the study and the report characteristics.
Participants
This review will include TIA and minor stroke partici-
pants. Studies will be excluded if they recruited major
stroke participants or mixed populations, where it is not
possible to extract the data of TIA or minor stroke par-
ticipants. As stroke is a confounding factor for outcomes
of interest, participants must have no previous history ofstroke and be stroke free in the follow-up period. Alter-
natively, the study must have subgroup analysis of stroke
free participants. Participants must be adults (over 18
years of age) to exclude childhood stroke. Studies that
include participants under 18 years of age will be in-
cluded if over 90% of the sample are adults.
There is not a standard definition of minor stroke
however, as suggested by Fischer et al. [3], this patient
group should have non-disabling symptoms following
stroke but be distinct from TIA patients. TIA patients
will be defined by short-lasting stroke symptoms (less than
24 hours) with no evidence of acute infarct. Studies where
authors describe their population as TIA, minor stroke,
mild stroke, reversible ischemic neurologic deficit or non-
disabling stroke will be included.
Comparators
Descriptive study designs will be included in this review
and, therefore, studies without a comparison group will
be included. However, if present, data will be extracted
for control groups where participants have no history of
stroke, minor stroke or TIA. Participants’ data on out-
comes before their TIA or minor stroke will also be used
as suitable a comparator.
Outcomes
Stroke causes a broad spectrum of impairments; anec-
dotal evidence from TIA and minor stroke patients em-
ulates these diverse impairments. Given this, exploratory
analysis will be conducted to identify the proportion of
TIA and minor stroke participants with the following; fa-
tigue, anxiety, depression, PTSD or cognitive impairment.
These principle outcomes will be defined by scores above
the predefined cut off limit for validated assessments.
Studies must either report the frequencies for outcomes
or data whereby frequencies can be calculated. There will
be no restrictions on the duration of participant follow-up
or time since TIA or minor stroke to develop understand-
ing about the temporal course of the outcomes. Informa-
tion on QoL, change in emotions and return to work or
performance at work will also be documented. Studies will
be included that report any of the above outcomes.
Study design
Initial scoping searches ascertained that a limited
amount of relevant studies have been conducted that in-
clude a comparator group. Therefore, all study designs
will be included with the exception of single case studies
and reviews. Intervention studies may be included if the
non-intervention arm consists of TIA or minor stroke
patients receiving usual care. Only data from this control
arm will be analyzed as this review is not investigating
interventions.
Table 1 The inclusion checklist for screened references
Study design Cross sectional
Cohort
Case control
Case series
Other (please specify)
Study objectives relevant to topic
Report characteristics Full article
Conference abstract
Thesis
Other (please specify)
Publication date 1993 to 2003
Participants TIA
Minor stroke
Study sample are adults
Participants have no previous history of
stroke/subgroup analysis of those with
no history of stroke
Participants stoke free during follow-up/
subgroup analysis of those stroke free
Comparator (Do NOT exclude
if no comparator)
Comparator group present?
(If no, go to outcomes)
No previous history of stroke,
minor stroke or TIA
Outcomes Measure for anxiety
Measure for depression
Measure for fatigue
Measure for PTSD
Measure for cognition
Quality of life reported
Change in emotions reported
Return to work reported
Frequencies reported/can be calculated
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Only human studies will be included. Full papers, con-
ference abstracts and theses will be included. To avoid
language bias, non-English papers will be included. For
pragmatic and quality of reporting reasons, the review
will limit the search to 20 years (1993 to 2013).
Information sources
Electronic searches of the following databases will be
conducted; MEDLINE, EMBASE, PsycINFO, Cumulative
Index to Nursing and Allied Health Literature (CINAHL),
Database of Abstracts of Reviews of Effects (DARE), the
Cochrane Central Register of Controlled Trials (CEN-
TRAL) and Cochrane Database of Systematic Reviews
(CDSR). Databases will be searched from January 1993 to
April 2013.
Ongoing studies will be identified by searching
clinicaltrials.gov, Stroke Trials Registry (www.strokecen
ter.org/trials/) and conference abstracts including the
American Heart Association International Stroke confer-
ence, European Stroke conference and UK Stroke Forum.
Conference Proceedings Citation Index (CPCI) will also
be searched for conference abstracts. These sources will
be searched from 2010 to 2013 as it will be assumed stud-
ies presented before these dates will have been completed
and published.
Grey literature will be explored including PubliCAT and
ScienceDaily.com. The first four pages of Google Scholar
results will be searched; this limit was established from
scoping searches. Dissertations and theses will be identi-
fied from the databases ProQuest Dissertation Thesis
Database and thesis.com. References from included stud-
ies will be scanned and tracked through the cited refer-
ence search in Science Citation Index (SCI).
Search
A comprehensive search strategy has been developed that
focuses on the following elements; TIA, minor stroke, fa-
tigue, anxiety, depression, PTSD and cognitive impair-
ment. Search terms have been established by scoping
searches. The MEDLINE search strategy is detailed in
Additional file 1. This search will be adapted for the other
databases.
Study selection
The titles and abstracts of the search results will be
screened and full text will be obtained for relevant stud-
ies. Two authors (GT and BF) will complete this process
independently and any difference in opinion will be re-
solved by a third reviewer (TM). Full text articles will be
reviewed to determine if studies included through screen-
ing meet the inclusion criteria. An inclusion checklist has
been developed, based on the eligibility criteria, and piloted
(Table 1).Data collection process
Data extraction will be performed in duplicate by two
independent reviewers (GT and BF) for all of the eligible
papers identified through the screening process. A data
extraction form has been developed which focuses on
population, comparator, outcomes and study design. This
form has been informed by the STROBE (STrengthening
the Reporting of OBservational studies in Epidemiology)
statement [36]. The data extraction form was piloted inde-
pendently by two researchers (GT and MF) on known pa-
pers. A Microsoft Excel document will be used to manage
the data extraction.
Quality assessment
Quality assessment of included studies will be performed
by two independent reviewers (GT and BF). A quality
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sampling, measurement of outcomes, attrition and ana-
lysis (Table 2). This form has been piloted independently
by two researchers on known papers (GT and MF). In
accordance with the Cochrane Collaboration recommen-
dations, an overall score will not be generated but a risk
of bias judgment of ‘yes’, ‘no’ or ‘unclear’ will be given
for individual domains [37]. The studies level of quality
will be presented in a table and narrative summary. The
impact of the studies quality on results will be evaluated
in the discussion. If appropriate, a sensitivity analysis will
be conducted excluding poor quality studies.
Synthesis and analysis of results
If the outcomes demonstrate homogeneity, the results
for individual outcomes will be pooled quantitatively using
meta-analysis. The temporal course of fatigue, psycho-
logical and cognitive impairment post-stroke has not been
well characterized. However, prevalence of post-stroke de-
pression has been shown to have immediate onset, peak at
three to six months but also remain high years after stroke
[38]. To explore the time course of these impairments fol-
lowing TIA and minor stroke, studies will be grouped into
short-term (less than three months after TIA or minor
stroke), medium-term (three to twelve months) and long-Table 2 The quality assessment criteria for included studies
Sampling Was the study design appropriate to answer the
Was the sampling method appropriate?
Did the study report how many people were ap
many agreed to take part?
Do those that participate have similar characteri
(for example, age, gender, comorbidities, how th
Is the sample size adequate?
Did the study describe how the sample size was
Was a suitable definition of TIA/minor stroke use
If applicable, was the control group comparable
recruitment and baseline characteristics)?
Did the study demonstrate if the outcomes wer
TIA/minor stroke (for example, history of depress
Measurement Was a suitable measurement for outcome used?
Has the outcome measure been validated for th
Was the outcome measure cut-off score predefin
Was the outcome measure administration suitab
investigator interview)?
Were potential confounding variables measured
Attrition Were numbers of dropouts/withdrawals docume
Were reasons given for dropouts/withdrawals?
Analysis Were all outcomes reported?
Were confounding variables adjusted for?term (over twelve months). If appropriate, frequencies for
each outcome will be combined to create pooled estimates
for short, medium and long term timeframes.
A sub-analysis of studies with a suitable control group
will also be conducted to determine whether outcome pro-
portions are higher in TIA and minor stroke patients com-
pared to healthy controls. Cognitive impairment covers a
spectrum of different domains. Anecdotal evidence suggests
that TIA and minor stroke patients experience residual
memory and attention complaints. Therefore, exploratory
analysis of specifically memory and attention domains of
cognitive impairment will be conducted. To investigate
the natural history of fatigue, psychological and cognitive
impairment after TIA and minor stroke, exploratory ana-
lysis of the outcomes for new cases compared to persistent
cases will be conducted for studies with more than one
time point.
If studies are methodologically heterogeneous, a narra-
tive synthesis of results will be more appropriate. In ac-
cordance with the Center for Reviews and Dissemination
(CRD), included studies will be summarized in a table de-
tailing study type, sample size, participant characteristics,
outcomes and outcome measures [39]. The Economic and
Social Research Council (ESRC) guidance report will be
used as a framework for a narrative synthesis [40].Judgment (yes/no/unclear)
Support for judgment
research question?
proached and how
stics to those that refused
ey were approached)?
determined?
d?
to cases (consider suitability,
e present before the
ion)?
e population?
ed?
le (for example, self reported,
?
nted at each time point?
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Currently the treatment goal for TIA and minor stroke
patients is the prevention of subsequent stroke [5]. These
patients are not acknowledged to have residual problems
which require management. This systematic review will
collate literature to establish whether evidence suggests
people experience fatigue, anxiety, depression, PTSD or
cognitive problems following a TIA or minor stroke. The
temporal nature of the prevalence of these impairments
after the event will also be investigated. In addition, im-
pact of TIA and minor stroke on QoL, change in emo-
tions and return to work will be explored. This systematic
review will identify if there is a lack of literature for any
of the outcomes and review the quality of the available
evidence.Implications of results
If it is found that TIA or minor stroke patients have an in-
creased prevalence of fatigue, psychological or cognitive
problems, then the current management, without address-
ing them, is unlikely to be adequate. Dissemination of re-
sults will increase the awareness of the treatment needs of
TIA and minor stroke survivors. This information will be
particularly valuable in the primary care setting where it is
likely that this patient group will present with residual
complaints.
The comprehensive and systematic search and review
of the literature will identify and inform where further
research is required. For instance, if a large number of
descriptive studies are available for the review, then the
findings will inform a subsequent analytical, hypothesis
testing, study. Alternatively, the findings from the review
might indicate that exploration research has already been
conducted and will therefore inform the design of an ac-
ceptability and feasibility study. This subsequent study will
investigate the effects of an intervention to manage and
treat fatigue, psychological and cognitive problems follow-
ing TIA and minor stroke.Additional file
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Fatigue, psychological and cognitive 
impairment following transient 
ischaemic attack and minor stroke: a 
systematic review 
TIA is characterised by short-lasting symptoms and minor stroke refers to strokes when 
symptoms last longer than 24 hours but where symptoms are mild and non-disabling. 1 It is 
assumed that patients do not have any ongoing impairments once symptoms have resolved; 
however, anecdotally, TIA and minor stroke have reported experiencing residual 
impairments.2 This chapter presents the findings of the systematic review described in 
Chapter 6 which aimed to establish the prevalence of fatigue, psychological and cognitive 
impairment post-TIA and minor stroke. 
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Transient ischaemic attack (TIA) and minor stroke are characterized by short-lasting
symptoms; however, anecdotal and empirical evidence suggests that these patients
experience ongoing cognitive/psychological impairment for which they are not rou-
tinely treated. The aims were (i) to investigate the prevalence and time course of fati-
gue, anxiety, depression, post-traumatic stress disorder(PTSD) and cognitive
impairment following TIA/minor stroke; (ii) to explore the impact on quality of life
(QoL), change in emotions and return to work; and (iii) to identify where further
research is required and potentially inform an intervention study. A systematic review
of MEDLINE, EMBASE, PSYCINFO, CINAHL, the Cochrane libraries and the
grey literature between January 1993 and April 2013 was undertaken. Literature was
screened and data were extracted by two independent reviewers. Studies were included
of adult TIA/minor stroke participants with any of the outcomes of interest: fatigue,
anxiety, depression, PTSD, cognitive impairment, QoL, change in emotions and
return to work. Random-eﬀects meta-analysis pooled outcomes by measurement tool.
Searches identiﬁed 5976 records, 289 were assessed for eligibility and 31 studies were
included. Results suggest high levels of cognitive impairment and depression post-
TIA/minor stroke which decreased over time. However, frequencies varied between
studies. Limited information was available on anxiety, PTSD and fatigue. Meta-
analysis revealed that the measurement tool administered inﬂuenced the prevalence of
cognitive impairment: Mini-Mental State Examination 17% [95% conﬁdence interval
(CI) 7, 26]; neuropsychological test battery 39% (95% CI 28, 50); Montreal Cognitive
Assessment 54% (95% CI 43, 66). There is evidence to suggest that TIA/minor stroke
patients may experience residual impairments; however, results should be interpreted
with caution because of the few high quality studies. Notwithstanding, it is important
to raise awareness of potential subtle but meaningful residual impairments.
Introduction
Transient ischaemic attack (TIA) and minor stroke are
characterized by short-lasting symptoms [1,2]. These
patients are discharged rapidly from hospital and treat-
ment guidelines focus on secondary prevention of
stroke [3]. However, there is evidence to suggest that
TIA and minor stroke patients may experience residual
impairments for which they are not routinely oﬀered
treatment. Coutts et al. [4] reported 15% of a sample of
TIA and minor stroke participants (n = 499) were
disabled at 90 days as deﬁned by a modiﬁed Rankin
Scale score ≥2. In addition, Fens et al. [5] found that
approximately half of a sample of TIA and minor
stroke participants (n = 55) self-reported cognitive and
communication diﬃculties, which was signiﬁcantly
higher (P ≤ 0.001) than angina controls (n = 72). Anec-
dotal evidence from patient interviews revealed that
TIA and minor stroke patients experienced a variety of
ongoing residual symptoms including memory and
speech diﬃculties; feeling confused and more emo-
tional; mild limb weakness and numbness [6]. Subtle
but meaningful impairment post-TIA and minor stroke
may go undetected. If untreated, these impairments
may result in a reduced quality of life (QoL), aﬀect peo-
ple’s ability to return to work and social activities and
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A retrospective cohort study to 
investigate fatigue, psychological or 
cognitive impairment after TIA: 
protocol paper 
The systematic review (Chapters 6 and 7) found limited evidence that suggested a relatively 
high prevalence of cognitive impairment and depression post-TIA and minor stroke. 
However, there were very few studies that measured fatigue, anxiety and PTSD. 
Furthermore, there was a lack of high quality studies which had a comparator group or 
controlled for confounding variables or presence of the impairment prior to TIA or minor 
stroke. The results were limited in terms of reliability and generalisability and it was unclear 
whether the prevalence of impairments post-TIA and minor stroke differed to people of a 
similar age and gender without TIA or minor stroke. Therefore, there was a need for further 
research to investigate the association between TIA or minor stroke and residual 
impairments. This chapter describes the protocol for a matched retrospective cohort study 
which addressed the limitations of existing studies and aimed to investigate the association 
between TIA and consultation for fatigue, cognitive, or psychological impairment in primary 
care. The protocol describes the use of electronic primary care medical records extracted 
from the THIN database to conduct a retrospective age, sex and general practice matched 
cohort study. 
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ABSTRACT
Introduction: Transient ischaemic attack (TIA) is
defined by short-lasting, stroke-like symptoms, and is
recognised as a medical emergency. Symptoms are
assumed to completely resolve, and treatment is
focused on secondary stroke/TIA prevention. However,
evidence suggests that patients with TIA may
experience ongoing residual impairments, which they
do not receive therapy for as standard practice.
TIA-induced sequelae could impact on patients’ quality
of life and ability to return to work or social activities.
We aim to investigate whether TIA is associated with
subsequent consultation for fatigue, psychological or
cognitive impairment in primary care.
Methods and analysis: A retrospective open cohort
study of patients with first-ever TIA and matched
controls. Relevant data will be extracted from The
Health Improvement Network (THIN) database, an
anonymised primary care database which includes data
for over 12 million patients and covers approximately
6% of the UK population. Outcomes will be the first
consultation for fatigue, anxiety, depression, post-
traumatic stress disorder or cognitive impairment.
Principal analysis will use Kaplan-Meier survivor
functions to estimate time to first consultation, with
log-rank tests to compare TIA and control patients. Cox
proportional hazard models will predict the effect of
demographic and patient characteristics on time to first
consultation.
Ethics and dissemination: Approval was granted by
a THIN Scientific Review Committee (ref: 14-008). The
study’s findings will be published in a peer-reviewed
journal and disseminated at national and international
conferences and through social media.
INTRODUCTION
Transient ischaemic attack (TIA) is deﬁned
by short-lasting, stroke-like symptoms which
usually resolve within 1–2 h without causing
cerebral infarction.1 TIA is associated with an
increased risk of subsequent stroke, and
treatment is focused on secondary stroke/
TIA prevention.2 It is currently assumed that
patients do not experience any TIA-induced
sequelae; however, patients have anecdotally
reported ongoing residual impairments
post-TIA.3 Fatigue, psychological and cogni-
tive impairments occur post-stroke and could
be potential sequelae of TIA. These impair-
ments are associated with reduced quality of
life, impaired functioning and increased
mortality post-stroke.4–7 It is important to
establish the holistic consequences of TIA; if
patients experience ongoing impairments,
they could impact on patients’ quality of life
and ability to return to work or social activ-
ities. Therefore, preventative medical man-
agement alone, without addressing residual
impairments, is unlikely to be adequate.
Additionally, these impairments may be
subtle and missed by clinicians, but are
meaningful for the patient.
We recently conducted a systematic review
investigating the prevalence of fatigue, psy-
chological and cognitive impairment follow-
ing TIA and minor stroke. There was
evidence to suggest these patients experience
residual impairments; however, existing
studies had important limitations.8 We were
unable to determine if the prevalence of
impairments post-TIA was greater than that
of the general population because few
studies included a control group. The associ-
ation between TIA and subsequent impair-
ments was unclear as most studies did not
measure or control for presence of impair-
ments prior to TIA or minor stroke.
This study will address the limitations of
existing studies and explore if TIA is asso-
ciated with subsequent fatigue, psychological
or cognitive impairment. If present, there is
the potential for TIA-induced impairment to
increase stroke risk through biological
mechanisms (such as increased blood pres-
sure from anxiety) or behavioural change
(such as non-adherence to stroke prevention
Moran GM, et al. BMJ Open 2015;5:e008149. doi:10.1136/bmjopen-2015-008149 1
Open Access Protocol
medication if these drugs were attributed to post-TIA
impairments). This study aims to investigate (1) whether
TIA is associated with subsequent consultation for
fatigue, psychological or cognitive impairment in
primary care and (2) if patients with TIA who consult
with these residual impairments are more likely to
experience a subsequent stroke.
METHODS AND ANALYSIS
Study design
A retrospective open cohort study of patients with ﬁrst-
ever TIA and controls matched by age (±2 years), sex
and general practice.
Data source
Data will comprise of anonymised UK primary care
patient records extracted from The Health
Improvement Network (THIN). Over 500 general prac-
tices contribute to the THIN database which covers
approximately 6% of the UK population and has data
for over 12 million patients, including 3.6 million
current patients.9 Practices that contribute data to THIN
use Vision patient records software which codes clinical
data using the Read code clinical classiﬁcation (V.2)10
and drug prescriptions which link to the British
National Formulary.11
Population
Relevant data will be extracted for patients with ﬁrst-ever
TIA aged 18 years and over with no previous history of
stroke. For each patient with TIA, we will select ﬁve12
controls free from stroke and TIA and matched on age
(±2 years), sex and general practice. The date of TIA will
be taken as the index date, and controls will be part of
the same general practice as their matched patients with
TIA on the index date (ﬁgure 1). Controls will be
selected from the pool of potential controls without
replacement to ensure they only act as a control once.
Control patients who experience a TIA in follow-up will
become part of the TIA group if they meet the eligibility
criteria. For data quality reasons, the index date must
occur between 1 January 2000 and the practice’s most
recent data collection, and have occurred after the prac-
tice date of acceptable mortality recording.13 TIA and
control patients must have been registered at their
practice for at least 1 year prior to diagnosis to obtain
baseline data. Patients will be followed up until they
leave the practice, die or suffer a TIA (control patients
only) or stroke.
Study variables
Outcome variables
The principal outcomes will be the ﬁrst consultation for
fatigue, anxiety, depression, post-traumatic stress dis-
order (PTSD) or cognitive impairment. The outcomes
will be deﬁned by relevant clinical codes (Read codes)
for symptoms and diagnoses, or drug codes (see online
supplementary appendix 1). Cognitive impairment will
include memory, attention and executive functioning
impairments but not dementia. The outcomes will be
grouped into three categories: (1) fatigue, (2) cognitive
impairment and (3) psychological impairment (com-
prised of anxiety, depression and PTSD). Stroke will be a
secondary outcome, and the ﬁrst occurrence of a stroke
is a censoring event for the principal outcomes.
Exposures variables
A comprehensive list of clinical codes for stroke and TIA
has been developed which will identify the eligible
population (see online supplementary appendix 2). TIA
and control patients must have no clinical codes indicat-
ing a previous stroke or TIA prior to the index date.
Follow-up
Follow-up of TIA and control patients will continue until
the ﬁrst occurrence of: death, stroke, patient leaves their
practice or the last data collection from the general
practice. Diagnosis of another TIA during the follow-up
period will be permitted for patients with TIA; however,
control patients will be censored on the date a TIA is
recorded, and subsequently will become part of the TIA
group. Three substudies will be formed for each
outcome category (fatigue, psychological or cognitive
impairment) and patients will be censored at the ﬁrst
consultation for the relevant outcome.
Predictor variables
The most recent baseline demographic and patient
characteristics prior to index date will be extracted includ-
ing age (at index date), sex, body mass index (BMI),
Figure 1 Summary of matching
and eligibility criteria for transient
ischaemic attack (TIA) and
control patients.
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Townsend deprivation quintiles,14 urban/rural residence,14
smoking status and alcohol consumption. Existing
comorbidities may be associated with fatigue, psychological
or cognitive impairment; therefore, comorbidities will be
measured and comprise of the long-term conditions
included in the Quality and Outcomes Framework (QOF),
identiﬁed by their corresponding Read codes (QOF busi-
ness rules V.27; see online supplementary appendix 3).15
Although other conditions may be potential confounders,
the QOF incentives scheme means that these conditions
are likely to be well recorded, and they include the majority
of important conditions. Number of consultations will be
reported because patients who consult more would have
increased opportunity to report residual impairments.
Furthermore, consultations for fatigue, psychological or
cognitive impairment prior to the index date will be
extracted to control for presence of the outcomes prior to
the index date.
Quality checks, missing data and extreme values
Data are unlikely to be missing at random;16 therefore,
no attempt will be made to impute numeric missing
data, and continuous variables will be categorised with
an additional ‘missing’ category included. Absence of
clinical codes for diagnoses will be taken to indicate the
diagnosis is not present. Clinically implausible values for
height, weight and BMI will be excluded with Health
Survey for England statistics used as a guide.17
Analysis
Data management and analysis will be performed using
STATA V.12 (StataCorp, College Station, Texas, USA).
The principal analysis will use Kaplan-Meier (K-M) sur-
vivor functions to estimate time to each outcome for
TIA and control patients (ie, ﬁrst consultation where
there is a clinical code indicating fatigue, anxiety,
depression, PTSD or cognitive impairment). Log-rank
tests will compare TIA and control patients’ K-M survivor
functions. Cox proportional hazard models will be used
to predict the effect of demographic and patient
characteristics on time to each outcome. Backwards
elimination, with a p-to-eliminate value of >0.05, will
select covariates included in the models. General prac-
tice will be included as a random effect, and age and
sex will be forced into the model to adjust for residual
confounding. Fatigue and cognitive impairment will be
analysed individually. Anxiety, depression and PTSD will
be combined as psychological impairments, but analysed
individually in an exploratory analysis. Sensitivity analysis
will restrict the analysis to patients with no record of
fatigue, psychological or cognitive impairment prior to
the index date. To investigate if patients with TIA who
consult for residual impairments are more likely to have
a stroke, secondary analysis will use K-M survivor func-
tions to estimate time to ﬁrst stroke for patients with TIA
with and without residual impairments. An exploratory
analysis will investigate the incidence of stroke in the
ﬁrst year post-TIA. Similar to the principal analysis,
demographic and patient characteristics will be adjusted
for using Cox proportional hazard models. Exploratory
analysis will also investigate the effect of excluding
patients with no consultations in follow-up, or those who
consult for outcomes within the ﬁrst month of follow-up.
DISCUSSION
Follow-up for patients with TIA is conducted in primary
care; therefore, it is important for primary care clini-
cians to understand if patients experience TIA-related
impairments which require additional treatment to sec-
ondary stroke prevention. A systematic review of the lit-
erature found evidence to suggest fatigue, psychological
and cognitive impairment following TIA. However, the
evidence was limited and the review highlighted the
need for further research comprised of a large, matched
cohort study.8 Our study will provide a valuable contribu-
tion to the literature, increase the understanding of the
needs of this patient group, and potentially inform an
intervention study.
This study is likely to have a large sample size, and data
will be representative of ‘real-life’ primary care practice as
data are collected in routine clinical care. Contrary to
most existing studies in this ﬁeld, we will include a
matched control group and will control for the presence
of fatigue, psychological and cognitive impairment prior
to TIA. Limitations of the study include the accuracy of
diagnosis and recording of TIA and our outcomes
(fatigue, cognitive and psychological impairment) in
primary care. General practitioners are incentivised to
keep a register of patients with TIA;15 however, it has
been recognised that TIA can be misdiagnosed.18
Although TIA may be underdiagnosed, our data will be
representative of the current state of TIA diagnoses in
primary care. Ideally, we would have included patients
with minor stroke in our sample; however, severity of
stroke is not coded in the Read clinical coding.
Our outcomes are likely to be under-reported because,
although residual impairments could impact on patients’
quality of life, they may be subtle and, consequently,
patients may not consult in primary care for them.
Furthermore, impairments may not be recognised by
primary care clinicians, for example, evidence suggests
poor recognition and recording of mild cognitive impair-
ment in primary care.19 However, we have developed an
extensive list of clinical codes which encompass symp-
toms as well as diagnoses and, where possible, included
related medication to deﬁne outcomes. Diagnosis of
depression is incentivised by QOF and is, therefore, likely
to be well recorded. General practices are expected to
differ in their recording of our outcomes, and to control
for this, we will match TIA and control patients on this
variable. It is important to note that the THIN database
comprises of primary care data; therefore, this study
will include primary care consultations for fatigue, psy-
chological and cognitive impairments rather than the
incidence of these impairments in the community.
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A limitation of using electronic medical records is that
duration of our outcomes cannot be determined as we
are unable to identify if or when symptoms resolve.
Patients may experience fatigue, psychological or cogni-
tive impairment before their index date, and have a clin-
ical code to indicate this. However, if the impairment is
still present after the index date, the presence of the
impairment may not be recorded again and we will not
be able to include the continued presence of this
impairment in our analysis. Furthermore, patients with
TIA may potentially consult more in primary care
because of TIA-related follow-up appointments. This
could introduce an ascertainment bias as patients with
TIA would have more opportunity to report fatigue, psy-
chological or cognitive impairments compared with
those who consult less frequently. We will descriptively
report the average number of consultations for TIA and
control patients, and discuss the potential impact on our
results.
Dissemination
The ﬁndings of the study will be published in a peer-
reviewed journal, and disseminated at national and inter-
national conferences and through social media.
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Appendices for Chapter 8 
Appendix 6  Page 
A6.1 Supplementary material Read and drug codes for: (a) fatigue, (b) 
anxiety, (c) depression, (d) anxiety and 
depression (e) post-traumatic stress 
disorder (PTSD) and (f) cognitive 
impairment. 
270 
 Read codes for (a) TIA and (b) stroke 285 
 Read codes for diagnoses including history 
of and resolved Read codes 
289 
A6.2 SRC approval  291 
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Fatigue, psychological and cognitive 
impairment following transient 
ischaemic attack (TIA): a retrospective 
cohort study in primary care 
 
The systematic review (Chapters 6 and 7) identified the need for a robust study which had a 
matched control group and adjusts for confounding variables and presence of the 
impairments prior to TIA. In response, a retrospective cohort study was designed (Chapter 8) 
which aimed to investigate the association between TIA and consultation for fatigue, 
psychological or cognitive impairment in an age and gender matched population from the 
THIN primary care database. This chapter presents the findings of the retrospective cohort 
study.  
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Dissemination 
Year Conference Location Oral/Poster 
2015 North American Primary Care Research 
Group (NAPCRG) Annual Meeting 
Cancun, Mexico Oral presentation 
 International Society for Quality of Life 
Research (ISOQOL) Annual Conference 
Vancouver, 
Canada 
Oral presentation 
 University of Birmingham’s Research 
Poster Conference 
Birmingham, UK Poster 
 
This chapter is has been formatted in the style of an original article for The Lancet. The paper 
is currently under review in a peer-reviewed journal. 
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Abstract 
Background 
Transient ischaemic attack (TIA) is defined as a brief episode of neurological dysfunction 
following cerebral ischaemia. Clinical management after TIA is focused on stroke prevention. 
A number of small studies suggest patients may experience ongoing fatigue, psychological 
and cognitive impairment.  
Methods 
A retrospective matched-cohort study using anonymised electronic primary care records 
extracted from The Health Improvement Network (THIN) database, which covers 
approximately 6% of the United Kingdom population. First-ever TIA patients with a diagnosis 
between 2009 and 2013 were matched 1:5 to controls by age, sex, and general practice. In 
three sub-studies, separate Kaplan-Meier (K-M) survivor functions estimated time to first 
consultation or drug prescription for fatigue, for psychological impairment and for cognitive 
impairment. Log rank tests compared TIA patients to controls and Cox regression models 
adjusted for potential confounders including patient and demographic characteristics. 
Findings 
The total sample included 55,930 individuals: 9,419 TIA patients and 46,511 controls. The 
median age was 74 years (IQR 63,82) and 48% were males. The K-M curves showed that TIA 
patients were more likely than controls to consult for fatigue, psychological impairment and 
cognitive impairment (P<0.0001). Adjusted hazards ratios were: fatigue 1·43 (95% CI 
1·33,1·54), psychological impairment 1·26 (95% CI 1·20,1·31); cognitive impairment 1·45 
(95% CI 1·28,1·65). 
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Interpretation 
TIA is associated with significantly increased subsequent consultation for fatigue, 
psychological impairment and cognitive impairment. These findings challenge the ‘transient’ 
characterisation of TIA. Sequelae of TIA may not be limited to increased stroke risk and 
patients may have ongoing health problems. 
Funding  
National Institute for Health Research (NIHR) School for Primary Care Research (SPCR). 
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Research in context 
Evidence before this study 
We conducted a systematic review investigating prevalence of fatigue, psychological, and 
cognitive impairment after transient ischaemic attack (TIA) and minor stroke. MEDLINE, 
EMBASE, PSYCINFO, CINAHL, the Cochrane libraries, and grey literature were searched 
between January 1993 and April 2013. The comprehensive search strategy included variants 
of the terms: “TIA”, “minor stroke”, “fatigue”, “anxiety”, “depression”, “PTSD”, and 
“cognitive impairment”. Studies that reported prevalence of fatigue, psychological, or 
cognitive impairment post-TIA/minor stroke were included. Studies where participants had a 
history of stroke or experienced stroke in follow-up were excluded unless subgroup analysis 
excluding stroke was reported. There was evidence to suggest patients experience cognitive 
impairment and depression post-TIA/minor stroke, but few studies measured fatigue, 
anxiety, or PTSD. Only a small number of studies included a comparison group or reported 
presence of the outcomes prior to TIA or minor stroke. Subsequent to the systematic review, 
a Dutch study observed higher levels of cognitive impairments following TIA compared to 
controls. Additionally, a Scottish study found similar frequencies of anxiety/depression in 
stroke and TIA patients and a German study found nearly a third of TIA patients had PTSD; 
however, neither study had a control group. 
Added value of this study 
We found TIA patients had increased risk of consulting for fatigue, psychological, and 
cognitive impairments in primary care compared to matched controls. This relationship 
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remained when adjusted for the potential confounding variables and the presence of the 
impairment prior to TIA.  
Implications of all the available evidence 
Our findings suggest that impairments exist after initial symptoms of TIA have resolved and 
challenge the ‘transient’ characterisation of TIA. We propose that sequelae of TIA are not 
limited to increased stroke risk; therefore, residual impairments should be an important 
consideration for primary care clinicians when treating patients following TIA. Future 
research should develop intervention(s) to improve detection and treatment of fatigue, 
psychological, or cognitive impairments post-TIA. 
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Introduction 
Transient ischaemic attack (TIA) occurs when a temporary blockage restricts blood flow to 
the brain producing a range of transient symptoms, including impaired: coordination, spatial 
awareness, vision, speech, articulation, and limb functioning.1 Classically, TIA was defined as 
symptoms lasting for less than 24 hours; however, more recently this time-based 
classification has been replaced by a tissue-based definition which describes TIA as: ‘a brief 
episode of neurologic dysfunction without evidence of acute infarction’.2 TIA is considered a 
medical emergency because patients are at increased risk of stroke.3  
Guidelines from the United Kingdom (UK) promote rapid evaluation of people with 
suspected TIA and focus on diagnosing TIA (ruling out an alternative diagnosis, such as 
migraine), determining the affected vascular territory, and assessing stroke risk.4,5 Follow-up 
is focused on management of stroke risk factors through medical, surgical, and lifestyle 
interventions.5 While it is recognised that stroke patients may experience ongoing 
impairments which require rehabilitation, these guidelines do not extend to TIA.5,6  
We conducted a systematic review investigating the prevalence of fatigue, psychological, 
and cognitive impairment after TIA and minor stroke.7 There was evidence to suggest a 
relatively high prevalence of cognitive impairment and depression post-TIA/minor stroke; 
however, few studies measured anxiety, post-traumatic stress disorder (PTSD), or fatigue. 
Furthermore, very few studies had a control group and we were unable to determine if 
prevalence of these impairments was higher than people at a similar age without TIA/minor 
stroke. Subsequent to the systematic review, a Dutch study observed evidence that TIA 
patients had higher levels of cognitive impairment compared to controls.8 Additionally, 
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Broomfield et al (2014) found similar rates of depression and anxiety post-TIA compared to 
post-stroke9 and Kiphuth et al (2014) reported PTSD in 30% of a sample of TIA patients;10 
however, neither study had a control group. Our study aimed to investigate the association 
between TIA and consultation for fatigue, cognitive, or psychological impairment in an age 
and gender matched population from an electronic primary care database. To our 
knowledge there are no studies that have investigated residual impairments after TIA using 
routinely collected electronic primary care medical records. 
Methods 
The full protocol for this study has been published elsewhere,11 methods are summarised in 
brief below. 
Study design and data source 
This is a retrospective matched cohort study of first-ever TIA patients using anonymised, 
routinely collected, primary care data from The Health Improvement Network (THIN) 
database.12 This database covers approximately 6% of the UK population and data are 
extracted from contributing general practices using Vision patient records software.12 
Analysis of THIN data is ethically approved by the National Health Service (NHS) South-East 
Multi-centre Research Ethics Committee subject to independent scientific review.13 This 
study received approval by a Scientific Review Committee in February 2014 (reference: 14-
008). 
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Population 
Patients aged 18 years and over with a first-ever diagnosis of TIA between January 2009 and 
December 2013 were matched with up to five14 TIA-free controls. TIA patients were 
matched to controls on: year of birth (+/- 2 years), sex, general practice, and date of TIA 
(index date). TIA patients and controls were free from stroke at baseline.  The index date 
must have occurred at least one year after the general practice began using Vision patient 
records software and after the date of acceptable mortality recording (markers of data 
quality).15 TIA patients and matched controls had be registered at their general practice for 
at least one year prior to the index date to allow baseline data to be recorded by their 
practice and had to have remained alive and registered for at least one month after the 
index date to allow time for the outcomes of interest to be recorded. 
Variables 
There were three separate sub-studies for each of the following outcomes: first consultation 
post-index date for (i) fatigue, (ii) psychological impairment (comprised of anxiety, 
depression, and PTSD), and (iii) cognitive impairment.  These outcomes were defined by 
appropriate clinical codes for diagnoses and symptoms. In addition, drug codes for anti-
depressant and anti-anxiety drugs were used to define psychological impairment. Cognitive 
impairment included memory, attention, and executive functioning impairments but not a 
diagnosis of dementia. For each sub-study, follow-up continued until the first consultation 
for the relevant outcome (for example consultation for fatigue in the fatigue sub-study) with 
censoring at the first occurrence of: death, stroke, the patient leaving the practice, or the 
last data collection from the general practice. Diagnosis of TIA in follow-up was permitted for 
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TIA patients but controls were censored at the date a TIA diagnosis was recorded and 
subsequently became eligible for inclusion in the TIA group. 
Potential confounding variables were identified using the most recent baseline demographic 
and clinical characteristics prior to the index date. These included age, sex, body mass index 
(BMI), Townsend deprivation,16 urban/rural residence,16 smoking status, alcohol 
consumption, and comorbidities. Comorbidities comprised of the chronic conditions 
included in the UK chronic disease monitoring programme, Quality and Outcomes 
Framework (QOF; business rules version 27; Table 1).17 Numbers of consultations in follow-
up were recorded because patients who consult more have more opportunities to report 
residual impairments. To control for presence of the outcomes at baseline (prior to the index 
date), the most recent consultations prior to the index date for fatigue, psychological, or 
cognitive impairment were extracted. 
Quality checks, missing data, and extreme values 
Absence of a clinical code or relevant drug code for an individual diagnosis prior to the index 
date was taken to indicate the diagnosis was not present. For clinical measurements (height, 
weight, BMI, blood pressure, and cholesterol), implausible values were excluded based on 
pre-defined cut-off scores (supplementary table S1). As data are unlikely to be missing at 
random,18 no attempt was made to impute numeric missing data. Instead, variables were 
categorised and a separate ‘missing’ category was created. Data were initially extracted 
between 2000 and 2013; however, there was evidence of underreporting of TIA before 
2008, with the number of incident TIA events before 2008 less than 15% of recorded TIA 
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after 2009 (supplementary figure S1). After 2009, this was more stable; therefore, only 
patients with a TIA recorded from the 1st January 2009 were included.  
Analysis 
All analysis was conducted using STATA version 12 (StataCorp, College Station, Texas). 
Kaplan-Meier (K-M) survivor functions were used to estimate time to consultation for each 
outcome for TIA patients and controls. Log rank tests compared survivor functions of TIA 
patients and controls. Cox proportional hazard models adjusted for potential confounding of 
demographic and clinical characteristics. Inclusion of covariates in the model was selected 
using backwards elimination with a p-to-eliminate value of >0·05. Age and sex were forced 
into the model, because these were identified as important confounding variables, and 
general practice was included as a random effect.19-21 Fatigue, psychological, and cognitive 
impairments were analysed separately in three sub-studies. Exploratory analysis investigated 
the impact of excluding patients with presence of the outcome prior to the index date for 
each sub-study. Further exploratory analyses are presented in the supplementary material. 
Role of the funding source 
This study is funded by the National Institute for Health Research (NIHR) School for Primary 
Care Research (SPCR). The funder had no role in study design, data analysis, data 
interpretation, or writing of the manuscript. GMT had full access to all the data in the study 
and had final responsibility for the decision to submit for publication. 
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Results 
The total cohort comprised of 55,930 individuals: 9,419 TIA patients and 46,511 controls. 
The median age was 74 years (IQR 63, 82) and 48% were males. Demographic and clinical 
characteristics for the fatigue, psychological, and cognitive impairment sub-studies are 
presented in Table 1. 
Fatigue 
A total of 55,754 individuals were included in the survival analysis for the fatigue sub-study: 
9,250 TIA patients matched to 46,504 controls (176 TIA patients/controls were excluded 
because fatigue was recorded on the index date). The median follow-up was 17·2 months 
(range 0 to 60·5 months) for TIA patients and 19·1 months (range 0 to 60·5 months) for 
controls. Fatigue was recorded in 3,632 individuals; the K-M curves show that TIA patients 
were more likely to consult for fatigue compared to controls (P<0·0001; Figure 1a). The 10th 
percentile for time to fatigue was 20·7 months (95% CI 18·6, 23·5) for TIA patients and 42·4 
months (95% CI 40·6, 44·8) for controls (Figure 1a). TIA patients had a 43% increased risk of 
consulting for fatigue compared to controls following adjustment for demographic and 
clinical characteristics (Hazard Ratio (HR) 1·43: 95% CI 1·33, 1·54; P<0·0001, Table 2). 
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Table 1: Demographic and clinical characteristics of TIA patients and controls included in 
the fatigue, psychological, and cognitive impairment sub-studies. 
  
Control TIA 
Frequency % Frequency % 
Total   46,511 100 9,419 100 
Age <45 1,416 3·0 279 3·0 
 45-49 1,576 3·4 293 3·1 
 50-54 2,378 5·1 495 5·3 
 55-59 3,092 6·6 600 6·4 
 60-64 4,338 9·3 879 9·3 
 65-69 5,559 12·0 1,120 11·9 
 70-74 6,303 13·6 1,247 13·2 
 75-79 7,223 15·5 1,502 15·9 
 80-84 6,886 14·8 1,378 14·6 
 85-89 5,013 10·8 1,009 10·7 
  ≥90 2,727 5·9 617 6·6 
Sex Male 22,245 47·8 4,504 47·8 
Smoking status Non 23,435 50·4 4,505 47·8 
 Ex 13,970 30·0 2,964 31·5 
 Current 5,748 12·4 1,555 16·5 
  Missing 3,358 7·2 395 4·2 
Alcohol intake Never 5,954 12·8 1,212 12·9 
 Light 7,930 17·0 1,671 17·7 
 Moderate 5,617 12·1 1,165 12·4 
 High 12,624 27·1 2,630 27·9 
  Missing 14,386 30·9 2,741 29·1 
BMI Healthy 14,872 32·0 2,971 31·5 
 Underweight 944 2·0 199 2·1 
 Overweight 16,552 35·6 3,469 36·8 
 Obese 10,220 22·0 2,179 23·1 
  Missing 3,923 8·4 601 6·4 
Deprivation 1 (least deprived) 12,353 26·6 2,383 25·3 
 2 11,171 24·0 2,241 23·8 
 3 9,399 20·2 1,908 20·3 
 4 7,635 16·4 1,623 17·2 
 5 (most deprived) 4,771 10·3 1,073 11·4 
  Missing 1,182 2·5 191 2·0 
Rurality Urban 17,642 37·9 3,522 37·4 
 Rural 28,867 62·1 5,893 62·6 
  Missing 2 0·0 4 0·0 
Continued on next page 
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Continued from previous page 
  Control TIA 
  Frequency % Frequency % 
Comorbidities Atrial fibrillation 3,273 7·0 1,055 11·2 
 Asthma 4,909 10·6 1,176 12·5 
 Cancer 4,387 9·4 1,074 11·4 
 CHD 6,631 14·3 1,680 17·8 
 CKD 7,553 16·2 1,779 18·9 
 COPD 2,700 5·8 689 7·3 
 Dementia 1,579 3·4 375 4·0 
 Depression 8,109 17·4 2,103 22·3 
 Diabetes 5,734 12·3 1,376 14·6 
 Epilepsy 618 1·3 199 2·1 
 Heart failure 1,695 3·6 421 4·5 
 Hypertension 20,112 43·2 4,617 49·0 
 Hypothyroidism 4,098 8·8 982 10·4 
  Learning disability 107 0·2 44 0·5 
 
Osteoporosis 3,128 6·7 770 8·2 
 PAD 1,376 3·0 414 4·4 
 Palliative care 319 0·7 89 0·9 
 Psychosis 499 1·1 112 1·2 
  Rheumatoid 
arthritis 
794 1·7 206 2·2 
Impairment prior to 
index date 
Fatigue 10,074 21·7 2,910 30·9 
Psychological 
impairment 
22,127 47·6 5,396 57·3 
  Cognitive 
impairment 
1,983 4·3 664 7·0 
BMI: Body Mass Index, CHD: Coronary Heart Disease, CKD: Chronic Kidney Disease, COPD: 
Chronic Obstructive Pulmonary Disease, PAD: Peripheral Artery Disease, TIA: Transient 
Ischaemic Attack 
*BMI: Healthy (18·5-25·9 kg/m2); Underweight (<18·5 kg/m2); Overweight (26-30 kg/m2); 
Obese (>30 kg/m2) 
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Table 2: Adjusted* hazard ratios for the effects of demographic and clinical characteristics 
on consultations for fatigue in TIA patients and controls. 
  
Hazard 
Ratio 
P value 95% CI 
TIA/ control TIA 1·43 <0·001 1·33 1·54 
Age <45 1·05 0·67 0·85 1·29 
 
45-49 0·81 0·07 0·64 1·02 
 
50-54 0·84 0·05 0·70 1·00 
 
55-59 0·90 0·22 0·76 1·06 
 
60-64 0·84 0·03 0·72 0·98 
 
65-69 0·82 0·01 0·71 0·95 
 
70-74 1·00 
   
 
75-79 1·05 0·49 0·92 1·19 
 
80-84 1·14 0·04 1·01 1·29 
 
85-89 1·08 0·27 0·94 1·24 
 
≥90 0·93 0·47 0·77 1·13 
Sex Female 1·11 0·01 1·03 1·20 
Impairment 
prior to index 
date 
Fatigue 2·77 <0·001 2·57 2·99 
Psychological impairment 1·18 <0·001 1·08 1·29 
Impairment post 
index date 
Psychological impairment 1·57 <0·001 1·46 1·70 
Cognitive impairment 1·18 0·03 1·01 1·37 
BMI Healthy 1·00 
   
 
Underweight 1·11 0·37 0·88 1·41 
 
Overweight 1·04 0·39 0·96 1·12 
 
Obese 0·99 0·78 0·90 1·08 
 
Missing 0·77 0·01 0·64 0·92 
Alcohol intake Never 1·00 
   
 
Light 1·24 <0·001 1·09 1·41 
 
Moderate 1·17 0·04 1·01 1·36 
 
Heavy 1·17 0·02 1·03 1·33 
 
Missing 1·18 0·01 1·04 1·34 
Comorbidities Dementia 0·65 <0·001 0·51 0·82 
 
Heart failure 1·17 0·04 1·01 1·35 
 
Palliative care 1·57 0·01 1·14 2·18 
 
Multimorbidity 1·09 <0·001 1·07 1·12 
Health authority  West Midlands 1·00 
   
 
Yorkshire & Humber 0·81 0·17 0·60 1·09 
 
North West 1·08 0·44 0·89 1·30 
 
East Midlands 1·04 0·77 0·79 1·37 
 
North East 1·09 0·55 0·82 1·44 
 
East of England 1·05 0·63 0·86 1·29 
 
London 0·93 0·49 0·76 1·14 
Continued on next page 
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Hazard 
Ratio 
P value 95% CI 
Health authority South East Coast 0·83 0·08 0·68 1·02 
 
South Central 1·05 0·65 0·84 1·32 
 
South West 1·02 0·82 0·83 1·26 
 
Northern Ireland 1·25 0·06 0·99 1·57 
 
Scotland 1·21 0·06 0·99 1·48 
 
Wales 1·02 0·86 0·84 1·23 
BMI: Body Mass Index, CI: Confidence Interval, TIA: Transient Ischaemic Attack 
* Each hazard ratio is adjusted for the other variables in the table 
†BMI: Healthy (18·5-25·9 kg/m2); Underweight (<18·5 kg/m2); Overweight (26-30 kg/m2); 
Obese (>30 kg/m2) 
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Figure 1: Kaplan-Meier (K-M) failure 
estimates for TIA patients and 
controls consulting for: 
(a) fatigue 
(b) psychological impairment 
(c) cognitive impairment  
The maximum follow-up time was 
60·5 months for each sub-study; 
however, the K-M graphs are cut-off 
at 48 months when approximately 
<10% of the sample remains. 
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Psychological impairment 
A total of 55,483 individuals were included in the survival analysis for the psychological 
impairment sub-study: 9,240 TIA patients matched to 46,243 controls (447 TIA 
patients/controls were excluded because psychological impairment was recorded on the 
index date). The median follow-up was 11·2 months (range 0 to 60·5 months) for TIA 
patients and 14·4 months (range 0 to 60·5 months) for controls. Psychological impairment 
was recorded in 14,285 individuals; of these, 11,040 consulted for depression, 2,691 anxiety, 
546 anxiety and depression, and 8 PTSD. The K-M curves show that TIA patients were more 
likely to consult for/ be prescribed drugs for psychological impairment compare to controls 
(P<0·0001; Figure 1b). The 25th percentile for time to psychological impairment was 7·1 
months (95% CI 6·2, 8·2) for TIA patients and 23·5 months (95% CI 22·5, 24·6) for controls 
(Figure 1b). Following adjustment for demographic and clinical characteristics, TIA patients 
had a 26% increased risk of consulting for psychological impairment compared to controls 
(HR 1·26: 95% CI 1·20, 1·31; P<0·0001, Table 3).  
 
 
 
 
 
 
155 
 
Table 3: Adjusted* hazard ratios for the effects of demographic and clinical characteristics 
on consultations for psychological impairment in TIA patients and controls. 
  
Hazard 
Ratio P value 95% CI 
TIA/ control TIA 1·26 <0·001 1·20 1·31 
Age <45 1·20 <0·001 1·08 1·33 
 
45-49 1·15 0·01 1·04 1·27 
 
50-54 1·13 0·01 1·04 1·24 
 
55-59 1·15 <0·001 1·05 1·25 
 
60-64 1·01 0·74 0·94 1·09 
 
65-69 1·01 0·86 0·93 1·09 
 
70-74 1·00 
   
 
75-79 1·10 0·01 1·02 1·17 
 
80-84 1·10 0·01 1·03 1·18 
 
85-89 1·18 <0·001 1·09 1·28 
 
≥90 1·24 <0·001 1·13 1·36 
Sex Female 1·28 <0·001 1·23 1·33 
Impairment 
prior to index 
date 
Psychological impairment 4·46 <0·001 4·25 4·68 
Cognitive impairment 1·21 <0·001 1·12 1·30 
Fatigue 1·16 <0·001 1·12 1·21 
Impairment post 
index date 
Cognitive impairment 1·40 <0·001 1·29 1·53 
Fatigue 1·30 <0·001 1·23 1·37 
Smoking status  Non 1·00 
   
 
Ex 1·15 <0·001 1·11 1·20 
 
Current 1·24 <0·001 1·17 1·31 
 
Missing 0·88 0·01 0·80 0·96 
Alcohol intake Never 
    
 
Light 0·89 <0·001 0·83 0·95 
 
Moderate 0·92 0·02 0·86 0·99 
 
Heavy 0·89 <0·001 0·84 0·95 
 
Missing 0·95 0·11 0·89 1·01 
BMI Healthy 1·00 
   
 
Underweight 1·06 0·36 0·93 1·21 
 
Overweight 1·00 0·99 0·96 1·05 
 
Obese 1·09 <0·001 1·04 1·15 
 
Missing 1·03 0·48 0·95 1·12 
Deprivation 1 (least deprived) 1·00 
   
 
2 0·98 0·54 0·94 1·04 
 
3 1·01 0·62 0·96 1·07 
 
4 1·08 0·01 1·02 1·15 
 
5 (most deprived) 1·17 <0·001 1·09 1·25 
 
Missing 1·11 0·08 0·99 1·25 
     Continued on next page 
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Hazard 
Ratio P value 95% CI 
Comorbidities Atrial fibrillation 0·53 <0·001 0·49 0·57 
 
Asthma 0·56 <0·001 0·53 0·60 
 
Cancer 0·56 <0·001 0·52 0·60 
 
CHD 0·58 <0·001 0·55 0·62 
 
CKD 0·56 <0·001 0·53 0·59 
 
COPD 0·63 <0·001 0·58 0·68 
 
Diabetes 0·66 <0·001 0·62 0·71 
 
Epilepsy 0·55 <0·001 0·47 0·63 
 
Heart Failure 0·57 <0·001 0·52 0·63 
 
Hypertension 0·57 <0·001 0·54 0·60 
 
Hypothyroidism 0·61 <0·001 0·57 0·65 
 
Osteoporosis 0·60 <0·001 0·56 0·64 
 
PAD 0·57 <0·001 0·52 0·63 
 
Rheumatoid arthritis 0·59 <0·001 0·53 0·67 
 
Multimorbidity 1·86 <0·001 1·80 1·92 
Health authority  West Midlands 1·00 
   
 
Yorkshire & Humber 1·37 <0·001 1·21 1·54 
 
North West 1·09 0·06 1·00 1·20 
 
East Midlands 1·12 0·04 1·01 1·25 
 
North East 1·16 0·05 1·00 1·35 
 
East of England 1·23 <0·001 1·11 1·36 
 
London 1·00 0·96 0·88 1·13 
 
South East Coast 1·17 <0·001 1·07 1·28 
 
South Central 1·24 <0·001 1·15 1·35 
 
South West 1·19 <0·001 1·08 1·31 
 
Northern Ireland 1·43 <0·001 1·29 1·58 
 
Scotland 1·16 <0·001 1·07 1·27 
 
Wales 1·29 <0·001 1·17 1·43 
BMI: Body Mass Index, CHD: Coronary Heart Disease, CI: Confidence Interval, CKD: 
Chronic Kidney Disease, COPD: Chronic Obstructive Pulmonary Disease, PAD: Peripheral 
Artery Disease, TIA: Transient Ischaemic Attack 
* Each hazard ratio is adjusted for the other variables in the table 
†BMI: Healthy (18·5-25·9 kg/m2); Underweight (<18·5 kg/m2); Overweight (26-30 kg/m2); 
Obese (>30 kg/m2) 
 
 
Continued from previous page 
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Cognitive impairment 
A total of 55,905 individuals were included in the survival analysis for the cognitive 
impairment sub-study: 9,397 TIA patient matched to 46,508 controls (25 TIA 
patients/controls were excluded because cognitive impairment was recorded on the index 
date). The median follow-up time was 18·8 months (range 0 to 60·5 months) for TIA patients 
and 20·0 months (range 0 to 60·5 months) for controls. Cognitive impairment was recorded 
in 1,425 individuals; the K-M curves show that TIA patients were more likely to consult for 
cognitive impairment compared to controls (P<0·0001; Figure 1c). The 5th percentile for time 
to cognitive impairment was 31·1 months (95% CI 25·9, 35·6) for TIA patients and 52·7 
months (95% CI 48·6, 56·4) for controls (Figure 1c). Following adjustment for demographic 
and clinical characteristics, TIA patients had a 45% increased risk of consulting for cognitive 
impairment compared to controls (HR 1·45: 95% CI 1·28, 1·65; P<0·0001, Table 4).  
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Table 4: Adjusted* hazard ratios for the effects of demographic and clinical characteristics 
on consultations for cognitive impairment in TIA patients and controls. 
  
Hazard Ratio P value 95% CI 
TIA/ control TIA 1·45 <0·001 1·28 1·65 
Age <50 0·14 <0·001 0·07 0·26 
 
50-54 0·36 <0·001 0·23 0·54 
 
55-59 0·44 <0·001 0·31 0·61 
 
60-64 0·39 <0·001 0·29 0·53 
 
65-69 0·67 <0·001 0·52 0·86 
 
70-74 1·00 
   
 
75-79 1·61 <0·001 1·33 1·94 
 
80-84 2·01 <0·001 1·66 2·44 
 
85-89 2·09 <0·001 1·72 2·54 
 
≥90 1·67 <0·001 1·28 2·19 
Sex Female 0·96 0·50 0·87 1·07 
Impairment prior 
to index date 
Cognitive impairment 5·55 <0·001 4·78 6·45 
Fatigue 1·47 <0·001 1·30 1·65 
Impairment post 
index date 
Psychological 
impairment 
1·74 <0·001 1·55 1·96 
BMI Healthy 1·00 
   
 
Underweight 1·13 0·47 0·81 1·59 
 
Overweight 0·90 0·10 0·80 1·02 
 
Obese 0·82 0·01 0·71 0·95 
 
Missing 0·66 <0·001 0·53 0·83 
Rurality Urban 1·24 0·01 1·06 1·46 
Comorbidities Dementia 0·35 <0·001 0·25 0·47 
Health authority  West Midlands 1·00 
   
 
Yorkshire & Humber 0·63 0·08 0·37 1·06 
 
North West 1·14 0·31 0·88 1·48 
 
East Midlands 0·96 0·90 0·54 1·72 
 
North East 0·98 0·90 0·72 1·33 
 
East of England 1·12 0·43 0·84 1·51 
 
London 0·98 0·87 0·77 1·25 
 
South East Coast 0·94 0·65 0·71 1·24 
 
South Central 0·87 0·25 0·68 1·11 
 
South West 1·04 0·79 0·79 1·37 
 
Northern Ireland 1·38 0·07 0·98 1·95 
 
Scotland 1·49 <0·001 1·13 1·95 
 
Wales 0·97 0·86 0·67 1·39 
BMI: Body Mass Index, CI: Confidence Interval, TIA: Transient Ischaemic Attack 
* Each hazard ratio is adjusted for the other variables in the table 
†BMI: Healthy (18·5-25·9 kg/m2); Underweight (<18·5 kg/m2); Overweight (26-30 kg/m2); 
Obese (>30 kg/m2) 
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Exploratory analysis 
The effect of excluding individuals with a record of the outcome prior to the index date was 
explored. In this exploratory analysis, 42,836 individuals were included in the survival 
analysis for the fatigue sub-study (6,400 TIA patients and 36,436 controls); 28,390 in the 
psychological impairment sub-study (4,013 TIA patients and 24,377 controls); and 53,265 in 
the cognitive impairment sub-study (8,739 TIA patients and 44,526 controls). Results showed 
that a significant difference between TIA patients and controls remained for all three 
impairments (P<0·0001; Figure 2). The 5th percentile for time to consultation for fatigue was 
15·9 months for TIA patients and 41·6 months for controls; the 10th percentile for time to 
consultation/ drug prescription for psychological impairment was 12·6 months for TIA 
patients and 24·2 months for controls; and the 5th percentile for time to consultation for 
cognitive impairment was 24·9 months for TIA patients and 48·2 months for controls. 
Adjusted hazards ratios increased to 1·75 (95% CI 1·57, 1·94) for fatigue, 1·66 (95% CI 1·50, 
1·84) for psychological impairment, and 1·54 (95% CI 1·35, 1·77) for cognitive impairment.  
Further exploratory analyses are presented in the supplementary material.  
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Figure 2: Kaplan-Meier (K-M) failure 
estimates for TIA patients and 
controls with no record of the 
impairment prior to the index date 
and consulting for: 
(a) fatigue 
(b) psychological impairment 
(c) cognitive impairment  
The maximum follow-up time was 
60·5 months for each sub-study; 
however, the K-M graphs are cut-off 
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Discussion 
We found TIA patients in a large UK general practice population had increased risk of 
consulting for fatigue, psychological, and cognitive impairment compared to matched 
controls. TIA patients had an increased risk of 43% for consulting for fatigue, 26% for 
psychological impairment, and 45% for cognitive impairment compared to controls. TIA 
patients remained more likely to consult for these impairments compared to controls 
following adjustment for potential confounding variables and when patients with these 
outcomes prior to the index TIA were excluded. Our findings suggest that for many patients 
TIA is not a transient event and patients experience impairments after initial symptoms have 
resolved. 
The systematic review conducted prior to our study found a limited number of studies that 
measured residual impairment after TIA and included a control group.7 None of the included 
studies that measured fatigue or PTSD had a control group. Only one study that measured 
anxiety included a control group and found a statistically significant difference in frequency 
of anxiety between TIA and control patients;22 however, two depression studies which 
included controls reported no difference.22,23 Three studies which measured cognitive 
impairment and included a comparison group were included in the systematic review.24-26 
Two of these studies found a statistically significant difference in frequency of cognitive 
impairment between TIA patients and controls. However, most of the studies included in the 
systematic review which had a control group did not adjust for confounding variables and 
the sample sizes were relatively small (<350 participants). Subsequent to the systematic 
review, a Dutch study found a reduction in cognitive functioning in TIA patients compared to 
controls in all cognitive domains except episodic memory; however, the sample size was 
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relatively small (n=189) and the TIA patients and controls were not matched.8 Other studies 
conducted after our systematic review which investigated psychological impairment post-TIA 
did not include a control group.9,10 Our study addressed limitations of existing studies and 
found increased risk of consulting for fatigue, psychological, and cognitive impairment in TIA 
patients compared to controls. 
TIA is characterised by transient stroke-like symptoms and, by definition, does not cause 
permanent cerebral infarction.2 In the absence of visible cerebral infarction, there are a 
number of potential explanations for our findings. Firstly, neurobiological consequences of 
TIA: contrary to the tissue-based definition, TIA may cause microinfarcts that are not 
detected by neuroimaging with computed tomographic (CT) or magnetic resonance imaging 
(MRI). Microinfarcts have been detected by histological examination and pooled analysis of 
autopsy studies from community prospective cohorts found an association between 
microinfarcts and dementia.27 Studies have found evidence of abnormal neural activity in TIA 
patients with no lesions on conventional MRI compared to controls.28,29 Furthermore, these 
studies reported an association between abnormal neural activity and cognitive impairment. 
Secondly, residual impairments post-TIA could be a result of the psychological impact of the 
event. Psychological impact of TIA and minor stroke has been described in qualitative 
research.30 A psychological mechanism has been proposed for post-stroke depression31 and 
depression after minor stroke has been found to be independent of cerebral lesions.32 
Furthermore, an association between depression and cognitive impairment has been 
reported post-stroke.33 Thirdly, diagnosis of TIA in clinical practice may not adhere to the 
tissue-based definition. Therefore, patients may have presence of cerebral infarction which 
could be responsible for the residual impairments and, by definition, should have a diagnosis 
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of stroke. Although the tissue based-definition was proposed in 2003, it has not been 
universally adopted. The time-based definition (symptoms lasting <24 hours) is still used by 
the World Health Organisation (WHO)34 and the National Institute for Health and Care 
Excellence (NICE) guidelines.5 Within the UK, brain imaging is not routinely used to diagnose 
TIA; therefore, diagnoses of TIA within our study would have been based on clinical diagnosis 
rather than the tissue based diagnosis.5 A systematic review found evidence of ischaemic 
lesion in a third of TIA patients diagnosed according to the time-based definition.35   
Our findings challenge the ‘transient’ characterisation of TIA, a misconception which may 
result in patients receiving inadequate health care post-TIA. Primary care is where TIA 
patients present with residual impairments. Although symptoms may be subtle and 
detection may present a challenge, primary care clinicians should consider the holistic 
consequences of TIA and recognise that these patients may require therapy additional to 
stroke prevention. Furthermore, policy makers should tailor recommendations and 
guidelines to facilitate optimal care for TIA patients in light of our findings. Regardless of the 
mechanism for impairments post-TIA, our findings represent ‘real-life’ TIA diagnoses in 
primary care and GPs need to understand their patients’ therapeutic needs in this context. 
Future research should establish the severity, onset, duration, and natural history of residual 
impairments post-TIA. Additional research should develop intervention(s) to identify TIA 
patients with fatigue, psychological, or cognitive impairments and improve the healthcare 
and rehabilitation of these patients in a cost-effective way. An intervention may be as simple 
as extending existing stroke services to TIA patients or more specialised intervention(s) may 
be necessary. It is important for future research to determine the mechanism underlying the 
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association between TIA and residual impairments. Understanding this association will 
facilitate the development of a rehabilitation intervention and could challenge the current 
definition of TIA. 
The main strengths of our study are the very large sample; data was available from different 
regions across the UK; and data are representative of real-life primary care practice. The 
study design addressed limitations of existing studies in this field by including a control 
group and controlling for confounding variables particularly presence of fatigue, 
psychological, or cognitive impairment prior to the index date. Recording of these 
impairments is likely to vary between general practices; therefore, we matched TIA patients 
and controls on this variable and included it as a random effect in the regression models.  
A limitation of the study concerns the recording of TIA in primary care; although GPs are 
incentivised to keep a register of TIA patients in the UK, TIA may be misdiagnosed36,37 or 
underreported.38 Misdiagnosis of a TIA ‘mimic’ (e.g. migraine with TIA-like symptoms) as TIA 
may dilute the association between TIA and residual impairments; alternatively, diagnosing 
minor stroke as TIA may overestimate the association. However, diagnosis of TIA within the 
THIN database has been validated.39 In addition, Read codes do not contain information on 
whether a tissue- or time-base definition was used to diagnose TIA. Furthermore, there are 
limitations regarding the recording of our outcomes; the use of primary care patient records 
relies on patients consulting with fatigue, psychological, or cognitive impairment and 
clinicians recording these in patients’ electronic medical records. Clinical codes for signs and 
symptoms were used in addition to clinical codes for diagnoses to define our outcomes. 
Therefore, our findings may not be equivalent to clinical diagnoses of fatigue, psychological, 
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or cognitive impairment; for example, there was no distinction between clinical diagnosis of 
anxiety and feeling anxious in our analysis. Our definition of depression and anxiety included 
prescriptions for drugs to treat these conditions; however, these could be repeat 
prescriptions which did not require a face-to-face consultation. Exploratory analysis revealed 
that the sharp increase in consultations for psychological impairment post-index date (Figure 
1b) was explained by prescriptions for anti-depressant drugs. Although presence of the 
impairment prior to the index date was adjusted for in the regression model, the primary 
analysis does not distinguish between prevalent and incident consultations; however, this 
was explored in supplementary analysis. Another limitation with the recording of our 
outcomes is that a patient could consult for an impairment prior to the index date but this 
may not be recorded again after the index date when the impairment persists. Therefore, 
the continued presence of this impairment would not be included in our analysis. Stroke 
prevention medication was not included as a confounder in the analysis. There is some 
evidence that beta-blockers may cause fatigue;40 however, as they are not recommended as 
a first line treatment for hypertension in this age group41 it is unlikely that many patients 
were prescribed them. Although TIA patients and controls were matched on age, sex, and 
general practice, a limitation is that they were not matched on vascular risk factors which 
are potential confounders. Bias may be introduced in our study because: (i) TIA patients 
consulted more in follow-up and, therefore, would have more opportunity to report 
impairment(s) and (ii) patients may be more conscious of their health following a TIA 
compared to controls resulting in increased reporting of impairments. It is important to 
emphasise that not all patients who experienced impairments post-TIA would have 
consulted their GP for them in primary care; therefore, our findings do not represent 
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incidence of fatigue, psychological, or cognitive impairment post-TIA in the community. 
Finally, time to consultation may not reflect the onset of the impairments as patients may 
have waited before consulting their GP. 
Conclusion 
TIA patients are more likely to consult for fatigue, psychological, and cognitive impairment in 
primary care compared to controls. These findings challenge the ‘transient’ characterisation 
of TIA and suggest that these patients may require therapy beyond stroke prevention. 
Dissemination of our finding to primary care clinicians and policy makers is important to 
increase detection and treatment of residual impairments after TIA. 
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Discussion 
This final chapter will discuss the key findings; strengths and limitations; interpretation and 
implications of findings; and areas for future research. The research within this thesis aimed 
to determine: (i) the extent to which people that had a stroke or TIA had prior missed 
opportunities for prevention with pharmacotherapy and (ii) if TIA patients experience 
ongoing residual impairments after initial symptoms have resolved. 
Summary of findings 
The first research theme investigated primary prevention of stroke and TIA. Primary 
prevention with pharmacotherapy was found to be inadequate in primary care; over half of 
people with stroke or TIA had not been prescribed appropriate drug therapy when one or 
more prevention drug had been clinically indicated (Chapters 3- 5). There were missed 
opportunities for prevention in 49% of stroke or TIA patients who had been eligible for lipid 
lowering drugs, 52% for anticoagulant drugs and 25% for antihypertensive drugs. There was 
a significant decrease in the proportion of missed opportunities for anticoagulant drug 
prescribing between 2009 and 2013, but no change for lipid lowering and antihypertensive 
drugs. Different clinical and demographic characteristics were associated with missed 
opportunities for each prevention drug (Chapters 3-5).  
The second research theme explored fatigue, psychological and cognitive impairments after 
TIA. A systematic review of the literature revealed there was limited evidence, but suggested 
a relatively high prevalence of cognitive impairment and depression post-TIA and minor 
stroke. However, there was a lack of high quality studies that included a control group and 
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adjusted for confounding variables or presence of the impairment pre-TIA or minor stroke 
(Chapters 6 and 7). The retrospective cohort study addressed the limitations of existing 
studies and found TIA patients had increased risk of consulting for fatigue, psychological, and 
cognitive impairment in primary care compared to matched controls (Chapters 8 and 9). This 
relationship remained when potential confounding variables and the presence of the 
impairment prior to TIA were adjusted for. 
Strengths and limitations 
The research contributes novel findings to the field of stroke and TIA research. Each study 
followed pre-specified, peer-reviewed protocols which were published in Open Access 
scientific journals (Chapters 3, 6 and 8).1-3 In addition, the findings were reported in 
accordance with PRISMA guidelines,4 for the systematic review, and STROBE guidelines, 5 for 
the case series analysis and retrospective cohort study. Findings have been disseminated 
through four publications and 16 presentations at national and international conferences: 
seven oral presentations, one elevator pitch presentation and eight poster presentations. 
Furthermore, the research has been recognised through a number of regional and 
international awards, including: 
Missed opportunities for prevention of stroke and TIA 
 Distinguished paper presentation at the North American Primary Care Research 
Group (NAPCRG) Annual Meeting. Cancun, Mexico, October 2015. 
 ‘Best abstract from Health and Population Sciences’ at the College of Medical and 
Dental Sciences Festival of Graduate Research. Birmingham, UK, March 2015 
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Residual impairments after TIA: systematic review 
 ‘Australian Association for Academic Primary Care (AAAPC) first time presenter 
award’ at the Primary Health Care Research Conference (PHCRC). Canberra, Australia, 
July 2014. 
 Second prize ‘Best poster competition’ at the National Institute for Health Research 
(NIHR) School for Primary Care Research (SPCR) Showcase. Oxford, UK, September 
2014. 
Missed opportunities for prevention of stroke and TIA 
The strengths and limitations of using routine electronic primary care medical records are 
discussed in Chapter 2. To summarise, the strengths include the large sample size (THIN 
includes data on >12 million patients); geographical spread of data across the UK and data 
are representative of the UK population;6 collection of data in a non-interventional manner 
which reflects real-life primary care practice; availability of clinical and prescribing data; and 
accessibility of the data which reduces time and resources required. The main limitations are 
that the data is reliant on GPs recording patients’ information and data are primarily 
collected for clinical management rather than research; therefore, there may be missing or 
incomplete data. Stroke and TIA were found to be underreported before 2009 (Appendix 
A2.1 and A3.1) and recording of TIA may be less reliable compared to stroke because of 
patients not seeking medical care and misdiagnosis. Furthermore, accuracy of clinical data is 
influenced by QOF incentives which may result in better recording of chronic conditions 
included in QOF. Conversely, non-QOF conditions may be underreported and changes to 
QOF may cause fluctuations in recording of related clinical data.7 In addition, data within 
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THIN are coded and some information, such as stroke severity or subtypes, is not included in 
the Read code system.8  
For the case series analysis, the identification of patients eligible for prevention drugs is 
likely to be reliable because recording of the comorbidities which define eligibility are 
incentivised by QOF. However, some of the clinical data used for the CVD risk equations, 
such as cholesterol, may be missing. Furthermore, BP is subject to fluctuations and there 
may be measurement error which has implications for identifying people eligible for 
antihypertensive drugs; however, the average of three BP measurements was used. The 
prescribing data, which was used to identify missed opportunities, is likely to be accurate 
because prescriptions are automatically retained in the patient’s electronic record through 
Vision software, which is used to print prescriptions.9 Use of data from routine primary care 
medical records are likely to be an accurate reflection of the information the GP had 
available to make prescribing decisions.10 
The generalisability of the results may be limited to the UK because UK national guidelines 
were used to define missed opportunities. In addition, the NHS provides universal, free 
access to health care; therefore, missed opportunities may be greater in countries with 
restricted access to primary health care. The guidelines are continually updated and the 
impacts of revised recommendations were investigated in exploratory analyses. However, 
the evidence which informs guideline recommendations is often known by GPs prior to the 
official updates. Therefore, generalisability of missed opportunities is dependent on whether 
knowledge of adherence to best evidence or adherence to the guidelines is required. 
Although outside the scope of this study, the methodology used does not provide insight 
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into why prevention drugs were not prescribed to eligible patients prior to stroke and if 
drugs were previously prescribed and subsequently stopped or never prescribed. 
Residual impairments after TIA: systematic review 
Systematic reviews are considered the gold standard to synthesise existing evidence.11 The 
advantages include the rigorous identification and synthesis of existing literature, 
assessment of the quality of the evidence and transparency in reporting. However, 
systematic reviews are a time-consuming approach that relies on accurate identification of 
all relevant literature. Although systematic and rigorous methods were employed to search 
literature, identification of all relevant studies cannot be guaranteed. The systematic review 
was conducted in accordance with Cochrane12 and CRD13 guidelines. At a review level, the 
strengths were that a comprehensive search strategy was employed which extended to grey 
literature; non-English language papers were included; and two reviewers independently 
completed the searches, screened titles and abstracts, identified eligible studies, extracted 
data and assessed quality of the included studies. However, the main limitations were that 
authors were not contacted to obtain missing data and the inclusion of abstracts limited the 
amount of data available to extract and the ability to assess quality. Furthermore, stroke in 
follow-up was an exclusion criterion; therefore, bias may have been introduced because the 
participants within the systematic review may be lower risk compared to TIA patients in the 
general population. 
The quality of the primary data included in the review was a significant limitation since 
evidence synthesised through relatively low quality studies limits the quality of the review’s 
findings and affects the reliability and generalisability of results. The majority of studies had 
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small sample sizes and were likely to be underpowered because the outcomes of interest for 
my systematic review were predominantly secondary outcomes in the individual studies. 
Furthermore, the individual studies may have included stroke patients in their sample, but 
only data on TIA and minor stroke patients were extracted for the review. A limited number 
of studies were available for fatigue, anxiety, PTSD and the secondary outcomes QoL, return 
to work and emotionalism. Most studies (22 out of 31) were conducted in secondary care; 
therefore, generalisability of results to the general TIA population may be reduced. For 
instance, TIA patients managed in a secondary care setting may have experienced stressors 
associated with the hospital environment which could have led to increased anxiety.  
The measurement tools used to measure impairments varied between studies which may 
impact on findings; this was particularly evident for cognitive impairment where MoCA and 
MMSE tests were found to give different frequencies of cognitive impairment when used in 
the same study at the same time point.14,15 The generalisability of results was affected by the 
variations in the definition of minor stroke (see Appendix 5.2), recruitment being limited to a 
single site in two-thirds of the studies and heterogeneity in the study populations and 
methodologies used. Most studies included did not have a comparator group so it was 
unclear if the frequency of outcomes post-TIA or minor stroke was different to that of the 
general population. The meta-analysis pooled prevalence of cognitive impairment by 
measurement tool (MoCA, MMSE and neuropsychological test battery). However, the 
pooled point estimates should be interpreted with caution because there was considerable 
heterogeneity and studies varied in terms of case mix, study design and time point of 
assessment. It could be argued that it was not appropriate to do a meta-analysis given this 
heterogeneity; however, the pooled estimates were used to demonstrate how the 
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prevalence of cognitive impairment post-TIA and minor stroke varies depending on 
measurement tool used rather than to quantify prevalence. 
Residual impairments after TIA: retrospective cohort study 
The strength and limitations of using routine electronic primary care medical records 
discussed previously apply to the retrospective cohort study. Use of these electronic medical 
records is novel to the field which researches residual impairments after TIA and the study 
addressed limitations of previous studies. The main strengths of the retrospective cohort 
study were the very large sample size (>55,000 people) and that matched controls, which 
were from the same source population as TIA patients, were included. Furthermore, 
potential confounding variables and presence of the impairment pre-TIA were adjusted for. 
As opposed to other studies in this field, the study explored multiple different impairments 
post-TIA (fatigue, psychological and cognitive impairment). The use of electronic medical 
records, which were collected in a non-interventional way, prevented bias that traditional 
prospective cohort studies are susceptible to, including volunteer and observer bias.16 
There were limitations related to the identification of the exposure (TIA) and outcomes 
(fatigue, psychological or cognitive problems). TIA diagnoses were identified using clinical 
codes (Read codes) and were not verified. TIA is difficult to diagnose17 and the association 
between TIA and residual impairments could be diluted if non-TIA patients were included in 
the TIA group. On the other hand, TIA is often underreported and it is likely that some of the 
control patients would have, unbeknown to them or the GP, had a TIA. The new proposed 
definition of TIA is tissue-based (no evidence of permanent brain infarction) rather than the 
old time-based definition (symptoms less than 24 hours).18 However, the clinical codes used 
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to identify TIA diagnoses do not contain information on how TIA is defined. Use of brain 
imaging to diagnose TIA is not routine in the UK;19 therefore, it is likely that some of the TIA 
group would have brain infarction and should technically be defined as minor stroke rather 
than TIA. However, the study is representative of current primary care practice and clinical 
diagnoses from medical records are more reliable than other methods such as self-report.20 
In terms of identification of outcomes, bias may be introduced because TIA patients 
consulted more in follow-up compared to controls and, therefore, had greater opportunity 
to report impairments to their GP. In addition, people may be more aware of their health 
following a TIA and, consequently, may be more likely to report impairments to their GP 
compared to controls.16 Furthermore, use of routine primary care data limits the information 
available on the outcomes such as onset, duration, severity and impact on people’s lives. 
The study used a primary care population; therefore, results may not be generalisable to the 
general UK population. There could be TIA patients with residual impairments who did not 
consult their GP which may result in underestimation impairments post-TIA. Alternatively, 
TIA patients consulting in primary care could represent the most impaired TIA patients 
overestimating the association between TIA and residual impairments. Due to time 
constraints, the retrospective cohort study did not include patient public involvement (PPI). 
Therefore, outcomes that are important to patients may have been missed. However, TIA 
patients were informally involved in the selection outcomes through anecdotal evidence and 
my personal experience working with TIA patients on a previous study. 
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Interpretation and implications of findings 
Missed opportunities for primary prevention of stroke and TIA 
Sixty percent of people who experienced a stroke or TIA had been eligible for one or more 
prevention drug and, therefore, had an opportunity for primary prevention with 
pharmacotherapy prior to their stroke or TIA. However, over half of people with one or more 
prevention drug clinically indicated were not prescribed these drugs at the time of their 
stroke or TIA, which amounts to a third of all first strokes and TIAs. The majority of these 
(83%: 7,969/9,579) had a missed opportunity for just one prevention drug. A large number 
of strokes and TIAs could potentially be prevented through improving prescribing of lipid 
lowering, anticoagulant and antihypertensive drugs in people in whom these drugs are 
clinically indicated. Despite evidence based guidelines, prescribing of stroke and TIA 
prevention drugs in primary care remains suboptimal.   
Lipid lowering drugs 
Out of the three prevention drugs, lipid lowering drugs were the most common clinically 
indicated; 55% (16,028/29,043) of the study population were eligible for these drugs at the 
time of their stroke or TIA. The largest absolute number of missed opportunities occurred for 
lipid lowering drugs: 7,836 compared to 1,647 for anticoagulant drugs and 1,740 for 
antihypertensive drugs. Furthermore, compared to anticoagulant and antihypertensive 
drugs, lipid lowering drugs had the potential to prevent the greatest number of strokes 
when findings were extrapolated to UK population and stroke incidence estimates (Chapters 
3 and 4). These findings suggest that, out of the three prevention drugs, improving 
prescribing of lipid lowering drugs would have the greatest impact on stroke prevention.  
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The potential impact on stroke and TIA prevention through improving prescribing of lipid 
lowering drugs is an important finding because these drugs are usually considered in the 
context of CHD prevention and there is controversy surrounding their prescription for 
prevention of stroke and CVD.21 The debate was further fuelled by the updated lipid 
lowering guidelines which lowered the recommended prescribing threshold from a 10-year 
CVD risk of 20% to 10%, thereby, increasing the number of people eligible for these drugs.22 
This promoted concerns about medicalisation of otherwise healthy patients and creates 
further challenges for clinicians to communicate stroke risk to an otherwise healthy 
patient.23 The majority of lipid lowering drugs prescribed are statins24 which have a bad 
reputation in the media,25,26 particularly in regard to statin-induced side effects.27 
Furthermore, the relative risk reduction of stroke for statins is low (22%; 95% CI 11% to 
32%); therefore, a large number of people need to be treated to prevent one stroke.28 
Inertia of previous practice, lack of agreement with the guidelines, lack of outcome 
expectancy and patients’ preferences are some of the barriers identified by Cabana et al 
(1999) for clinicians adhering to guidelines and these are likely to be relevant to statin 
prescribing.29 However, it is important to overcome these barriers because statins have the 
potential to be the most effective drug to prevent strokes and TIAs and subsequently reduce 
the burden of these conditions. 
Other studies have investigated the proportion of all eligible patients offered preventative 
treatment rather than looking at the extent to which opportunities were missed in stroke 
and TIA patients. Very high rates of compliance with lipid lowering guidelines have been 
reported in UK primary care for primary prevention (80%) and secondary prevention (74%).30 
However, younger patients were more likely to be on treatment and their study’s population 
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mean age was 20 years younger than our analysis. This is broadly consistent with our 
findings that many older patients who went on to have a stroke/TIA were not treated. A 
more comparable study analysed data from the THIN database between 2008 and 2010. 
Similarly to us, they found 56% of patients eligible for primary CVD prevention lipid lowering 
drugs were not on treatment.31 Other studies have found between 21% and 50% of patients 
with hypercholesterolemia were not on lipid lowering drugs.32-34  
Anticoagulant drugs 
Strokes in people with AF cause more death and disability compared to strokes in people 
without AF.35 Therefore, primary prevention of stroke and TIA is particularly important in 
these patients to reduce the burden of stroke. Anticoagulant drugs should be prescribed to 
AF patients at high stroke risk36 and in practice this is the majority of people; 90% of people 
in our sample with a diagnosis of AF were eligible for anticoagulant drugs at the time of their 
stroke or TIA. Although nearly all patients with AF should be prescribed anticoagulant drugs, 
this class of prevention therapy had the highest proportion of missed opportunities: 52% 
compared to 49% for lipid lowering drugs and 25% for antihypertensive drugs. Anticoagulant 
drugs have the greatest relative risk reduction of stroke out of the three prevention 
drugs;28,37-39 therefore, it is counterintuitive that these drugs are least likely to be prescribed.  
Risk of bleeding is one of the main reasons for GPs not prescribing anticoagulant drugs40 
and, in preventative health care, clinicians need to balance the risk of inflicting harm to the 
patient verses reducing a patient’s risk of stroke. Shared decision making is important for 
patient-centred care and patients should be actively engaged in this decision.41 Older age 
had also been reported as a reason for not prescribing anticoagulant drugs.40 It could be 
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argued that non-prescribing in the elderly is reasonable, particularly given increased 
bleeding risk42 and polypharmacy.43 Furthermore, there may be organisational restraints 
related to warfarin prescribing such as access to a warfarin clinic and international 
normalisation ratio (INR) monitoring .44,45 Updated AF guidelines recommend aspirin is not 
prescribed for stroke prevention;36 however, in previous guidelines aspirin was considered 
acceptable for people with moderate stroke risk.46 Reluctance of clinicians to change 
practice and patients to change medication may also be barriers of anticoagulant 
prescribing.29  
Despite the barriers to anticoagulant drug prescribing, the benefits of anticoagulation have 
been shown to outweigh this risk.47 Furthermore, the net benefit of anticoagulation is 
greatest in the elderly,47 new novel oral anticoagulants have been approved which reduce 
the need for INR monitoring48 and there is strong evidence base to support the 
recommendation that aspirin should not be prescribed for stroke prevention.36 Therefore, 
under prescribing of anticoagulants may not be justifiable. There have been a number of 
improvements in management of AF, including better understanding of stroke risk in these 
patients and development of CHA2DS2-VASc;
49 introduction of novel oral anticoagulants;48 
updated guideline recommendations36 and QOF incentives;50 and development of audit tools 
like GRASP-AF (identifies AF patients eligible for anticoagulation).51 The significant reduction 
in missed opportunities for anticoagulant drugs between 2009 and 2013 may reflect these 
changes. 
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Prescription of antihypertensive drugs for stroke prevention in AF has been explored by 
other studies and, concurrent with my finding, most reported underuse of these drugs.52 
Similar to my study, Holt et al (2012) reported missed opportunities for stroke prevention 
with anticoagulants in 48% of eligible AF patients using the QResearch database.53 However, 
their study used a score of CHADS2 ≥2 to define eligibility and did not report the number of 
people who had suffered a stroke; therefore, it was unclear what proportions of 
anticoagulants were being prescribed for primary or secondary stroke prevention. Other UK 
primary care studies found 45% of AF patients with a CHADS2 score ≥254 and 40% with a 
CHA2DS2-VASc ≥1
55 were not prescribed anticoagulant drugs, but again the proportion of 
people in their samples with stroke were not reported. International studies have reported 
similar levels of under prescribing of anticoagulant drugs in eligible AF patients which ranged 
from 38% to 46%.56-59 
Antihypertensive drugs 
The smallest proportion of missed opportunities for prevention of stroke and TIA was found 
in people eligible for antihypertensive drugs. However, because a larger number of people 
were eligible for these drugs compared to anticoagulant drugs, the absolute numbers of 
missed opportunities for antihypertensive prescribing was second highest out of the three 
prevention drugs. Hypertension is highly prevalent60 and was the most common comorbidity 
in our sample (as defined by QOF Read codes). However, the missed opportunities analysis 
focused on uncontrolled hypertension. People with a Read code indicating hypertension but 
their average recorded BP was <140/90 mmHg were excluded from the analysis, which 
comprised of 64% (9,405/14,646) of people with a clinical code for hypertension. This 
suggests that the most primary care patients with a record of hypertension have controlled 
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BP and the majority with uncontrolled BP are prescribed antihypertensive drugs. The well-
established evidence base and safety profile are potential reasons why antihypertensive 
drugs were better prescribed compared to lipid lowering and antihypertensive drugs.61 In 
addition, patients’ awareness of BP and that lowering BP will improve health may facilitate 
prescribing of antihypertensive drugs.62 Lessons learnt from antihypertensive drug 
prescribing could potentially be applied to improve prescription of lipid lowering and 
anticoagulant drugs. On the other hand, although prescription of antihypertensive drugs 
may be high, the proportion of people with controlled BP remains low.30,63  
Other studies which have investigated the use of antihypertensive drugs in the context of 
CVD prevention vary in the proportions they report of treated hypertensive patients.30,34,64-66 
England has been found to have worse treatment rates compared to the United States and 
Canada.64,66 A UK study comparable to the study within this thesis used primary care data 
from 19 general practices in the West Midlands and found high levels of antihypertensive 
drug prescribing in 86% of eligible people without CVD and 91% of people with CVD.30 This 
was concurrent with my finding that people with CVD were more likely to be treated 
compared to those without. However, the median age of their sample was lower than my 
study (54 years vs 74 years, respectively) which might explain the higher prescribing rates. A 
German study also found a higher proportion of hypertensive patients with CVD were 
treated compared to those without CVD, but a bigger difference in prescribing was 
observed: 85% of people with CVD compared to 55% without CVD.63 However, this study did 
not differentiate between pharmacotherapy and non-pharmacotherapy interventions. 
Improving prescribing of antihypertensive drugs to eligible people without existing CVD 
(primary prevention) should be a target for future research. Other international studies have 
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reported higher proportions of antihypertensive drugs prescribed to hypertensive patients, 
compared to my study, ranging from 87% to 97%.32,34,65 
Behavioural change to improve prescribing of prevention drugs 
Lipid lowering, anticoagulant and antihypertensive drugs for primary prevention of stroke 
and TIA are currently under prescribed in primary care (Chapters 3-5). Improving prescribing 
of these drugs has the potential to reduce the incidence and subsequent burden of stroke 
and TIA; however, interventions are required to change behaviour and should target 
clinicians, patients and policy makers. The behaviour change wheel framework is a 
comprehensive and systematic approach to intervention development to change behaviour 
which could be used in the context of improving prescribing of stroke and TIA prevention 
drugs (Figure 1).67 The basis of the framework is the understanding of behaviour to identify 
targets for interventions and selection of appropriate intervention functions and policy 
categories to change behaviour.67 The centre of the behaviour change wheel is the 
‘behaviour system’, a model to understand behaviour known as COM-B: Capability (physical 
and psychological), Opportunity (social and physical) and Motivation (automatic and 
reflective), which have a bidirectional relationship with Behaviour.67 When developing an 
intervention, the COM-B model can be used to understand behaviour and which 
component(s) need to be targeted to achieve behaviour change. The middle circle of the 
behaviour change wheel comprises of nine intervention functions: education, persuasion, 
incentivisation, coercion, training, enablement, modelling, environmental restructuring and 
restrictions (Figure 1).67 The outer circle contains seven policy categories: environmental/ 
social planning, communication/ marketing, legislation, service provision, regulation, fiscal 
measures and guidelines.67  Different approaches are likely to be required for each 
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prevention drug because different behaviours are associated with non-prescribing of lipid 
lowering, anticoagulant and antihypertensive drugs.32,33,52,68,69 However, some intervention 
functions will be relevant for all three drugs and are discussed below and summarised in 
Figure 1. 
There are potential medicolegal implications of missed opportunities for prevention of 
stroke and TIA. For a person in whom prevention drugs were indicated but not prescribed 
prior to stroke or TIA, an argument of medical negligence could be made on the grounds of 
failure to follow national, evidence-based guidelines without adequate justification. 
Identifying missed opportunities for prevention of stroke and TIA would be facilitated by 
accessibility and ease of searching electronic medical records. It has been suggested that 
medical negligence lawyers could take advantage of this by fishing for missed opportunity 
cases by searching electronic medical records of anyone who has suffered a stroke or TIA.70 
Dissemination of medicolegal accountability could be an effective form of coercion to 
improving prescription of primary prevention drugs. However, an important consideration is 
that guidelines are recommendations and not the law. Medicolegal fear may also have 
negative repercussions for shared decision making and clinicians’ professional judgment 
during prescribing decisions.  
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Figure 1: The behaviour change wheel with examples of potential intervention functions 
targets to improve prescribing of stroke and TIA prevention drugs. Adapted from Michie 
(2012).67 
Training for GPs: 
Provide training on guideline 
recommendations and how to 
communicate stroke risk to 
patients. 
Medicolegal implications: 
Raise awareness of 
medicolegal repercussions of 
medical negligence in people 
who experience a stroke or 
TIA and had a prior missed 
opportunity for prevention. 
Specific guidelines for under 
prescribed populations: 
Develop specific guidelines for 
complex patients who are less likely 
to be prescribed stroke prevention 
medication, such as the very elderly. 
‘Role model’ general 
practices: 
Disseminate prescribing 
statistics, tips and tricks and 
case example from general 
practices with good 
adherence to stroke 
prevention guidelines. 
Software to identify people 
at high stroke risk: 
Develop software similar to 
GRASP-AF to identify people 
eligible for prevention drugs. 
Stroke and CVD prevention 
clinics: 
Establish specific clinics for 
primary stroke and CVD 
prevention targeted at high 
risk patients. 
Computer alerts and justification 
of non-prescribing: 
Use software to alert GPs of 
inappropriate prescribing (e.g. 
when aspirin is prescribed instead 
of anticoagulants) and alerts which 
require GPs to justify non-
prescribing in patients eligible for 
prevention drugs. 
Accessible information for 
patients and GPs: 
Make information available 
through different forms of media 
such as You Tube videos, mobile 
phone apps, blogs, and leaflets. 
Develop accessible decision 
making tools to facilitate shared 
decision making. 
Positive media coverage: 
Use media to 
communicate benefits of 
prevention drugs and 
debunk myths and 
preconceptions. 
Pay-for-
performance 
incentives:  
Further 
develop the 
existing Quality 
and Outcomes 
Framework 
(QOF) 
incentives. 
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In contrast to coercion, incentivisation through pay-for-performance could improve 
prescribing of prevention drugs. The latest QOF guidance (2015/2016) for AF is now in line 
with the 2014 AF NICE guideline recommendations36 and incentivises prescription of 
anticoagulants to AF patients with a recorded CHA2DS2-VASc score ≥2.
50 The impact of this 
on prescribing behaviour should be evaluated. QOF also incentivises prescription of statins 
to people who have a new diagnosis of hypertension, are aged between 30 and 75 years and 
have a 10-year CVD risk of ≥20%.50 Extension of this QOF indicator to include all people with 
10-year CVD risk of ≥10% or 20% and people with existing CVD has the potential to improve 
statin prescribing. Antihypertensive prescribing for primary stroke prevention could also be 
further incentivised by QOF. However, there may be substantial cost implications of this 
approach. 
Strokes and TIAs predominantly occur in the elderly, the median age of the sample for the 
missed opportunities study was 74 years (IQR 64 to 82). The study’s findings were 
extrapolated to the UK population and stroke incidence to estimate numbers of strokes that 
potentially could be prevented by prescribing all eligible patients prevention drugs (Chapters 
4 and 5). These estimates suggested that the greatest reduction in strokes can be obtained 
through prescribing in the very elderly. This has important implications because the 
population is ageing and age is one of the most important risk factors for stroke and TIA. 
However, very elderly age was associated with non-prescribing of all three prevention drugs. 
Therefore, interventions to improve prescribing in the very elderly may be the most efficient 
way to reduce incidence of stroke and TIA. Development of guidelines specifically tailored to 
prescribing prevention drugs in the elderly, particularly the very elderly, which address 
issues concerning side effects and polypharmacy may facilitate prescribing of stroke 
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prevention drugs to these high risk patients. However, there is a lack of evidence for this 
population and further research is required. 
Organisational barriers, including time constraints in consultations and ability to identify 
patients at high stroke risk,29 are likely to hinder primary prevention of stroke and TIA. 
Specialised stroke and TIA prevention clinics could be established for people at high stroke 
risk. This could be done in primary care or the community and would allow protected time to 
address stroke and TIA prevention with patients; however, organisational, time and financial 
barriers may hinder this approach. The GRASP-AF audit tool has been developed for use in 
primary care to identify AF patients at high stroke risk.51 Similar software could be developed 
to identify patients eligible for lipid lowering and antihypertensive drugs to facilitate the 
prescribing of these drugs. Alternatively software could be developed to discourage 
inappropriate prescribing or non-prescribing, such as alerts if aspirin is prescribed instead of 
anticoagulant drugs to AF patients or compulsory recording of reasons for not prescribing 
stroke prevention drugs to patients who are eligible. Patients’ adherence to medication has 
been cited as a barrier to not prescribing stroke prevention drugs.71-73 Patients’ adherence 
could potentially be improved by training and education interventions67 which provide 
accessible information on stroke risk and prevention drugs,  potentially through different 
forms of media such as information sheets, You Tube videos, mobile phone applications and 
blogs. Specific training for GPs on communication of stroke risk and further development of 
decision making tools could also facilitate shared decision making.41 
Negative perceptions of stroke prevention drugs, particularly statins, may affect wiliness of 
clinicians to prescribe drugs and deter patients from taking these drugs.25-27 Therefore, 
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persuasion-based interventions through a media campaign to promote a positive image of 
stroke prevention medication may reduce misconceptions about these drugs and could also 
be used to educate people about stroke risk. The media campaign to raise awareness of 
symptoms of stroke (the F.A.S.T campaign) has been shown to be effective.74 General 
practice are likely to vary in their prescribing habits and use of ‘role model’67 general 
practices, who have a good record of prescribing stroke prevention drugs, could be used to 
act as examples for other practices to aspire to, provide tips and tricks and take part in 
educational events.75 
Residual impairments after TIA 
Systematic review 
The systematic review demonstrated that residual impairments post-TIA are under-
researched and existing studies had important methodological limitations. However, the 
review suggested there may be a relatively high prevalence of depression and cognitive 
impairment post-TIA and minor stroke. This finding was supportive of the hypothesis that 
these patients may experience ongoing residual impairments; however, it was unclear if the 
prevalence of depression and cognitive impairment post-TIA and minor stroke was different 
to people the same age and sex without TIA or minor stroke. In addition, there were very 
few studies that measured fatigue, anxiety and PTSD post-TIA and minor stroke. The 
systematic review also highlighted methodological issues regarding choice of measurement 
tool to detect residual impairments in TIA and minor stroke patients. Residual impairments 
in these patients may be subtle and, therefore, measurement tools validated in stroke 
patients may not be appropriate.14,15 Furthermore, most studies did not report presence of 
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the impairment pre-TIA or minor stroke. Therefore, impairments post-TIA and minor stroke 
could represent prevalent cases rather than TIA/minor stroke-related impairment. Most 
studies also did not adjust for potential confounding variables; therefore, the true 
relationship between TIA or minor stroke and residual impairments may be distorted.76 The 
association between TIA or minor stroke and fatigue, psychological and cognitive 
impairments could not be determined from the findings of the systematic review. Therefore, 
there was a need to conduct a matched cohort study to robustly measure this association. 
Retrospective cohort study 
To my knowledge, use of electronic primary care medical records to conduct a retrospective 
cohort study is a novel method for the field of research which investigates residual 
impairments after TIA. However, due to the use of Read codes to identify diagnoses, minor 
stroke patients could not be included using this method. The retrospective cohort study 
found that people presenting with a diagnosis of TIA in primary care had significantly 
increased risk of consulting for fatigue, psychological and cognitive impairments compared 
to matched controls. This association remained when presence of the impairment pre-TIA 
and potential confounding variables were adjusted for. These findings suggest that some 
patients may experience residual impairments post-TIA and consult for these impairments in 
primary care.  
The association between TIA and consultation for fatigue, psychological and cognitive 
impairment is complicated by the definition of TIA. TIA was first classified in 195877 and the 
definition has continuously been updated, evolving from a time-based to tissue-based 
definition which was most recently updated in 2009.18 However, the tissue-based definition 
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is not consistently used in clinical practice or research and, in the UK, brain imaging is not 
routinely employed to diagnose TIA.19 Consequently, the people with a diagnosis of TIA 
included in the retrospective cohort study are likely to comprise of people with and without 
presence of brain infarcts.78 According to the tissue-based definition, this sample would 
technically be considered a mix of TIA and minor stroke patients. The mechanism of TIA-
related impairments is unknown, but a potential mechanism could be presence of brain 
infarcts in minor stroke patients which have been diagnosed as TIA. Therefore, to distinguish 
between TIA and minor stroke, it is important to establish whether the association between 
TIA and residual impairments remains if the study population is restricted to TIA patients 
with no evidence of brain infarction. 
The importance of distinguishing between TIA and minor stroke is debatable. If TIA patients 
with no evidence of brain infarction do not experience residual impairments, routine use of 
brain imaging to differentiate between TIA and minor stroke could be useful for clinicians to 
understand the prognosis of their patients and provide appropriate care. Furthermore, 
studies have found that the short-term stroke risk in ‘TIA patients with infarction’ is 
significantly higher than ‘TIA without infarction’.79-81 This suggests distinction between TIA 
and minor stroke would be useful to understand patients’ risk of stroke. Routine 
neuroimaging, within 24 hours, has been recommended by the AHA/ASA.18 However, the 
cost-benefit and practical implications of this should be considered.  
The time-based definition of TIA is used by the NICE guidelines for diagnosis and initial 
management of stroke and TIA.82 Therefore, it may be more informative for clinicians to 
understand the prognosis of people presenting in primary care with a diagnosis of TIA in the 
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context of how TIA is routinely diagnosed currently, which is represented by the 
retrospective cohort study, and the precise definition of TIA or mechanism of impairments is 
less important. In addition, as opposed to presence of brain infarcts, the mechanism of TIA-
related impairments could be a result of presence of microinfarcts which are not detectable 
by existing imaging technologies83 or the psychological impact of experiencing a TIA84,85 as 
discussed in Chapter 9. The inconsistent use of the definition of TIA is confusing for clinicians 
and patients and has implications for policy recommendations and research of TIA patients. 
The definition of TIA should be standardised; however, this has practical implications 
because it would require the routine use of brain imaging. In the meantime, it is important 
for guidelines and researchers to be explicit in their definition of TIA.  
TIA was originally considered to be a benign condition; however, evidence of the association 
between TIA and increase risk of stroke changed this view.86 TIA is now considered a medical 
emergency and the importance of stroke prevention in these patients is recognised.87 The 
findings of the retrospective cohort study challenge the understanding of TIA further 
because they suggest that TIA may not be a transient condition and the holistic 
consequences of TIA are not limited to increased stroke risk. These novel findings suggest 
that further care, beyond stroke prevention, may be required for TIA patients. Although the 
mechanism of post-TIA impairments is not understood and may be affected by how TIA is 
defined, appropriate care and treatment of TIA patients is required in the current context of 
TIA diagnoses and presentation of TIA in primary care. Residual impairments are likely to 
impact on patients’ QoL and ability to return to work or normal activities. The Oxford 
vascular study found that TIA patients had statistically significant lower QoL compared to 
matched controls at one month and five years post-TIA.88 A study of first-ever minor stroke 
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patients found that patients with depression attributed to minor stroke had a higher 
proportion of disability and lower QoL scores at one year.89 Qualitative research which 
interviewed family members of minor stroke patients reported that patients had difficulty 
with complex activities and this caused burden to family members.90 It is important to 
establish the health and social care needs of these patients and their families to ensure 
patients receive adequate follow-up care. 
TIA patients, their carers and family members, clinicians and policy makers, are the key 
stakeholders for this research and important targets for knowledge transfer. Although 
further understanding of residual impairments post-TIA is required, immediate 
dissemination of findings are important. TIA patients should be informed that they may have 
ongoing fatigue, cognitive or psychological impairments following resolution of initial 
symptoms and be encouraged to consult in primary care if they experience these 
impairments. Furthermore, this information should be disseminated to carers and family 
members to facilitate recognition of impairments. Awareness of residual impairments post-
TIA should be raised amongst stroke doctors and nurses in secondary care so they can equip 
patients upon discharge. Furthermore, primary care clinicians should be made aware of 
residual impairments to improve detection and treatment of impairments when TIA patients 
are followed up in primary care. Screening people with a diagnosis of TIA for residual 
impairments in primary care could potentially facilitate identification of impairments. 
Findings should also be disseminated to policy makers and guideline recommendations 
updated to incorporate potential impairments post-TIA both in the context of detection and 
rehabilitation. 
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Future research 
Missed opportunities for prevention of stroke and TIA 
In accordance with the behavioural change wheel framework, future research to improve 
prescribing of drugs for stroke and TIA prevention in primary care requires an understanding 
of prescribing behaviour.67 The barriers and facilitators for prescribing of prevention drugs 
need to be identified and intervention(s) developed to target these. A multifaceted 
intervention including involvement of clinicians, policy makers and patients is likely to be 
required. Differences in the barriers to prescribing for each prevention drug should also be 
taken into consideration.32,33,52,68,69 The proposed future research focuses on stroke and TIA 
prevention in the context of prescribing prevention drugs; however, other areas of 
intervention to improve stroke and TIA prevention include public health campaigns to 
reduce stroke and TIA risk factors and interventions to improve patients’ adherence to 
stroke prevention medication. 
Areas for future research have been suggested in Chapters 4 and 5. However, a 
comprehensive and systematic programme of research has the greatest potential to develop 
an effective intervention(s) which can be successfully translated into practice.67,91 This could 
comprise of a mixed methods approach with three phases: (i) identify barriers and 
facilitators to prescribing; (ii) develop an intervention(s); and (iii) evaluate the intervention(s) 
as described in detail below. 
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Phase one: Identify barriers and facilitators for primary stroke and TIA 
prevention 
A mixed method approach, comprised of a systematic review, qualitative interviews and 
THIN database analysis, to understand prescribing behaviour and identify barriers and 
facilitators linked to the COM-B model.67 
Cabana et al (1999) developed a framework of barriers to physicians’ adhering to 
guidelines.29 Other studies have identified barriers specifically related to dyslipidaemia, AF 
and hypertension guidelines.32,33,52,68,69 The existing literature should be synthesised through 
a systematic review to identify the barriers and facilitators relevant to prescribing of lipid 
lowering, anticoagulant and antihypertensive drugs. Qualitative interviews should be 
conducted to further develop an understanding of barriers and facilitators from the 
perspective of primary care clinicians and patients. Results should be compared with the 
findings of the systematic review. In addition, quantitative analysis using the THIN database 
could be used to determine the proportion of missed opportunities for primary stroke and 
TIA prevention in all patients, not just prior to stroke or TIA. This analysis could also quantify 
the proportion of people with missed opportunities who had previously been prescribed 
stroke and TIA prevention drugs and prescriptions were stopped compared to those never 
prescribed prevention drugs. This would inform the intervention to determine the extent it 
would need to be targeted at supporting initiation or continuation of prevention drugs. 
Phase two: Develop an intervention(s)  
Based on the findings in phase one, relevant intervention functions and policy categories 
should be identified.67 Potential interventions are detailed in Figure 1. The intervention may 
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be complex with multiple components and should be designed in accordance with the 
Medical Research Council (MRC) guidance for developing  a complex intervention.91 Primary 
care clinicians, patients and policy makers are key stakeholders and their involvement to co-
create the intervention would be essential to ensure the quality, relevance and success of 
the intervention. Existing interventions and their effectiveness should be considered. 
Phase three: Evaluate feasibility and effectiveness of the intervention 
The feasibility and effectiveness of intervention(s) developed in phase two should be 
evaluated. A pilot study may be required to test the feasibility and acceptability followed by 
a clinical trial to evaluate the effectiveness. Clinical trials are considered the gold standard to 
evaluate an intervention.91 A mixed methods approach which collects qualitative and 
quantitative data should be conducted to obtain a comprehensive assessment of the 
intervention. A health economics component would also be important to measure the cost-
effectiveness. Key stakeholders should be included in the trial design and interpretation and 
dissemination of findings.  
Residual impairments after TIA  
Research investigating residual impairments after TIA is in the early stages and further 
research is required to develop a more comprehensive understanding of these impairments 
and expand the evidence base. The future research suggested below is described in the 
context of TIA patients; however, would also relevant to minor stroke patients.  
The natural history of fatigue, psychological and cognitive impairment post-TIA should be 
established to determine the onset and duration of these impairments. The severity of 
fatigue, psychological and cognitive impairment post-TIA should also be established. Severity 
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should be considered in terms of clinical relevance and impact on patients’ QoL. These 
outcomes could be achieved through a prospective cohort study which includes 
measurement of impairments at multiple time points in follow-up using validated tools and 
patient reported outcomes. Recruitment and follow-up for a prospective cohort study which 
investigated functional, cognitive and emotional outcomes after TIA (FACE TIA) has been 
completed, but the results of this study have not yet been published.57 However, it is likely 
that further prospective cohort studies will be required to establish a comprehensive 
understanding of impairments post-TIA. Furthermore, future studies should include PPI 
(input from patients, carers and family members) as an integral component to develop the 
research question, co-design the study, interpret findings and develop dissemination plans. 
Working with TIA patients and their families would be important for the success of the study 
through ensuring the research is relevant to patients, improve the quality of the study (such 
as advising on language used in questionnaires), making sure the research is acceptable for 
participants and targeting key stakeholders for dissemination.92 
The mechanism of residual impairments post-TIA should be explored. The first step would to 
be to determine if TIA patients with no evidence of brain infarction experience fatigue, 
psychological or cognitive impairment. This could potentially be included as an outcome in 
the prospective cohort study proposed above. The mechanism that proposes TIA-related 
impairments are induced through psychological impact of a TIA could be investigated by 
exploring if psychological impairment in the acute stage post-TIA is associated with ongoing 
residual impairments. The neurobiological mechanism (presence of microinfarcts) was 
another mechanism proposed in Chapter 9. However, with current imaging technologies it 
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would be challenging to determine if presence of microinfarcts are associated with 
impairment post-TIA.83 
Future research is required to develop interventions focused on improving identification of 
impairments post-TIA in primary care and providing appropriate therapy or rehabilitation. A 
greater understanding of impairments post-TIA will optimise development of an 
intervention; however, in the meantime, it is still important to address patients’ needs in the 
context of current diagnosis of TIA and the findings of the retrospective cohort study. The 
first step to improve detection of fatigue, psychological or cognitive problems post-TIA in 
primary care is to educate primary care clinicians to increase awareness of potential 
impairments post-TIA. Following this, the optimum way to screen for residual impairments in 
primary care should be identified. Additional investigation is required to determine the 
impact of residual impairments post-TIA on patients’ lives and, in turn, inform what therapy, 
rehabilitation and support is required by these patients. This should comprise of qualitative 
interviews with patients, carers and family members and quantitative measures including 
patient reported outcomes and return to work. It may be possible to extend existing stroke 
services to TIA patients or an intervention tailored to TIA patients may be required. 
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Conclusion 
The studies presented within this thesis addressed two important topics in the area of stroke 
and TIA research: (i) primary prevention of stroke and TIA and (ii) residual impairments after 
TIA. The findings demonstrated inadequate prescribing, in primary care, of lipid lowering, 
anticoagulant and antihypertensive drugs in people whom these drugs were clinically 
indicated prior to stroke or TIA. Approximately two thirds of people who experienced stroke 
or TIA had a primary prevention drug clinically indicated, but over half of these (54%) had 
one or more missed opportunity for prevention. Different clinical and demographic 
characteristics were associated with missed opportunities for each prevention drug and a 
reduction in missed opportunities between 2009 and 2013 was only observed for 
anticoagulant drugs. Improving prescribing of lipid lowering, anticoagulant and 
antihypertensive drugs has the potential to reduce the incidence and subsequent burden of 
stroke and TIA.  
Robust estimates of the prevalence of fatigue, psychological, and cognitive impairment in 
patients with TIA and minor stroke could not be determined from the existing literature, 
which was limited. However, the retrospective cohort study found TIA patients had 
increased risk of consulting for fatigue, psychological, and cognitive impairments in primary 
care compared to matched controls. The findings challenge the transient characterisation of 
TIA and suggest that existing guideline recommendations for management of TIA, which 
focus on stroke prevention, may not be adequate. Dissemination of findings to patients, 
primary care clinicians and policy makers is important to increase detection and treatment 
of residual impairments after TIA and improve patient care. 
203 
 
References 
1. Moran GM, Calvert M, Feltham MG, Marshall T. Retrospective case review of missed 
opportunities for primary prevention of stroke and TIA in primary care: protocol paper. BMJ 
Open. 2014;4(11):e006622. 
2. Moran GM, Calvert M, Feltham MG, Ryan R, Marshall T. A retrospective cohort study to 
investigate fatigue, psychological or cognitive impairment after TIA: protocol paper. BMJ 
Open. 2015;5(4):e008149. 
3. Moran GM, Fletcher B, Calvert M, Feltham MG, Sackley C, Marshall T. A systematic review 
investigating fatigue, psychological and cognitive impairment following TIA and minor stroke: 
protocol paper. Systematic Reviews. 2013;2:72. 
4. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.  
http://www.prisma-statement.org/. Accessed October, 2015. 
5. STROBE Statement: strengthening the reporting of observational studies in epidemiology.  
http://www.strobe-statement.org/?id=available-checklists. Accessed October, 2015. 
6. Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement 
Network (THIN) database: demographics, chronic disease prevalence and mortality rates. 
Informatics in Primary Care. 2011;19(4):251-255. 
7. Welch C. Longitudinal Recording of Health Indicators. 2012; 
https://www.ucl.ac.uk/pcph/research-groups-themes/thin-
pub/mi/recording_in_thin/long_record. Accessed October, 2015. 
8. Health and Social Care Information Centre (HSCIC). Read codes.  
http://systems.hscic.gov.uk/data/uktc/readcodes. Accessed October, 2015. 
9. In Practice Systems (INPS). Vision Software.  http://www.inps.co.uk/vision/health-
improvement-network-thin. Accessed October, 2015. 
10. Shephard E, Stapley S, Hamilton W. The use of electronic databases in primary care research. 
Family Practice. 2011;28(4):352-354. 
11. Mulrow CD. Systematic Reviews: Rationale for systematic reviews. BMJ. 1994;309(6954):597-
599. 
12. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 
5.1.0. The Cochrane Collaboration 2011. 
13. Centre for Reviews and Dissemination (CRD). Systematic Reviews. CRDs guidance for 
undertaking reviews in health care. 2008; 
https://www.york.ac.uk/media/crd/Systematic_Reviews.pdf. Accessed October, 2015. 
14. Blackburn DJ, Bafadhel L, Randall M, Harkness KA. Cognitive screening in the acute stroke 
setting. Age and Ageing. 2013;42(1):113-116. 
15. Pendlebury ST, Markwick A, de Jager CA, Zamboni G, Wilcock GK, Rothwell PM. Differences in 
cognitive profile between TIA, stroke and elderly memory research subjects: a comparison of 
the MMSE and MoCA. Cerebrovascular Diseases. 2012;34(1):48-54. 
16. Delgado-Rodríguez M, Llorca J. Bias. Journal of Epidemiology and Community Health. 
2004;58(8):635-641. 
17. Castle J, Mlynash M, Lee K, et al. Agreement regarding diagnosis of transient ischemic attack 
fairly low among stroke-trained neurologists. Stroke. 2010;41(7):1367-1370. 
 
 
 
 
 
204 
 
18. Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack: a 
scientific statement for healthcare professionals from the American Heart 
Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery 
and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on 
Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease: The 
American Academy of Neurology affirms the value of this statement as an educational tool 
for neurologists. Stroke. 2009;40(6):2276-2293. 
19. Tyrrell P, Swain S, Rudd A. Diagnosis and initial management of transient ischaemic attack. 
Royal College of Physicians; 2010. 
20. Bergmann MM, Byers T, Freedman DS, Mokdad A. Validity of self-reported diagnoses leading 
to hospitalization: a comparison of self-reports with hospital records in a prospective study 
of American adults. American Journal of Epidemiology. 1998;147(10):969-977. 
21. Kmietowicz Z. New analysis fuels debate on merits of prescribing statins to low risk people. 
BMJ. 2014;348:g2370. 
22. National Institute for Health and Care Excellence (NICE). Lipid modification: cardiovascular 
risk assessment and the modification of blood lipids for the primary and secondary 
prevention of cardiovascular disease. Clinical Guideline 181. National Clinical Guideline 
Centre; 2014. 
23. Goldacre B, Smeeth L. Mass treatment with statins. BMJ. 2014;349:g4745. 
24. Health and social care information centre (HSCIC). Prescription cost analysis, England - 2013 
http://www.hscic.gov.uk/catalogue/PUB13887. Accessed October, 2015. 
25. Hope J. Mail Online: Statins can weaken muscles and joints: Cholesterol drug raises risk of 
problems by up to 20 per cent. 2013; http://www.dailymail.co.uk/health/article-
2335397/Statins-weaken-muscles-joints-Cholesterol-drug-raises-risk-problems-20-cent.html. 
Accessed October, 2015. 
26. Naish J. Mail Online: Why taking statins might be pointless - and even bad for you. 2010; 
http://www.dailymail.co.uk/health/article-1340299/Why-taking-statins-pointless--bad-
you.html. Accessed October, 2015. 
27. Hope J. Mail Online: Have benefits of statins been exaggerated? Advocates distorted 
statistics and downplayed side-effects say experts 2015; 
http://www.dailymail.co.uk/health/article-2962513/Have-benefits-statins-exaggerated.html. 
Accessed October, 2015. 
28. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular 
disease. Cochrane Database of Systematic Reviews. 2013;1:CD004816.  
29. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice 
guidelines? A framework for improvement. JAMA. 1999;282(15):1458-1465. 
30. Sheppard JP, Fletcher K, McManus RJ, Mant J. Missed opportunities in prevention of 
cardiovascular disease in primary care: a cross-sectional study. The British Journal of General 
Practice. 2014;64(618):e38-46. 
31. Wu J, Zhu S, Yao GL, Mohammed MA, Marshall T. Patient factors influencing the prescribing 
of lipid lowering drugs for primary prevention of cardiovascular disease in UK general 
practice: a national retrospective cohort study. PLoS ONE. 2013;8(7):e67611. 
32. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III. Management of cardiovascular risk 
factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 
European countries. European Journal of Cardiovascular Prevention and Rehabilitation. 
2010;17(5):530-540. 
33. Missault L, Witters N, Imschoot J. High cardiovascular risk and poor adherence to guidelines 
in 11 069 patients of middle age and older in primary care centres. European Journal of 
Cardiovascular Prevention and Rehabilitation. 2010;17(5):593-598. 
205 
 
34. Roccatagliata D, Avanzini F, Monesi L, et al. Is global cardiovascular risk considered in current 
practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to 
patients' risk level. Vascular Health and Risk Management. 2006;2(4):507-514. 
35. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham 
Study. Stroke. 1996;27(10):1760-1764. 
36. National Institute for Health and Clinical Excellence (NICE). Atrial fibrillation: the 
management of atrial fibrillation. Clinical Guideline 180. National Clinical Guideline Centre; 
2014. 
37. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular 
atrial fibrillation and no previous history of stroke or transient ischemic attacks. The 
Cochrane Database of Systematic Reviews. 2005(3):Cd001927. 
38. Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing 
stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient 
ischemic attacks. The Cochrane Database of Systematic Reviews. 2007(3):Cd006186. 
39. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various 
antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 
2003;289(19):2534-2544. 
40. Pugh D, Pugh J, Mead GE. Attitudes of physicians regarding anticoagulation for atrial 
fibrillation: a systematic review. Age and Ageing. 2011;40(6):675-683. 
41. Seaburg L, Hess EP, Coylewright M, Ting HH, McLeod CJ, Montori VM. Shared decision 
making in atrial fibrillation: where we are and where we should be going. Circulation. 
2014;129(6):704-710. 
42. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-
BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart 
Survey. Chest. 2010;138(5):1093-1100. 
43. Hughes M, Lip GYH. Risk factors for anticoagulation-related bleeding complications in 
patients with atrial fibrillation: a systematic review. QJM. 2007;100(10):599-607. 
44. Ingelgard A, Hollowell J, Reddy P, Gold K, Tran K, Fitzmaurice D. What are the barriers to 
warfarin use in atrial fibrillation?: Development of a questionnaire. Journal of Thrombosis 
and Thrombolysis. 2006;21(3):257-265. 
45. Nieuwlaat R, Capucci A, Lip GY, et al. Antithrombotic treatment in real-life atrial fibrillation 
patients: a report from the Euro Heart Survey on Atrial Fibrillation. European Heart Journal. 
2006;27(24):3018-3026. 
46. National Collaborating Centre for Chronic Conditions. Atrial fibrillation: national clinical 
guideline for management in primary and secondary care. Clinical Guideline 36. National 
Clinical Guideline Centre; 2006. 
47. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly 
community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of 
the Aged Study, BAFTA): a randomised controlled trial. The Lancet. 2007;370(9586):493-503. 
48. Biondi-Zoccai G, Malavasi V, D'Ascenzo F, et al. Comparative effectiveness of novel oral 
anticoagulants for atrial fibrillation: evidence from pair-wise and warfarin-controlled network 
meta-analyses. HSR Proceedings in Intensive Care and Cardiovascular Anesthesia. 
2013;5(1):40-54. 
49. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for 
predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based 
approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-272. 
50. Health and social care information centre (HSCIC). 2015/ 2016 General Medical Services 
(GMS) Contract Quality and Outcomes Framework (QOF). 2014; 
http://www.hscic.gov.uk/qofbrv32. Accessed October, 2015. 
206 
 
51. GRASP-AF audit tool.  http://www.nottingham.ac.uk/primis/tools-audits/list-of-audit-
tools/grasp-suite/grasp-af/grasp-af.aspx. Accessed October, 2015. 
52. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial 
fibrillation: a systematic review. The American Journal of Medicine. 2010;123(7):638-
645.e634. 
53. Holt TA, Hunter TD, Gunnarsson C, Khan N, Cload P, Lip GY. Risk of stroke and oral 
anticoagulant use in atrial fibrillation: a cross-sectional survey. The British Journal of General 
Practice. 2012;62(603):e710-717. 
54. Cowan C, Healicon R, Robson I, et al. The use of anticoagulants in the management of atrial 
fibrillation among general practices in England. Heart. 2013;99(16):1166-1172. 
55. Shantsila E, Wolff A, Lip GY, Lane DA. Optimising stroke prevention in patients with atrial 
fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort. The British 
Journal of General Practice. 2015;65(630):e16-23. 
56. Akao M, Chun YH, Esato M, et al. Inappropriate use of oral anticoagulants for patients with 
atrial fibrillation. Circulation Journal. 2014;78(9):2166-2172. 
57. Friberg L, Hammar N, Ringh M, Pettersson H, Rosenqvist M. Stroke prophylaxis in atrial 
fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial 
Fibrillation (SCAF-study). European Heart Journal. 2006;27(16):1954-1964. 
58. Lip GY, Rushton-Smith SK, Goldhaber SZ, et al. Does sex affect anticoagulant use for stroke 
prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in 
the FIELD-Atrial Fibrillation. Circulation. Cardiovascular Quality and Outcomes. 2015;8(2 
Suppl 1):S12-20. 
59. Sabouret P, Depret-Bixio L, Cotte FE, Marie P, Bedira N, Blin P. Sex differences in stroke 
prevention in atrial fibrillation in French primary care. Results of the AFIGP (Atrial Fibrillation 
In General Practice) database. Clinical Research in Cardiology. 2014;103(11):887-893. 
60. Danaei G, Finucane MM, Lin JK, et al. National, regional, and global trends in systolic blood 
pressure since 1980: systematic analysis of health examination surveys and epidemiological 
studies with 786 country-years and 5.4 million participants. The Lancet. 2011;377(9765):568-
577. 
61. National Institute for Health and Clinical Excellence (NICE). Hypertension: the clinical 
management of primary hypertension in adults. Clinical Guideline 127. National Clinical 
Guideline Centre; 2011. 
62. Oliveria SA, Chen RS, McCarthy BD, Davis CC, Hill MN. Hypertension knowledge, awareness, 
and attitudes in a hypertensive population. Journal of General Internal Medicine. 
2005;20(3):219-225. 
63. Sharma AM, Wittchen HU, Kirch W, et al. High prevalence and poor control of hypertension 
in primary care: cross-sectional study. Journal of hypertension. 2004;22(3):479-486. 
64. Joffres M, Falaschetti E, Gillespie C, et al. Hypertension prevalence, awareness, treatment 
and control in national surveys from England, the USA and Canada, and correlation with 
stroke and ischaemic heart disease mortality: a cross-sectional study. BMJ Open. 
2013;3(8):e003423. 
65. Liddy C, Singh J, Hogg W, et al. Quality of cardiovascular disease care in Ontario, Canada: 
missed opportunities for prevention - a cross sectional study. BMC Cardiovascular Disorders. 
2012;12(1):74. 
66. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five 
European countries, Canada, and the United States. Hypertension. 2004;43(1):10-17. 
67. Michie S, van Stralen M, West R. The behaviour change wheel: a new method for 
characterising and designing behaviour change interventions. Implementation Science. 
2011;6(1):42. 
207 
 
68. Palm F, Kleemann T, Dos Santos M, et al. Stroke due to atrial fibrillation in a population-
based stroke registry (Ludwigshafen Stroke Study) CHADS2, CHA2DS2-VASc score, underuse 
of oral anticoagulation, and implications for preventive measures. European Journal of 
Neurology. 2013;20(1):117-123. 
69. Partington SL, Abid S, Teo K, Oczkowski W, O'Donnell MJ. Pre-admission warfarin use in 
patients with acute ischemic stroke and atrial fibrillation: The appropriate use and barriers to 
oral anticoagulant therapy. Thrombosis Research. 2007;120(5):663-669. 
70. Marshall T. Electronic ambulance chasing: patient records, guidelines, and the law. British 
Journal of General Practice. 2015;65(632):152-153. 
71. Kedward J, Dakin L. A qualitative study of barriers to the use of statins and the 
implementation of coronary heart disease prevention in primary care. The British Journal of 
General Practice. 2003;53(494):684-689. 
72. Lin ND, Martins SB, Chan AS, et al. Identifying barriers to hypertension guideline adherence 
using clinician feedback at the point of care. Annual Symposium Proceedings / AMIA 
Symposium. 2006:494-498. 
73. Midlov P, Ekesbo R, Johansson L, et al. Barriers to adherence to hypertension guidelines 
among GPs in southern Sweden: a survey. Scandinavian Journal of Primary Health Care. 
2008;26(3):154-159. 
74. Flynn D, Ford GA, Rodgers H, Price C, Steen N, Thomson RG. A time series evaluation of the 
FAST national stroke awareness campaign in England. PLoS ONE. 2014;9(8):e104289. 
75. AF Association and BMS-Pfizer Alliance. Grasp the initiative: Supporting the use of GRASP-AF 
in primary care to help reduce the risk of AF-related stroke. 2012:1-28. 
76. Skelly AC, Dettori JR, Brodt ED. Assessing bias: the importance of considering confounding. 
Evidence-Based Spine-Care Journal. 2012;3(1):9-12. 
77. Fisher CM. Intermittent cerebral ischemia. Cerebral Vascular Diseases; 1958; New York, NY. 
78. Brazzelli M, Chappell FM, Miranda H, et al. Diffusion-weighted imaging and diagnosis of 
transient ischemic attack. Annals of Neurology. 2014;75(1):67-76. 
79. Ay H, Koroshetz WJ, Benner T, et al. Transient ischemic attack with infarction: a unique 
syndrome? Annals of Neurology. 2005;57(5):679-686. 
80. Purroy F, Montaner J, Rovira A, Delgado P, Quintana M, Alvarez-Sabin J. Higher risk of further 
vascular events among transient ischemic attack patients with diffusion-weighted imaging 
acute ischemic lesions. Stroke. 2004;35(10):2313-2319. 
81. Redgrave JN, Coutts SB, Schulz UG, Briley D, Rothwell PM. Systematic review of associations 
between the presence of acute ischemic lesions on diffusion-weighted imaging and clinical 
predictors of early stroke risk after transient ischemic attack. Stroke. 2007;38(5):1482-1488. 
82. National Institute for Health and Clinical Excellence (NICE). Stroke: Diagnosis and initial 
management of acute stroke and transient ischaemic attack (TIA). NICE guideline 68. 2008. 
83. Smith EE, Schneider JA, Wardlaw JM, Greenberg SM. Cerebral microinfarcts: the invisible 
lesions. The Lancet Neurology. 2012;11(3):272-282. 
84. Altieri M, Maestrini I, Mercurio A, et al. Depression after minor stroke: prevalence and 
predictors. European Journal of Neurology. 2012;19(3):517-521. 
85. Fang J, Cheng Q. Etiological mechanisms of post-stroke depression: a review. Neurological 
Research. 2009;31(9):904-909. 
86. Giles MF, Rothwell PM. Risk of stroke early after transient ischaemic attack: a systematic 
review and meta-analysis. The Lancet Neurology. 2007;6(12):1063-1072. 
87. Intercollegiate Stroke Working Party. National clinical guideline for stroke. Fourth ed. 
London: Royal College of Physicians; 2012. 
88. Luengo-Fernandez R, Gray AM, Bull L, Welch S, Cuthbertson F, Rothwell PM. Quality of life 
after TIA and stroke: ten-year results of the Oxford Vascular Study. Neurology. 
2013;81(18):1588-1595. 
208 
 
89. Shi YZ, Xiang YT, Yang Y, et al. Depression after minor stroke: the association with disability 
and quality of life - a 1-year follow-up study. International Journal of Geriatric Psychiatry. 
2015:doi: 10.1002/gps.4353. 
90. Tellier M, Rochette A, Lefebvre H. Impact of mild stroke on the quality of life of spouses. 
International Journal of Rehabilitation Research. 2011;34(3):209-214. 
91. Medical Research Council (MRC). Developing and evaluating complex interventions: new 
guidance. 
92. INVOLVE. Briefing note three: Why involve members of the public in research?  
http://www.invo.org.uk/posttyperesource/why-should-members-of-the-public-be-involved-
in-research/. Accessed October, 2015. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
209 
 
 
 
 
 
 
 
 
Appendices 
 
 
 
 
210 
 
Appendix 1: Missed opportunities for 
stroke and TIA prevention: protocol 
A1.1 Supplementary material 
Supplementary material published online for Publication 1 (presented as published): 
Moran GM, Calvert M, Feltham MG, Marshall T. Retrospective case review of missed 
opportunities for primary prevention of stroke and TIA in primary care: protocol paper. BMJ 
Open 2014;4:e006622. doi:10.1136/bmjopen-2014-006622 
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Appendix 1: Read code lists for stroke and transient ischaemic attack (TIA)  
Stroke Read codes 
Read code Description 
G60..00 Subarachnoid haemorrhage 
G600.00 Ruptured berry aneurysm 
G601.00 Subarachnoid haemorrhage from carotid siphon and bifurcation 
G602.00 Subarachnoid haemorrhage from middle cerebral artery 
G603.00 Subarachnoid haemorrhage from anterior communicating artery 
G604.00 Subarachnoid haemorrhage from posterior communicating artery 
G605.00 Subarachnoid haemorrhage from basilar artery 
G606.00 Subarachnoid haemorrhage from vertebral artery 
G60X.00 Subarachnoid haemorrhage from intracranial artery, unspecified 
G60z.00 Subarachnoid haemorrhage NOS 
G61..00 Intracerebral haemorrhage 
G61..11 CVA - cerebrovascular accident due to intracerebral haemorrhage 
G61..12 Stroke due to intracerebral haemorrhage 
G610.00 Cortical haemorrhage 
G611.00 Internal capsule haemorrhage 
G612.00 Basal nucleus haemorrhage 
G613.00 Cerebellar haemorrhage 
G614.00 Pontine haemorrhage 
G615.00 Bulbar haemorrhage 
G616.00 External capsule haemorrhage 
G617.00 Intracerebral haemorrhage, intraventricular 
G618.00 Intracerebral haemorrhage, multiple localized 
G61X.00 Intracerebral haemorrhage in hemisphere, unspecified 
G61X000 Left sided intracerebral haemorrhage, unspecified 
G61X100 Right sided intracerebral haemorrhage, unspecified 
G61z.00 Intracerebral haemorrhage NOS 
G62..00 Other and unspecified intracranial haemorrhage 
G62z.00 Intracranial haemorrhage NOS 
G630.00 Basilar artery occlusion 
G631.00 Carotid artery occlusion 
G631.11 Stenosis, carotid artery 
G631.12 Thrombosis, carotid artery 
G632.00 Vertebral artery occlusion 
G63y000 Cerebral infarct due to thrombosis of precerebral arteries 
G63y100 Cerebral infarction due to embolism of precerebral arteries 
G63z.00 Precerebral artery occlusion NOS 
 
Continued on next page 
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Continued from previous page 
Read code Description 
G64..00 Cerebral arterial occlusion 
G64..11 CVA - cerebral artery occlusion 
G64..12 Infarction – cerebral 
G64..13 Stroke due to cerebral arterial occlusion 
G640.00 Cerebral thrombosis 
G640000 Cerebral infarction due to thrombosis of cerebral arteries 
G641.00 Cerebral embolism 
G641.11 Cerebral embolus 
G641000 Cerebral infarction due to embolism of cerebral arteries 
G64z.00 Cerebral infarction NOS 
G64z.11 Brainstem infarction NOS 
G64z.12 Cerebellar infarction 
G64z000 Brainstem infarction 
G64z100 Wallenberg syndrome 
G64z111 Lateral medullary syndrome 
G64z200 Left sided cerebral infarction 
G64z300 Right sided cerebral infarction 
G64z400 Infarction of basal ganglia 
G66..00 Stroke and cerebrovascular accident unspecified 
G66..11 CVA unspecified 
G66..12 Stroke unspecified 
G66..13 CVA - Cerebrovascular accident unspecified 
G660.00 Middle cerebral artery syndrome 
G661.00 Anterior cerebral artery syndrome 
G662.00 Posterior cerebral artery syndrome 
G663.00 Brain stem stroke syndrome 
G664.00 Cerebellar stroke syndrome 
G665.00 Pure motor lacunar syndrome 
G666.00 Pure sensory lacunar syndrome 
G667.00 Left sided CVA 
G668.00 Right sided CVA 
G671000 Acute cerebrovascular insufficiency NOS 
G676000 Cerebral infarct due cerebral venous thrombosis, nonpyogenic 
G677000 Occlusion and stenosis of middle cerebral artery 
G677100 Occlusion and stenosis of anterior cerebral artery 
G677200 Occlusion and stenosis of posterior cerebral artery 
G677300 Occlusion and stenosis of cerebellar arteries 
G6W..00 Cerebral infarction due unspecified occlusion/stenosis precerebral 
arteries 
G6X..00 Cerebral infarction due/ unspecified occlusion or stenosis/cerebral 
arteries 
Gyu6000 [X]Subarachnoid haemorrhage from other intracranial arteries 
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Read code Description 
Gyu6100 [X]Other subarachnoid haemorrhage 
Gyu6200 [X]Other intracerebral haemorrhage 
Gyu6300 
[X]Cerebral infarction due/unspecified occlusion or stenosis/cerebral 
arteries 
Gyu6400 [X]Other cerebral infarction 
Gyu6500 [X]Occlusion and stenosis of other precerebral arteries 
Gyu6600 [X]Occlusion and stenosis of other cerebral arteries 
Gyu6E00 [X]Subarachnoid haemorrhage from intracranial artery, unspecified 
Gyu6F00 [X]Intracerebral haemorrhage in hemisphere, unspecified 
Gyu6G00 
[X]Cerebral infarct due unspecified occlusion/stenosis precerebral 
arteries 
Fyu5600 [X]Other lacunar syndromes 
Fyu5700 [X]Other vascular syndromes/brain in cerebrovascular diseases 
 
TIA Read codes 
Read code Description 
G65..00 Transient cerebral ischaemia 
G65..11 Drop attack 
G65..12 Transient ischaemic attack 
G65..13 Vertebro-basilar insufficiency 
G650.00 Basilar artery syndrome 
G650.11 Insufficiency - basilar artery 
G651.00 Vertebral artery syndrome 
G651000 Vertebro-basilar artery syndrome 
G652.00 Subclavian steal syndrome 
G653.00 Carotid artery syndrome hemispheric 
G654.00 Multiple and bilateral precerebral artery syndromes 
G656.00 Vertebrobasilar insufficiency 
G657.00 Carotid territory transient ischaemic attack 
G65y.00 Other transient cerebral ischaemia 
G65z.00 Transient cerebral ischaemia NOS 
G65z000 Impending cerebral ischaemia 
G65z100 Intermittent cerebral ischaemia 
G65zz00 Transient cerebral ischaemia NOS 
Fyu5500 [X]Other transient cerebral ischaemic attacks+related 
syndromes 
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Appendix 2: Read codes for diagnoses including history of and resolved Read codes. 
Diagnosis Read codes 
Atrial fibrillation* G573.% (excluding G5731, G5736)  
Asthma* H33..%, H3120, 173A.  
Cancer* B0... - B32z., B34.. -B6z0. (excluding B677.), Byu.. - Byu41, 
Byu5. - ByuE0, K1323, K01w1  
CHD* G3-G309, G30B-G330z (except G310), G33z-G3401, G342-
G365X, G38-G3z, Gyu3% (except Gyu31)   
CKD* 1Z12. -1Z16, 1Z1B. – 1Z1L.,  K053. - K055. 
COPD* H3…, H31..% (excluding H3101, H31y0, H3122), H32..%, H36.. - 
H3z.. (excluding H3y0., H3y1.), H5832  
Dementia* Eu02.%, E00..%, Eu01.%, E02y1, E012.%, Eu00.%, E041., 
Eu041,     F110. – F112., F116. 
Depression* E0013, E0021, E112.%, E113.%, E118., E11y2, E11z2, E130., 
E135., E2003, E291., E2B.., E2B1., Eu204, Eu251, Eu32.% 
(excluding Eu32A, Eu32B, Eu329), Eu33.%, Eu341, Eu412 
Diabetes mellitus* C10.., C109J, C109K, C10C., C10D., C10E.%, C10F.% (Excluding 
C10F8), C10G.%, C10H.%, C10M.%, C10N.%, PKyP. 
Epilepsy* F25..% (excluding F2501, F2504, F2511, F2516, F256.%, F258. 
– F25A., F25y4, F25G., F25H.), F1321, SC200   
Familial 
hypercholesterolemia 
1W2.., C320.11, C3200, C3201, C3204, C3205 
Heart Failure* G58..%, G1yz1, 662f. – 662i., 585f., G5yy9 
Hypertension* G2..., G20..%, G24.. - G2z.. (Excluding G24z1, G2400, G2410, 
G27..), Gyu2., Gyu20 
Hypothyroidism* C03..%, C04..%  
Learning disabilities* E3…%, Eu7..%, Eu814 – Eu817, Eu81z, 918e 
Osteoporosis* N330.% (Excluding N3308, N3309), N3312, N3313, N3316, 
N3318 – N331B, N331H – N331M, NyuB0, NyuB1, NyuB8, 
N3314, N3315, N3746, NyuB2 
PAD* G73.., G73z.% (Excluding G73z1), Gyu74, G734., G73y. 
Palliative care* 1Z01., 2JE.., 8B2a., 8BA2., 8Bae., 8BAP., 8BAS., 8BAT., 8BJ1., 
8CM1.% (excluding 8CM15), 8CM4., 8CMb., 8CME., 8CMQ., 
8CMW3, 8H6A., 8H7g., 8H7L., 8HH7., 8IEE., 9367, 9c0L0, 
9c0M., 9c0N., 9c0P., 9EB5., 9G8.., 9K9.., 9Ng7., 9NgD., 9NNd., 
9NNf0, ZV57C 
Psychosis, 
schizophrenia, bipolar 
affective disease* 
E10..%, E110.%, E111.%, E1124, E1134, E114. – E117z, E11y.% 
(excluding E11y2), E11z., E11z0, E11zz, E12..%, E13..% 
(excluding E135.), E2122, Eu2..%, Eu30.%, Eu31.%, Eu323, 
Eu328, Eu333, Eu32A, Eu329 
Rheumatoid arthritis* N040.%, N041., N042.% (excluding N0420), N047., N04X., 
N04y0, N04y2, Nyu11, Nyu12, Nyu1G, Nyu10, G5yA., G5y8. 
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Read code Description 
History of Read codes 
Asthma 14B4.00 
Atrial fibrillation 14AN.00 
CHD 14A3.00-14A5.00, 14AH.00, 14AJ.00, 14AL.00, 14AT.00, 
14AW.00, G32..12 
COPD 14B3.12 
Dementia 1461.00 
Diabetes 1434.00 
Epilepsy 1473.00 
Heart failure 14A6.00, 14AM.00 
Hypothyroidism 1432.00 
Osteoporosis 14GB.00 
Psychosis, 
schizophrenia 
1464.00, 146H.00, ZV11000- ZV11112 
Rheumatoid arthritis 14G1.00 
Resolved Read codes 
Atrial Fibrillation 212R.00 
Asthma 2126200, 212G.00 
Depression 212S.00 
Diabetes 2126300, 212H.00 
Epilepsy 2126000, 212J.00 
Heart failure 2126400 
Hypertension 2126100, 212K.00 
Osteoporosis 2126500 
Psychosis, 
schizophrenia, bipolar 
affective disease 
212T.00-212X.00, E100500, E101500, E102500, E103500, 
E105500, E107500, E110600, E111600, E114600, E115600, 
E116600, E117600, Eu22300, Eu26.00, Eu31700, Eu32900, 
Eu32A00 
 
CHD: Coronary Heart Disease, CKD: Chronic Kidney Disease, COPD: Chronic Obstructive 
Pulmonary Disease, PAD: Peripheral  Arterial Disease 
*QOF business rules version 27 (http://www.pcc-cic.org.uk/article/qof-business-rules-v27) 
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Appendix 3: British National Formulary (BNF) chapters and Read codes indicating 
on medication 
BNF chapters (version 67)* 
 BNF chapter Description 
Anticoagulant drugs 2.8.1 Parenteral anticoagulants 
 2.8.2 Oral anticoagulants 
Antihypertensive 
drugs 
2.2.1 Thiazides and related diuretics 
2.4 Beta-adrenoceptor blocking drugs (excluding 
propranolol) 
 2.5.1 Vasodilator antihypertensive drugs 
 2.5.2 Centrally acting antihypertensive drugs 
 2.5.3 Adrenergic neurone blocking drugs 
 2.5.5 Drugs affecting the renin-angiotensin system 
 2.6.2 Calcium-channel blockers 
Lipid regulating 
drugs 
2.12 Lipid-regulating drugs (excluding Omega-3 fatty 
acid compounds: Omacor®, Prestylon®, Maxepa®) 
Indicates smoking 
lifestyle intervention 
4.10.2 Nicotine dependence 
* BNF v67 2014. http://www.bnf.org/bnf/index.htm 
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Read codes indicating prescribed anticoagulant or lipid regulating drugs* 
Prevention drug Read code Description 
Anticoagulant drugs 66Q..00 Warfarin monitoring 
66Q..11 Anticoagulant monitoring 
 
66Q1.00 Initial warfarin assessment 
 
66Q2.00 Follow-up warfarin assessment 
 
66Q4.00 Warfarin dose changed 
 
66Q6.00 Warfarin therapy started 
 
66Q9.00 Warfarin dose unchanged 
 
66QA.00 Warfarin treatment plan 
 
66QB.00 Annual warfarin assessment 
 
66QC.00 Anticoagulation monitoring - secondary care 
 
66QD.00 Anticoagulation monitoring - primary care 
 
66QF.00 Slow induction of warfarin therapy 
 
66QG.00 International normalised ratio derived 
warfarin dose 
 
66QH.00 Warfarin daily dose 
 
66QZ.00 Warfarin monitoring NOS 
 
88A5.00 Anticoagulant therapy 
88A5000 Bridging anticoagulant therapy with low 
molecular weight heparin 
 
8B2K.00 Anticoagulant prescribed by third party 
 
8B3T.00 Aspirin OTC  
 
8B61.00 Anticoagulant prophylaxis 
 
8B61000 Warfarin anticoagulation prophylaxis 
 
8CAu.00 Patient advised of anticoagulant dose 
 
8CMW900 On anticoagulation care pathway 
 
8HHW.00 Referral for warfarin monitoring 
 
9k27.00 Home visit for anticoagulation monitoring 
 
9NkC.00 Seen in community anticoagulation clinic 
 
9NkD.00 Seen in hospital anticoagulation clinic 
 
9NkE.00 Seen in general practitioner anticoagulation 
clinic 
 
Z1Q2C00 Giving anticoagulant therapy 
 
ZV1C200 [V]personal history of long term (current) 
use of warfarin 
Lipid regulating drugs 8B3z.00 Over the counter statin therapy 
 
* There were no Read codes indicating antihypertensive drugs prescribed 
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Appendix 4: Read codes indicating exceptions and white coat hypertension 
 Read codes Description 
Exception Read codes 
Anticoagulant drugs 14LP.00 Warfarin allergy  
 8I25.00 Warfarin contraindicated 
 8I2o.00 Dabigatrin contraindicated 
 8I2R.00 Anticoagulation contraindicated 
 8I3d.00 anticoagulation declined 
 8I3E.00 Warfarin declined 
 8I71.00 Warfarin not tolerated 
 8I7R.00 Dabigatran not tolerated 
 8IES.00 Dabigatran declined 
 9hF1.00 Excepted from atrial fibrillation qual indic: Inform 
dissent 
 TJ42.00 Adverse reaction to anticoagulants 
 TJ42100 Adverse reaction to warfarin 
 TJ42200 Adverse reaction to nicoumalone 
 TJ42300 Adverse reaction to phenindione 
 TJ42z00 Adverse reaction to anticoagulants NOS 
 U604200 [x]anticoagulant causing adverse effects in 
therapeutic use 
 U604211 [x] adverse reaction to anticoagulants 
 U604212 [X] Adverse reaction to heparin 
 U604213 [x] adverse reaction to warfarin sodium 
 U604214 [X] Adverse reaction to acenocoumarol 
 U604215 [X] Adverse reaction to phenindione 
 U604216 [x] adverse reaction to anticoagulants NOS 
 ZV14A00 Personal history of allergy to warfarin 
Antihypertensive drugs 8I3N.00 Hypertension treatment refused 
TJC7z00 Adverse reaction to antihypertensives NOS 
Lipid lowering drugs 8I27.00 Statins contraindicated 
8I27000 Simvastatin contraindicated 
 8I2C.00 Lipid lowering therapy contraindicated 
 8I3C.00 Statin declined 
 8I3J.00 Lipid lowering therapy declined 
 8I76.00 Statin not tolerated 
 TJC2.00 Adverse reaction to antilipaemic/anti-
arteriosclerotic drugs 
 TJC2400 Adverse reaction to simvastatin 
 TJC2500 Adverse reaction to pravastatin 
 TJC2z00 Adverse reaction to antilipaemic/antiarterioscler 
drugs NOS 
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 Read codes Description 
Lipid lowering drugs U60C600 [X]Antihyperlipidaem/antiarterioscl drug cause 
adv ef ther use 
 U60C611 [X] Adverse react to antilipaemic & anti-
arteriosclerot drug 
 U60C615 [X] Adverse reaction to simvastatin 
 U60C616 [X] Adverse reaction to pravastatin 
 U60C617 [X] Adverse react to antilipaemic/antiarterioscler 
drugs NOS 
 U60C900 [X]lipid-lowering drug adverse reaction 
 U60CA00 [X]statin causing adverse effect in therapeutic use 
White coat 
hypertension 
246M.00 White coat hypertension 
 
 
 
 
 
 
 
 
 
 
 
 
Continued from previous page 
220 
 
Appendix 5: Read codes indicating lifestyle interventions 
Read code Description 
Alcohol 
 6792.00 Health ed. Alcohol 
67H0.00  Lifestyle advice regarding alcohol  
8BA8.00 Alcohol detoxification 
8CAM.00  Patient advised about alcohol  
8CAM000 Advised to abstain from alcohol consumption 
8CAv.00 Advised to contact primary care alcohol worker 
8CE1.00 Alcohol leaflet given 
8G32.00 Aversion therapy – alcoholism 
8H35.00 Admitted to alcohol detoxification centre 
8H7p.00 Referral to community alcohol team 
8HHe.00 Referral to community drug and alcohol team 
8HkG.00 Referral to specialist alcohol treatment service 
8HkJ.00 Referral to alcohol brief intervention service 
9k14.00 Alcohol counselling by other agencies 
9k1A.00 Brief intervention for excessive alcohol consumption completed 
9k1B.00 Extended intervention for excessive alcohol consumption completed 
9NN2.00 Under care of community alcohol team 
Z191.00 Alcohol detoxification 
Z191100 Alcohol withdrawal regime 
Z191200  Planned reduction of alcohol consumption   
Z191211 Alcohol reduction programme 
Z191400 Self-monitoring of alcohol intake 
Z4B1.00 Alcoholism counselling 
ZC22200  Advice to change alcoholic drink intake  
ZC2H.00  Advice to change alcohol intake  
ZG23100  Advice on alcohol consumption  
ZR1E.00 Alcohol dependence scale 
Diet 
 13A3.00  Weight reducing diet  
66C3.00 Understands reducing diet 
66C4.00 Has seen dietician – obesity 
66C6.00  Treatment of obesity started    
66CR.00 Interview risk health assessment overweight obesity advice about diet physical 
activity 
66CS.00 Interview risk health overweight obesity advice diet physical activity consider 
drugs 
66CT.00 Interview risk health overweight obesity advice diet physical activity consider 
drugs consider surgery 
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Read code Description 
6799.00 Health ed. Diet 
8B57.00  Weight reducing diet  
8B5C.00  Calorie restricted diet   
8B5C.11  Low calorie diet   
8B5C011 Very low calorie diet 
8CA4000  Pt advised re weight reducing diet  
8CA4011 Patient advised to lose weight 
8H4n.00 Referral to weight management special interest GP 
ZC1..00 Actions to lose weight 
ZC14.00 Attending slimming club 
ZC2C700  Patient advised about weight reducing diet   
ZC2C711  Dietary advice for weight reduction  
ZC2CO00  Dietary advice for weight loss  
ZC2F.11 Advice to change high calorie food intake 
Exercise 
 1384.00 Enjoys moderate exercise 
1385.00 Enjoys heavy exercise 
1389.00 Aerobic exercise 1 time/week 
67H2.00 Lifestyle advice regarding exercise    
6798.00 Health ed. – exercise 
138A.00 Aerobic exercise 2 times/week 
138B.00 Aerobic exercise 3+ times/week 
138D.00 Anaerobic exercise 1 time/week 
138E.00 Anaerobic exercise 2 times/week 
138F.00 Anaerobic exercise 3+ times/week 
138G.00 Attends exercise classes 
138H.00 Enjoys intermediate exercise 
138P.00 Aerobic exercise three times a week 
138Q.00 Aerobic exercise four times a week 
138R.00 Aerobic exercise five times a week 
13CR.00 Physical activity target light exercise 
13CS.00 Physical activity target moderate exercise 
13CT.00 Physical activity target strenuous exercise 
67H2.00  Lifestyle advice regarding exercise  
8BAH.00  Exercise on prescription  
8CA5.00  Patient advised re exercise  
8CA5000 Advice about aerobic exercise 
8CA5100 Advice about muscle strengthening exercise 
8CAn.00 Pt given written advice on benefits of physical activity 
8E79.00 Home exercise programme 
8E7A.00 Group exercise programme 
  Continued on next page 
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Read code Description 
8E7B.00 Graded exercise therapy 
8E7C.00 Aerobic exercises 
8E7D.00 Exercise circuits 
8H7q.00 Referral for exercise therapy 
8H7q000 Referral for graded exercise therapy 
8H7s.00 Referral to physical activity programme 
8HHc.00 Referred for exercise programme 
8HkX.00  Referral to exercise on referral programme  
Z4G1400 Giving encouragement to exercise 
Z4G1411 Offering encouragement to exercise 
Z4M1200 Reassuring about exercise 
Z65..00 Exercise therapy 
Z658.00 Aerobic exercises 
Z65A.00 Exercise circuits 
Z65B.00 Home exercise programme 
Z67..00 Exercise class 
Z67..11 Group exercise 
Z68..00 Exercises 
Z6D3.00 Cardiovascular exercises in water 
Z6D3100 Aquaerobic exercises 
ZC17.00 Exercising to lose weight 
ZG12.00 Advice to undertake activity 
ZG16.00  Advice about exercise  
ZG16100  Advice to exercise   
Smoking 
 67H1.00 Lifestyle advice regarding smoking    
6791.00 Health ed. smoking  
137b.00 Ready to stop smoking 
137c.00 Thinking about stopping smoking 
137G.00  Trying to give up smoking   
13p0.00  Negotiated date for cessation of smoking   
13p5.00  Smoking cessation programme start date  
13p5000  Practice based smoking cessation programme start date   
67H6.00  Brief intervention for smoking cessation 
745H.00  Smoking cessation therapy  
745H000 Nicotine replacement therapy using nicotine patches 
745H100 Nicotine replacement therapy using nicotine gum 
745H200 Nicotine replacement therapy using nicotine inhalator 
745H300 Nicotine replacement therapy using nicotine lozenges 
745H400  Smoking cessation drug therapy  
745Hy00  Other specified smoking cessation therapy   
  Continued on next page 
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Read code Description 
745Hz00  Smoking cessation therapy NOS  
8B2B.00 Nicotine replacement therapy 
8B3f.00 Nicotine replacement therapy provided free 
8B3Y.00   Over the counter nicotine replacement therapy  
8BP3.00 Nicotine replacement therapy provided by community pharmacist 
8CAg.00 Smoking cessation advice provided by community pharmacist 
8CAL.00  Smoking cessation advice  
8CdB.00  Stop smoking service opportunity signposted  
8H7i.00  Referral to smoking cessation advisor  
8HBM.00 Stop smoking face to face follow-up 
8HBP.00 Smoking cessation 12 week follow-up 
8HkQ.00  Referral to NHS stop smoking service   
8HTK.00  Referral to stop smoking clinic  
8T08.00  Referral to smoking cessation service   
9kc..00 Smoking cessation - enhanced services administration 
9kc0.00 Smoking cessation monitor template completed - enhanced service admin 
9kc0.11 Smoking cessation ESA monitoring template completed 
9N2k.00 Seen by smoking cessation advisor 
9Ndf.00 Consent given for follow-up by smoking cessation team 
9NdV.00 Consent given follow-up after smoking cessation intervention 
9NS0200 Referral for smoking cessation service offered 
9OO..00 Anti-smoking monitoring admin. 
9OO..11 Stop smoking clinic admin. 
9OO..12 Stop smoking monitoring admin. 
9OO1.00  Attends stop smoking monitor.  
9OO3.00 Stop smoking monitor default 
9OO4.00 Stop smoking monitor 1st letter 
9OO5.00 Stop smoking monitor 2nd letter 
9OO6.00 Stop smoking monitor 3rd letter 
9OO7.00 Stop smoking monitor verbal inv. 
9OO8.00 Stop smoking monitor phone inv. 
9OOA.00 Stop smoking monitor check done 
9OOB.00  Stop smoking invitation short message service text message   
9OOB000 Stop smoking invitation first SMS text message 
9OOB100 Stop smoking invitation second SMS text message 
9OOB200 Stop smoking invitation third SMS text message 
9OOZ.00 Stop smoking monitor admin. NOS 
ZG23300  Advice on smoking   
Weight 
 13A3.00 Weight reducing diet 
66C4.00 Has seen dietician – obesity 
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Read code Description 
66C5.00 Treatment of obesity changed 
66C6.00 Treatment of obesity started 
66C9.00 Target weight discussed 
66C9.11  Weight loss advised   
66CA.00 Ideal weight discussed 
66CC.00 Wants to lose weight 
66CG.00 Weight management programme offered 
66CH.00  Weight management plan started   
67H7.00 Lifestyle advice regarding diet    
67H8.00 Lifestyle advice regarding hypertension    
679P.00 Health education - weight management 
67I9.00  Advice about weight  
67K9.00 Cycle of change stage, weight management 
6B4..00 Counterweight weight management programme 
6B4..11 Counterweight programme 
8B57.00 Weight reducing diet 
8B5B.00 Weight gain diet 
8CA4011 Patient advised to lose weight     
8Cd7.00  Advice given about weight management  
8CdC.00 Weight management service opportunity signposted 
8CP5.00 Discussion about weight management programme 
8H4n.00 Referral to weight management special interest GP 
8HHH.00  Refer to weight management programme    
8HHH000  Referral to local authority weight management programme  
8HHH100  Referral to residential weight management programme  
9NS0300 Referral to weight management service offered 
ZC1..00 Actions to lose weight 
ZC17.00 Exercising to lose weight 
ZC2C700 Patient advised about weight-reducing diet 
ZC2C711 Dietary advice for weight reduction 
ZC2CM00 Dietary advice for obesity 
ZC2CN00 Dietary advice for weight gain 
ZC2CO00 Dietary advice for weight loss 
ZG53.00  Advice about weight  
ZG53100  Patient advised to lose weight   
ZV65319 [V]dietary counselling in obesity 
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A1.2 Scientific Review Committee (SRC) approval 
 
SRC Feedback  
  
Researcher Name:  Grace Turner     
Organisation: University of Birmingham  
SRC Reference Number: 13-023  
Date: 31
st
 May 2013  
Study title:   Missed opportunities for primary prevention of stroke and TIA in primary care      
Committee opinion: Approved  
______________________________________________________________  
  
The following feedback has been supplied by the SRC.   
  
Notes from the Chair:   
  
We have approved it with minor comments for the researchers only.    
Advice   
(General advice for the researchers as information only – No response required)  
  
This is a very well thought out and important study. My only concern is that it potentially 
involves multiple comparisons of effects of variables on missed opportunities, especially when 
one considers the analysis by individual primary care practices and types of practice, and care 
will be needed to ensure that interpretation is appropriate to the number of comparisons 
made, and the power of the study for looking at any one of them. There is no power 
calculation provided and it would be beneficial to consider this at the outset - although one 
suspects there will be ample power for providing a precise estimate of the primary analysis of 
missed opportunities, there may be less power for analyses of some of the proposed modifying 
factors.   
  
  
  
  
______________________________________________________________  
  
We are pleased to inform that you can proceed with the study as this is now approved. CSD Medical 
Research will let the relevant Ethics committee know this study has been approved by the SRC.  
  
Once the study has been completed and published, it is important for you to inform CSD Medical 
Research in order for us to advise the SRC and your reference number to be closed.  
  
References to all published studies are added to our website enabling other researchers to become 
aware of your work. Copies of publication(s), where available, will be appreciated.   
  
I wish you and your team all the best with the study progression.   
  
   
Mustafa Dungarwalla   
Research Associate  
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 Appendix 2: Missed opportunities for 
stroke and TIA prevention: Lipid 
lowering drugs  
A2.1 Supplementary material 
eTable 1: Values outside clinically plausible ranges which were excluded. 
Variable Cut-off range 
Height (m)    1 - 2.5 
Weight (kg)  35 - 200  
Body mass index (units)   10 - 60  
Systolic blood pressure (mmHg)  60 - 260 
Diastolic blood pressure (mmHg)  40 - 160  
Total cholesterol (mm/L)    1 - 12 
High-density lipoprotein (HDL) cholesterol (mm/L)  0.1 - 12 
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eFigure 1: Crude incidence of stroke and transient ischaemic attack (TIA) recorded in The 
Health Improvement Network (THIN) database. 
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eTable 2: Summary of logistic regression predictor variables. All variables were categorical 
unless otherwise stated. 
Predictor variable  Total 
Included in final 
regression model?  
Age <45 115 Y 
 45-49 221 Y 
 50-54 494 Y 
 55-59 811 Y 
 60-64 1,489 Y 
 65-69 2,049 Y 
 70-74 2,638 Y 
 75-79 2,329 Ref 
 80-84 2,514 Y 
 85-89 2,068 Y 
 90-94 1,012 Y 
 ≥95 288 Y 
Sex Male 8,941 Ref 
 Female 7,087 Y 
Deprivation 1 (least deprived) 3,709 Ref 
 2 3,497 N 
 3 3,210 N 
 4 3,047 N 
 5 (most deprived) 2,187 N 
 Missing 378 N 
Rurality* Rural 5,997 Ref 
 Urban 10,021 N 
BMI Healthy 4,655 Ref 
 Underweight 339 Y 
 Overweight 5,995 Y 
 Obese 4,172 Y 
 Missing 867 Y 
Smoking Non 3,927 Ref 
 Ex 7,910 Y 
 Current 3,716 Y 
 Missing 475 Y 
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Predictor variable  Total 
Included in final 
regression model?  
Alcohol Never 2,093 Ref 
 Light 2,855 N 
 Moderate 1,859 N 
 High 4,633 N 
 Missing 4,588 N 
Lifestyle intervention: Any N 9,310 Ref 
Y 6,718 N 
Lifestyle intervention: Alcohol N 15,437 Ref 
Y 591 N 
Lifestyle intervention: Diet N 15,222 Ref 
Y 806 N 
Lifestyle intervention: Exercise N 14,161 R 
Y 836 N 
Lifestyle intervention: Smoking N 10,798 Ref 
Y 5,230 Y 
Lifestyle intervention: Weight N 14,964 Ref 
Y 1,064 Y 
Year of event† 2009 2,777 N 
 2010 3,213  
 2011 3,149  
 2012 3,482  
 2013 3,407  
Health authority/ Country West Midlands 1,422 Ref 
East Midlands 453 Y 
 East of England 952 Y 
 London 1,100 Y 
 North East 546 Y 
 North West 1,738 Y 
 South Central 1,977 Y 
 South East Coast 1,409 Y 
 South West 1,926 Y 
 Yorkshire & Humber 381 Y 
 Northern Ireland 692 Y 
 Scotland 2,242 Y 
 Wales 1,119 Y 
 Missing 71 Y 
Continued from previous page 
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Predictor variable 
 
Total 
Included in final 
regression model? 
Number of comorbidities† 0 1,318 N 
1 2,441  
 2 3,727  
 3 3,681  
 4 2,539  
 5 1,354  
 6 652  
 7 229  
 8 87  
Atrial fibrillation N 13,636 Ref 
 Y 2,392 N 
Asthma N 14,304 Ref 
 Y 1,724 N 
Cancer N 14,117 Ref 
 Y 1,911 N 
CHD N 10,485 Ref 
 Y 5,543 Y 
CKD N 10,254 Ref 
 Y 5,774 Y 
COPD N 14,558 Ref 
 Y 1,470 N 
Dementia N 15,291 Ref 
 Y 737 N 
Depression N 12,608 Ref 
 Y 3,420 N 
Diabetes N 11,542 Ref 
 Y 4,486 Y 
Epilepsy N 15,741 Ref 
 Y 287 N 
Heart failure N 14,690 Ref 
 Y 1,338 N 
Hypertension N 6,362 Ref 
 Y 9,666 Y 
Hypothyroidism N 14,304 Ref 
 Y 1,724 N 
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Predictor variable 
 
Total 
Included in final 
regression model? 
Learning disability N 15,974 Ref 
 Y 54 N 
Osteoporosis N 14,763 Ref 
 Y 1,265 N 
PAD N 14,597 Ref 
 Y 1,431 Y 
Palliative care N 15,805 Ref 
 Y 223 Y 
Psychosis N 15,766 Ref 
 Y 262 N 
Rheumatoid arthritis N 15,634 Ref 
 Y 394 N 
*10 missing, missing category not included in the model as too few events 
† Continuous variable 
BMI: Body Mass Index, CHD: Coronary Heart Disease, CKD: Chronic Kidney Disease, COPD: 
Chronic Obstructive Pulmonary Disease, N: No, PAD: Peripheral Artery Disease, Ref: 
Reference category, Y: Yes 
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Exploratory analyses 
Methods 
Exploratory analyses investigated the effect of duration of registration and consultation 
frequency in the year prior to stroke/TIA. The Framingham risk equation is only valid for 
patients between 30-74 years; therefore, we investigated the impact of defining all patients 
over 74 years as high risk as suggested by the guidelines.1 The most recent UK dyslipidaemia 
guidelines (2014) lowered the definition of high CVD risk from ≥20% to ≥10% over 10 years;2 
therefore, the effect of lowering the CVD risk threshold was explored. In addition, the 
influence of the individual elements of the high CVD risk definition (CHD, CKD, PAD, diabetes 
mellitus and ≥40 years or 10-year CVD risk ≥20%) were analysed. To reflect the updated 
2014 NICE lipid modification guidelines, where the QRISK2 risk calculation was 
recommended over the Framingham risk equation,2 sensitivity analysis investigated the 
impact of using QRISK2-2014 to calculate CVD risk. The difference in variables included in the 
Framingham and QRISK2-2014 equations are presented in eTable 3. 
 
 
 
 
 
 
233 
 
eTable 3: Variables included in Framingham and QRISK2-2014 equations. 
Variable Framingham QRISK2-2014 
Age   
Sex   
Ethnicity   
BMI   
Deprivation score   
Systolic blood pressure   
Total cholesterol   
HDL cholesterol   
Family history of CHD/Stroke   
Smoking status   
Treated hypertension   
Diabetes   
ECG-LVH   
Atrial fibrillation   
Rheumatoid arthritis   
Chronic kidney disease   
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Results 
In multivariable analysis, frequency of consultations in the year prior to stroke or TIA and 
duration of registration were not associated with lipid lowering drug prescribing. When 
entered into the regression model, a 10-year CVD risk ≥20% was associated with a 
statistically significant 2.4-fold increase in odds of having a missed opportunity. Given that 
CHD, CKD, PAD and diabetes were all protective in the regression model, we subsequently 
investigated the impact of not having a ‘high risk comorbidity’ (i.e. no CHD, CKD, PAD, 
diabetes or familial hypercholesterolemia). A variable for ‘no high risk comorbidities’ was 
entered into the regression model and associated with a 3-fold increase in odds of having a 
missed opportunity (OR 2.8; 95% CI 2.5, 3.2). There were 2,780 patients with a 10-year CVD 
risk ≥20% but no ‘high risk comorbidities’; 81% (2,238/2,780) had a missed opportunity.  
Further exploratory analysis investigated the impact of definitions of high risk: (i) original 
definition (CHD, CKD, PAD, diabetes and ≥40 years or 10-year CVD risk ≥20%); (ii) including 
all patients >74 years; (iii) lowering 10-year CVD risk to ≥10%; (iv) include all patients >74 
years and lowering 10-year CVD risk to ≥10% (eTable 4). Considering all patients over the age 
of 74 years as high risk increased the number of patients eligible for lipid lowering 
medication from 16,028 to 22,077; 58% had a missed opportunity. Lowering the 10-year CVD 
risk threshold to ≥10% increased the number of eligible patients to 19,462, of which, 54% 
had a missed opportunity. Combining these two definitions of high risk, the number of 
eligible patients became 25,111 with 61% having a missed opportunity. When QRISK2 was 
used to calculate CVD risk, the number of eligible patients increased to 19,253 and 53% had 
a missed opportunity (10,237/19,253). 
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eTable 4: The impact of different definitions of high risk on proportion of eligible stroke 
and transient ischaemic attack (TIA) patients with a missed opportunity for lipid lowering 
primary prevention therapy. 
Definition of high risk 
Missed 
opportunities 
% missed 
opportunities 
(i) Original definition* (n=16,028)   7,836 48.9 
(ii) Include all patients >74 years (n=22,077) 12,739 57.7 
(iii) Lower 10-year CVD risk to ≥10% (n=  19,462) 10,575 54.3 
(iv) Include all patients >74 years and  lower 10-
year CVD risk to ≥10% (n=25,511) 
15,478 60.7 
* Original definition: Coronary Heart Disease (CHD), Chronic Kidney Disease (CKD), 
Peripheral Artery Disease (PAD), diabetes and aged ≥40 years or 10-year CVD risk ≥20% 
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eTable 5: Number of strokes that potentially could be prevented through prescribing lipid lowering drugs. 
Age 
band 
Number of 
strokes in the 
THIN sample 
Estimated number of 
strokes that could be 
prevented in the 
THIN sample 
Proportion of strokes 
that could be 
prevented in the 
THIN sample (%) 
Number of 
strokes per year 
in UK 
Estimated number 
of strokes that 
could be 
prevented in UK 
  Male Female Male Female Male Female Male Female Male Female 
<35 115 124 1 1 1% 1% 0 0 0 0 
35-44 301 258 8 7 3% 3% 1,469 896 39 23 
45-54 841 652 57 23 7% 4% 2,453 1,097 165 39 
55-64 1,669 1,034 182 50 11% 5% 6,712 4,413 731 212 
65-74 2,462 1,903 289 133 12% 7% 18,817 12,744 2,208 889 
75-84 2,613 2,925 167 188 6% 6% 14,656 20,001 939 1,287 
≥85 1,232 2,468 115 281 9% 11% 9,747 16,677 913 1,899 
All ages       18,597          1,502                    8.1%       109,682       9,343 
<85       14,658          1,103                    7.5%         83,258       6,531 
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Appendix 3: Missed opportunities for 
stroke and TIA prevention: 
Anticoagulant and antihypertensive 
drugs 
A3.1 Supplementary material 
Supplementary Table S1: Values outside clinically plausible ranges which were excluded. 
Variable Cut-off range 
Height (m)    1 - 2.5 
Weight (kg)  35 - 200  
Body mass index (units)   10 - 60  
Systolic blood pressure (mmHg)  60 – 260 
Diastolic blood pressure (mmHg)  40 - 160  
Total cholesterol (mm/L)    1 – 12 
High-density lipoprotein (HDL) cholesterol (mm/L)  0.1 – 12 
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Supplementary Figure S1: Crude incidence of stroke and transient ischaemic attack (TIA) 
recorded in The Health Improvement Network (THIN) database. 
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Supplementary Table S2: Summary of logistic regression predictor variables. All variables were categorical unless otherwise stated. 
  Eligible for anticoagulant drugs Eligible for antihypertensive drugs 
Predictor variable Total 
Included in final 
regression model?  Total 
Included in final 
regression model? 
Age <45 6‡  69 Y 
 45-49 9‡  109 Y 
 50-54 15‡ Y 190 Y 
 55-59 39 Y 311 Y 
 60-64 70 Y 556 Y 
 65-69 170 Y 832 Y 
 70-74 291 Y 1,091 Y 
 75-79 604 Ref 1,133 Ref 
 80-84 760 Y 1,179 Y 
 85-89 719 Y 974 Y 
 90-94 399 Y 453 Y 
 ≥95 112 Y 111 Y 
Sex Male 1,469 Ref 3,440 Ref 
 Female 1,725 Y 3,568 Y 
Deprivation 1 (least deprived) 815 Ref 1,630 Ref 
 2 763 N 1,582 N 
 3 670 N 1,405 N 
 4 528 N 1,323 N 
 5 (most deprived) 347 N 900 N 
 Missing 71 N 168 N 
      
      
      
      
      
Continued on next page 
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  Eligible for anticoagulant drugs Eligible for antihypertensive drugs 
Predictor variable 
 
Total 
Included in final 
regression model? Total 
Included in final 
regression model? 
Rurality Rural 1,236 Ref 2,555 Ref 
 Urban 1,957 N 4,451 N 
 Missing* 1 N 2 N 
BMI Healthy 1,108 Ref 1,953 Ref 
 Underweight 98 Y 135 N 
 Overweight 1,141 Y 2,599 N 
 Obese 651 Y 2,010 N 
 Missing 196 Y 311 N 
Smoking Non 886 Ref 1,626 Ref 
 Ex 1,865 Y 3,702 N 
 Current 335 Y 1,487 N 
 Missing 108 Y 193 N 
Alcohol Never 391 Ref 902 Ref 
 Light 649 N 1,282 N 
 Moderate 376 N 809 N 
 High 851 N 1,999 N 
 Missing 927 N 2,016 N 
Lifestyle intervention: Any N 2,269 Ref 4,110 Ref 
 Y 925 N 2,898 N 
Lifestyle intervention: Alcohol N 3,102 Ref 6,742 Ref 
 Y 92 N 266 N 
      
      
      
      
      
Continued on next page 
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  Eligible for anticoagulant drugs Eligible for antihypertensive drugs 
Predictor variable 
 
Total 
Included in final 
regression model? Total 
Included in final 
regression model? 
Lifestyle intervention: Diet N 3,062 Ref 6,631 Ref 
 Y 132 N 377 N 
Lifestyle intervention: Exercise N 3,027 Ref 6,599 Ref 
 Y 167 N 409 N 
Lifestyle intervention: Smoking N 2,559 Ref 4,808 Ref 
Y 635 N 2,200 N 
Lifestyle intervention: Weight N 3,037 Ref 6,476 Ref 
 Y 157 N 532 Y 
Year of event 2009 532 Ref 1,322 Ref 
 2010 634 Y 1,406 N 
 2011 660 Y 1,374 N 
 2012 731 Y 1,495 N 
 2013 637 Y 1,411 N 
Health authority/ Country West Midlands 281 Ref 641 Ref 
 East Midlands 90 N 210 N 
 East of England 232 N 421 N 
 London 196 N 481 N 
 North East 108 N 206 N 
 North West 332 N 776 N 
 South Central 470 N 903 N 
 South East Coast 287 N 584 N 
 South West 390 N 927 N 
 Yorkshire & Humber 69 N 152 N 
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  Eligible for anticoagulant drugs Eligible for antihypertensive drugs 
Predictor variable 
 
Total 
Included in final 
regression model? Total 
Included in final 
regression model? 
Health authority/ Country Northern Ireland 153 N 259 N 
 Scotland 393 N 952 N 
 Wales 185 N 464 N 
 Missing 8* N 32 N 
Number of comorbidities† 0 0 N 364 Y 
 1 136  1,230  
 2 535  1,872  
 3 830  1,649  
 4 739  1,036  
 5 477  501  
 6 287  252  
 7 137  73  
 8+ 53  31  
Atrial fibrillation N 0* Ref 6,085 Ref 
 Y 3,194 N 923 Y 
Asthma N 2,874 Ref 6,272 Ref 
 Y 320 N 736 Y 
Cancer N 2,774 Ref 6,212 Ref 
 Y 420 N 796 Y 
CHD N 2,111 Ref 4,985 Ref 
 Y 1,083 N 2,023 Y 
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  Eligible for anticoagulant drugs Eligible for antihypertensive drugs 
Predictor variable 
 
Total 
Included in final 
regression model? Total 
Included in final 
regression model? 
CKD N 2,037 Ref 4,665 Ref 
 Y 1,157 N 2,343 Y 
COPD N 2,885 Ref 6,461 Ref 
 Y 309 N 547 N 
Dementia N 2,981 Ref 6,782 Ref 
 Y 213 Y 226 Y 
Depression N 2,581 Ref 5,595 Ref 
 Y 613 N 1,413 N 
Diabetes N 2,536 Ref 5,212 Ref 
 Y 658 Y 1,796 Y 
Epilepsy N 3,147 Ref 6,891 Ref 
 Y 47 N 117 N 
Heart failure N 2,543 Ref 6,571 Ref 
 Y 651 Y 437 Y 
Hypertension N 897 Ref 1,767 Ref 
 Y 2,297 N 5,241 Y 
Hypothyroidism N 2,754 Ref 6,253 Ref 
 Y 440 N 755 Y 
Learning disability* N 3,188 Ref 6,992 Ref 
 Y 6 N 16 N 
Osteoporosis N 2,822 Ref 6,430 Ref 
 Y 372 N 578 N 
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  Eligible for anticoagulant drugs Eligible for antihypertensive drugs 
Predictor variable 
 
Total 
Included in final 
regression model? Total 
Included in final 
regression model? 
PAD N 2,978 Ref 6,432 Ref 
 Y 216 N 576 Y 
Palliative care N 3,142 Ref 6,941 Ref 
 Y 52 N 67 N 
Psychosis N 3,164 Ref 6,912 Ref 
 Y 30 N 96 N 
Rheumatoid arthritis N 3,114 Ref 6,838 Ref 
 Y 80 N 170 N 
‡Categories combined 
*Not included in regression model as too few events 
† Continuous variable 
BMI: Body Mass Index, CHD: Coronary Heart Disease, CKD: Chronic Kidney Disease, COPD: Chronic Obstructive Pulmonary Disease, 
N: No, PAD: Peripheral Artery Disease, Ref: Reference category, Y: Yes  
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Exploratory analysis 
Methods 
Exploratory analyses investigated the effects of duration of registration and consultation 
frequency in the year prior to stroke/TIA. The impact of CHADS2 score on proportion of 
missed opportunities for anticoagulant prescribing was explored to investigate if level of risk 
was predictive of prescribing. The most recent UK atrial fibrillation guidelines recommend 
use of the CHA2DS2-VASc score to estimate stroke risk in patients with atrial fibrillation.
1 
Therefore, sensitivity analysis investigated the impact of using this score to identify patients 
eligible for anticoagulants to reflect the updated guidelines. The difference between CHADS2 
and CHA2DS2-VASc scores are presented in Table S3. The proportion of patients prescribed 
aspirin rather than anticoagulants was calculated. The impact of allowing a prescription of 
aspirin in patients with a CHADS2 score of 1 was explored in accordance with the 2006 atrial 
fibrillation guidelines.2 
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Supplementary Table S3: Comparison between the CHADS2 and CHA2DS2-VASc stroke risk 
scores. 
CHADS2 CHA2DS2-VASc 
Variables Score Variables Score 
Congestive heart failure 1 Congestive heart failure 1 
Hypertension 1 Hypertension 1 
Age ≥75 years 1 Age ≥75 years 2 
Diabetes mellitus 1 Diabetes mellitus 1 
Stroke or TIA 2 Stroke or TIA 2 
  Vascular disease 1 
  Age 65-74  years 1 
  Sex: female 1 
 
Separate analyses were conducted for patients eligible for antihypertensive drugs because of 
high BP (≥160/100mmHg) or moderately high BP (≥140/100mmHg) with high cardiovascular 
disease (CVD) risk respectively. To reflect updated guideline recommendations where the 
QRISK2 CVD risk score has been recommended over the Framingham risk score,2 QRISK2-
2014 was used in exploratory analysis to calculate CVD risk. The difference in variables 
included in the Framingham and QRISK2-2014 equations are presented in Table S4. In 
addition, the influence of the individual elements of the high CVD risk definition (CHD, CKD, 
PAD, diabetes mellitus and ≥40 years or 10-year CVD risk ≥20%) were analysed. 
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Supplementary Table S4: Variables included in Framingham and QRISK2-2014 equations. 
Variable Framingham QRISK2-2014 
Age   
Sex   
Ethnicity   
BMI   
Deprivation score   
Systolic blood pressure   
Total cholesterol   
HDL cholesterol   
Family history of CHD/Stroke   
Smoking status   
Treated hypertension   
Diabetes   
ECG-LVH   
Atrial fibrillation   
Rheumatoid arthritis   
Chronic kidney disease   
 
 
 
 
 
 
 
 
 
 
 
 
248 
 
Results 
Anticoagulant prescribing 
Exploratory analysis investigated the impact of using CHA2DS2-VASc to calculate stroke risk 
as recommended in the most recent atrial fibrillation guidelines published in 2014.1 Using 
this stroke-risk score, the number of patients eligible for anticoagulant therapy increased by 
280 and the proportion of missed opportunities became 50% (1,738/3,474). We investigated 
the proportion of missed opportunities by CHADS2 score and observed a general decrease in 
missed opportunities as CHADS2 score increased; however, the sample size was very small 
for the higher scores (Table S5). When entered into the regression model, duration of 
registration was not associated with anticoagulant drug prescribing; however frequency of 
consultations in the year prior to stroke or TIA was associated with a decrease in missed 
opportunities (OR 0.97 [per unit increase]; 95% CI 0.96, 0.98, P<0.01). Aspirin was prescribed 
in 71% (1,168/1,647) of patients with a missed opportunity for anticoagulant drug 
prescribing. Allowing patients with a CHADS2 score of 1 to be prescribed aspirin or 
anticoagulant drugs reduced the proportion of missed opportunities to 40% (1,277/3,194). 
Aspirin was still inappropriately prescribed in 62% (798/1,277) of patients with a missed 
opportunity under this definition (i.e. patients with CHADS2 ≥2). 
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Supplementary Table S5: CHADS2 score and the proportion of atrial fibrillation patients 
with a missed opportunity for prescription of anticoagulant drugs prior to stroke or 
transient ischaemic attack (TIA). 
CHADS2 score Missed opportunities (%) 
1 (n= 986) 525 (53.2) 
2 (n=1,431) 755 (52.8) 
3 (n= 489) 226 (46.2) 
4 (n= 226) 114 (50.4) 
5 (n= 55) 25 (45.5) 
6 (n= 7) 2 (28.6) 
 
Antihypertensive prescribing 
Missed opportunities for antihypertensive drug prescribing were recorded in 27% 
(540/2,038) of patients with high BP and 24% (1,484/6,272) of patients with moderately high 
BP and at high CVD risk (Table S6). Variables associated with having a missed opportunity for 
antihypertensive drug prescribing are presented in Tables S7 and S8 for patients eligible 
because of high BP or moderately high BP with high CVD risk, respectively. 
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Supplementary Table S6: Proportion of stroke and transient ischaemic attack (TIA) patients 
with a prior missed opportunity for antihypertensive drug prescribing in eligible patients 
(either BP ≥160/100mmHg or ≥140/90mmHg in patients at high cardiovascular disease 
(CVD) risk). 
 Proportion of missed opportunities (frequency) 
 Untreated BP 
≥160/100mmHg  
Untreated BP ≥140/90mmHg 
& high CVD risk 
Stroke 28.3  (348/1,232) 23.8  (802/3,376) 
TIA 23.7  (154/649) 22.4  (444/1,984) 
Stroke with previous TIA 24.2  (38/157) 26.1  (238/912) 
Total 26.5  (540/2,038) 23.7  (1,484/6,272) 
BP: Blood Pressure, CVD: Cardiovascular Disease, TIA: Transient Ischaemic Attack 
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Supplementary Table S7: Adjusted* odds ratios for effects of patient and demographic 
characteristics on having a missed opportunity for prescription of antihypertensive drugs 
prior to stroke or transient ischaemic attack (TIA) in patients with high BP 
(≥160/100mmHg). 
  Odds Ratio 95% CI P Value 
Age <45 1.75 0.82, 3.70   0.15 
 45-49 1.40 0.72, 2.73   0.32 
 50-54 1.61 0.90, 2.90   0.11 
 55-59 2.12 1.27, 3.53 <0.01 
 60-64 0.92 0.55, 1.52   0.74 
 65-69 1.32 0.82, 2.12   0.26 
 70-74 1.04 0.68, 1.59   0.86 
 75-79 1.00   
 80-84 0.96 0.62, 1.50   0.87 
 85-89 1.25 0.82, 1.91   0.30 
 90-94 1.62 0.97, 2.72   0.07 
 >95 5.23 2.39, 11.46 <0.01 
Sex Male 1.00   
 Female 0.85 0.67, 1.07   0.17 
Rurality Rural 1.00   
 Urban 1.32 1.04, 1.67   0.02 
Comorbidities CKD 0.72 0.51, 0.99   0.05 
 Hypertension 0.14 0.10, 0.18 <0.01 
 Atrial 
fibrillation 
0.56 0.36, 0.86   0.01 
 Diabetes 0.42 0.29, 0.62 <0.01 
 CHD 0.49 0.34, 0.71 <0.01 
 Dementia 2.39 1.24, 4.60   0.01 
*Each odds ratio is adjusted for the other variables in the table. 
CHD: Coronary Heart Disease, CI: Confidence Interval CKD: Chronic 
Kidney Disease 
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Supplementary Table S8: Adjusted* odds ratios for effects of patient and demographic 
characteristics on having a missed opportunity for prescription of antihypertensive drugs 
prior to stroke or transient ischaemic attack (TIA) in patients with moderately high BP 
(≥140/90mmHg) and high CVD risk. 
  Odds Ratio 95% CI P Value 
Age <45 1.81 0.70, 4.70   0.22 
 45-49 1.54 0.83, 2.87   0.17 
 50-54 1.62 1.07, 2.44   0.02 
 55-59 1.53 1.10, 2.15   0.01 
 60-64 1.18 0.87, 1.60   0.28 
 65-69 1.30 0.98, 1.72   0.07 
 70-74 1.17 0.92, 1.50   0.21 
 75-79 1.00   
 80-84 0.95 0.74, 1.22   0.69 
 85-89 1.27 0.95, 1.70   0.11 
 90-94 1.68 1.21, 2.33 <0.01 
 >95 3.23 1.86, 5.60 <0.01 
Sex Male 1.00   
 Female 0.87 0.75, 1.01   0.07 
Comorbidities Diabetes 0.46 0.38, 0.56 <0.01 
 CHD 0.29 0.24, 0.36 <0.01 
 Hypertension 0.10 0.09, 0.12 <0.01 
 Heart failure 0.60 0.40, 0.90   0.01 
 CKD 0.53 0.44, 0.65 <0.01 
 PAD 0.68 0.53, 0.89   0.01 
 AF 0.38 0.29, 0.50 <0.01 
 Dementia 2.01 1.41, 2.87 <0.01 
Multimorbidity One unit 
increase 
1.17 1.08, 1.27 <0.01 
Lifestyle 
intervention 
Weight 0.62 0.46, 0.82 <0.01 
*Each odds ratio is adjusted for the other variables in the table. 
AF: Atrial Fibrillation, CHD: Coronary Heart Disease, CKD: Chronic Kidney 
Disease, PAD: Peripheral Artery Disease 
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When entered into the regression model, duration of registration was not associated with 
antihypertensive drug prescribing; however frequency of consultations in the year prior to 
stroke or TIA was associated with a decrease in missed opportunities (OR 0.98 [per unit 
increase]; 95% CI 0.98, 0.99, P<0.01). The most recent guidelines, released 2014, regarding 
estimation of CVD risk recommend the use of QRISK2 over the Framingham risk equation.3 
When QRISK2-2014 was used to calculate 10-year CVD risk ≥20%, the number of patients 
eligible for antihypertensive drugs (moderately high BP with high CVD risk) increased to 
7,759; the proportion of missed opportunities was similar 24.6% (1,912/7,759). 
For patients eligible for antihypertensive drugs because of moderately high BP and high CVD 
risk (n=6,272), the impact of definitions of ‘high CVD risk’ was investigated (n=1,647). A 10-
year Framingham risk of ≥20% was associated with increased odds of having a missed 
opportunities (OR 1.5; 95% CI 1.2, 1.9, P<0.01). The other components of the definition of 
high CVD risk (coronary heart disease, chronic kidney disease, peripheral artery disease and 
diabetes) were all protective in the regression model. Therefore, we entered the variable ‘no 
high risk comorbidities’ (i.e. no CHD, CKD, PAD, or diabetes) (n=1,076) into the regression 
which gave an odds ratio of 1.5 (95% CI 1.2, 1.9, P<0.01). 
References 
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cardiovascular risk assessment and the modification of blood lipids for the primary 
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Supplementary Table S9: Number of strokes that potentially could be prevented through prescribing anticoagulant drugs. 
Age 
band 
Number of 
strokes in the 
THIN sample 
Estimated number 
of strokes that could 
be prevented in the 
THIN sample 
Proportion of strokes 
that could be 
prevented in the 
THIN sample (%) 
Number of 
strokes per year 
in UK 
Estimated number 
of strokes that 
could be 
prevented in UK 
  Male Female Male Female Male Female Male Female Male Female 
<35 115 124 0 0 0% 0% 0 0 0 0 
35-44 301 258 0 0 0% 0% 1,469 896 0 0 
45-54 841 652 1 1 0% 0% 2,453 1,097 4 3 
55-64 1,669 1,034 7 3 0% 0% 6,712 4,413 28 14 
65-74 2,462 1,903 20 21 1% 1% 18,817 12,744 154 140 
75-84 2,613 2,925 70 102 3% 3% 14,656 20,001 394 698 
≥85 1,232 2,468 58 151 5% 6% 9,747 16,677 460 1,022 
All ages 18,597 436                2.3%     109,682          2,918 
<85 14,658 227               1.5%        83,258          1,435 
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Supplementary Table S10: Number of strokes that potentially could be prevented through prescribing antihypertensive drugs. 
Age 
band 
Number of 
strokes in the 
THIN sample 
Estimated number of 
strokes that could be 
prevented in the 
THIN sample 
Proportion of strokes 
that could be 
prevented in the THIN 
sample (%) 
Number of 
strokes per year 
in UK 
Estimated number 
of strokes that 
could be prevented 
in UK 
  Male Female Male Female Male Female Male Female Male Female 
<35 115 124 0 1 0% 1% 0 0 0 0 
35-44 301 258 6 3 2% 1% 1,469 896 27 12 
45-54 841 652 23 11 3% 2% 2,453 1,097 67 18 
55-64 1,669 1,034 63 21 4% 2% 6,712 4,413 253 90 
65-74 2,462 1,903 107 55 4% 3% 18,817 12,744 815 371 
75-84 2,613 2,925 55 64 2% 2% 14,656 20,001 311 435 
≥85 1,232 2,468 36 68 3% 3% 9,747 16,677 282 458 
All ages 18,597       512                      2.8% 10,9682           3,137 
<85 14,658        408                     2.8% 83,258           2,398 
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Supplementary Table S11: Combinations of stroke and TIA prevention drugs clinically 
indicated. 
Number of prevention 
drug classes clinically 
indicated 
Prevention drugs 
clinically indicated 
Number of strokes and TIAs 
with prevention drugs 
clinically indicated (n (%)) 
0 None 11,363 (39.1)  
1 Lipid lowering drugs  8,365 (28.8) 
 Anticoagulants drugs  918   (3.2) 
 Antihypertensive drugs  670   (2.3) 
2 Lipid lowering and 
anticoagulant drugs 
1,389   (4.8) 
 Lipid lowering and 
antihypertensive drugs 
5,451 (18.8) 
 Anticoagulant and 
antihypertensive drugs 
64   (0.2) 
3 Lipid lowering, 
anticoagulant and 
antihypertensive drugs 
823   (2.8) 
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Supplementary Table S12: Combinations of missed opportunities for different stroke and 
TIA prevention drugs. 
Prevention drugs clinically 
indicated 
Number of 
missed 
opportunities 
Missed opportunities Number of 
strokes and TIAs 
with missed 
opportunities (n) 
Lipid lowering drugs only 0 None 4,231 
 1 Lipid lowering drugs 4,134 
Anticoagulants drugs only 0 None 408 
 1 Anticoagulant drugs 510 
Antihypertensive drugs only 0 None 427 
 1 Antihypertensive drugs 243 
Lipid lowering and 
anticoagulant drugs 
0 None 429 
2 Both drugs missed 320 
 1 Lipid lowering drugs only 286 
  Anticoagulant drugs only 354 
Lipid lowering and 
antihypertensive drugs 
0 None 2,369 
2 Both drugs missed 1,036 
 1 Lipid lowering drugs only 1,684 
  Antihypertensive drugs only 362 
Anticoagulant and 
antihypertensive drugs 
0 None 25 
2 Both drugs missed 10 
 1 Anticoagulants drugs only 27 
  Anticoagulant drugs only 2 
Lipid lowering, anticoagulant 
and antihypertensive drugs 
0 None 212 
1 Lipid lowering drugs only 145 
 Anticoagulant drugs only 209 
  Antihypertensive drugs only 13 
 2 Lipid lowering and 
anticoagulant drugs 
170 
  Lipid lowering and 
antihypertensive drugs 
27 
  Anticoagulant and 
antihypertensive drugs 
13 
 3 All three drugs missed 34 
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Appendix 4: Residual impairments after 
TIA: Systematic review protocol 
A4.1 Supplementary material 
Supplementary material published online for Publication 2 (presented as published): 
Moran GM, Fletcher B, Calvert M, Feltham MG, Sackley C, Marshall T. A systematic review 
investigating fatigue, psychological and cognitive impairment following TIA and minor 
stroke: protocol paper. Systematic Reviews 2013; 2: 72. doi: 10.1186/2046-4053-2-72 
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Appendix: Search strategy for MEDLINE (via Ovid) 1993 to April 2013. 
1. transient isch?emic attack$.mp. or exp Ischemic Attack, Transient/  
2. TIA.mp.  
3. TIAs.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier]  
4. (transient adj (brain isch?emia$ or cerebral isch?emia$ or CVA$ or cerebral vasc$ or 
cerebro vasc$)).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier]  
5. mini stroke.mp.  
6. minor stroke$.mp.  
7. mild stroke$.mp.  
8. NDS.mp.  
9. non$disabling stroke$.mp.  
10. (minor adj (cerebrovasc$ accident$ or cerebrovasc$ stroke$ or CVA$ or brain isch?emia$ 
or cerebral stroke$)).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare 
disease supplementary concept, unique identifier]  
11. Non$severe stroke$.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare 
disease supplementary concept, unique identifier] 
12. RIND or reversible isch?emic neurologic$ deficit$ 
13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 
14. "quality of life".mp. or exp "Quality of Life"/  
15. exp Anxiety/ or exp Anti-Anxiety Agents/ or exp Anxiety Disorders/ or anxiety.mp.  
16. exp Stress Disorders, Post-Traumatic/ or stress disorder$.mp.  
17. (anxiety disorder$ or agoraphobia$ or obsessive$compulsive disorder$ or panic 
disorder$ or phobic disorder$ or distress$ or panic$).mp. [mp=title, abstract, original 
title, name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept, rare disease supplementary concept, unique identifier]  
18. (feel$ adj3 (apprehens$ or dread or disaster$ or fear$ or worry or worried or terror)).mp. 
[mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept, rare disease supplementary 
concept, unique identifier]  
19. exp Depression/ or depress$.mp.  
20. exp Antidepressive Agents/ or antidepress$.mp. or exp Depressive Disorder/  
21. mood disorder$.mp. or exp Mood Disorders/  
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22. posttraumatic stress disorder$.mp.  
23. post traumatic stress disorder$.mp.  
24. PTSD.mp.  
25. (flashback$ or avoidance$ or avoid$ or re$experience).mp. [mp=title, abstract, original 
title, name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept, rare disease supplementary concept, unique identifier]  
26. exp Cognition Disorders/ or cognit$ disorder$.mp. or exp Cognition/   
27. exp Attention/ or cognit$ impair$.mp.  
28. (cognition or orientation or attention or perception or mental processing or problem 
solving or memory).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept, rare 
disease supplementary concept, unique identifier]  
29. exp Fatigue/ or exp Fatigue Syndrome, Chronic/ or fatigue.mp.  
30. CFS.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier]  
31. (fatigue adj (chronic or syndrome$)).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol supplementary 
concept, rare disease supplementary concept, unique identifier]   
32. 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 
or 30 or 31  
33. 13 and 32   
34. limit 33 to (humans and yr="1993 -Current") 
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Appendix 5: Residual impairments after 
TIA: Systematic review results 
A5.1 Supplementary material 
Supplementary material published online for Publication 3 (presented as published): 
Moran GM, Fletcher B, Feltham MG, Calvert M, Sackley C, Marshall T. Fatigue, psychological 
and cognitive impairment following transient ischaemic attack and minor stroke: a 
systematic review. European Journal of Neurology 2014 21(10):1258-67. doi: 
10.1111/ene.12469 
262 
 
263 
 
264 
 
      
265 
 
266 
 
267 
 
 
 
 
 
268 
 
A5.2: Criteria used by studies included in the systematic review to 
define TIA and minor stroke 
 
Diagnosis Definition Number 
of studies 
TIA WHO criteria (a focal neurological deficit of sudden onset with a 
vascular cause, with resolution of focal symptoms within 24 hours) 
5 
 Diagnosis confirmed by neurologist/ stroke physician (criteria not 
defined) 
5 
 Diagnosis at discharge (criteria not defined) 1 
 Symptoms of retinal or cerebral TIA 1 
 Self-reported ("Have you ever experienced transient speech 
dysfunction, numbness/tingling, weakness/paralysis and resolved 
within 24 hours which people call TIA or 'mini stroke'?") 
1 
 Unclear 8 
Minor 
stroke 
SSS >45 1 
Barthel index 50-100 (one week after stroke onset) 1 
 Diagnosis confirmed by neurologist/ stroke physician (criteria not 
defined) 
2 
 Direct discharge home within 3 weeks post-stroke 1 
 Modified Rankin grade of ≥3 2 
 NIHSS ≤3 at discharge 1 
 NIHSS ≤5 at discharge 2 
 NIHSS <6 at discharge 1 
 NIHSS ≤6 at discharge from hospital and ≤3 after 6m, Rankin score 
<1 at 6m 
1 
 Pts showing no neurological symptoms or mild non-disabling 
symptoms (standard neurological examination) 3 weeks post stroke 
1 
 Self-reported and verified against mobility, self-care, pain, usual 
activities and depression scores 
1 
 able to walk 10m independently, living at home, independent in 
activities of daily living 
1 
 Unclear 2 
NIHSS: National Institutes of Health Stroke Scale; SSS: Scandinavian Stroke Scale; TIA: 
Transient Ischaemic Attack; WHO: World Health Organisation 
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Appendix 6: Residual impairments after 
TIA: Retrospective cohort study 
protocol 
A6.1 Supplementary material 
Supplementary material published online for Publication 4 (presented as published): 
Moran GM, Calvert M, Feltham MG, Ryan R, Marshall T. A retrospective cohort study to 
investigate fatigue, psychological or cognitive impairment after TIA: protocol paper. BMJ 
Open 2015;5:e008149. doi:10.1136/bmjopen-2015-008149 
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Appendix 1: Read and drug codes for: (a) fatigue, (b) anxiety, (c) depression, (d) 
anxiety and depression (e) post-traumatic stress disorder (PTSD) and (f) cognitive 
impairment. 
a) Fatigue 
Read code Description 
168..00 Tiredness symptom 
168..11 Fatigue – symptom 
168..12 Lethargy – symptom 
168..13 Malaise – symptom 
168..14 C/O "muzzy head" 
1682.00 Fatigue 
1683.00 Tired all the time 
1683.11 C/O - "tired all the time" 
1684.00 Malaise/lethargy 
1684.11 C/O - debility – malaise 
1684.13 C/O - postviral syndrome 
1688.00 Exhaustion 
168Z.00 Tiredness symptom NOS 
1B3..12 Weakness symptoms 
1B32.00 Weakness present 
8HkW.00 Referral to chronic fatigue syndrome specialist team 
8HlL.00 Referral for chronic fatigue syndrome activity management 
8Q1..00 Activity management for chronic fatigue syndrome 
E205.00 Neurasthenia - nervous debility 
E205.11 Nervous exhaustion 
E205.12 Tired all the time 
Eu46011 [X]Fatigue syndrome 
F286.00 Chronic fatigue syndrome 
F286.11 CFS - chronic fatigue syndrome 
F286.12 Postviral fatigue syndrome 
F286.13 PVFS - post viral fatigue syndrome 
F286.14 Post-viral fatigue syndrome 
F286.15 Myalgic encephalomyelitis 
F286.16 ME - myalgic encephalomyelitis 
F286000 Mild chronic fatigue syndrome 
F286100 Moderate chronic fatigue syndrome 
F286200 Severe chronic fatigue syndrome 
R007.00 [D]Malaise and fatigue 
R007000 [D]Malaise 
R007100 [D]Fatigue 
R007200 [D]Asthenia NOS 
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Read code Description 
R007211 [D]General weakness 
R007300 [D]Lethargy 
R007400 [D]Postviral (asthenic) syndrome 
R007411 [D]Post viral debility 
R007500 [D]Tiredness 
R007600 [D]Post polio exhaustion 
R007z00 [D]Malaise and fatigue NOS 
R007z11 [D]Lassitude 
CFS Chronic fatigue syndrome; ME Myalgic encephalomyelitis; NOS Not otherwise 
specified; PVFS Post viral fatigue syndrome; C/O Complaining of; [D] Diagnosis; [X] 
Cross referenced to specific ICD-10 codes (READ 2 relates to ICD-9) 
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b) Anxiety 
Read code Description 
1466.00 H/O: Anxiety state 
16ZB100 Feeling low or worried 
173f.00 Anxiety about breathlessness 
1B1H.00 Frightened 
1B1H.11 Fear 
1B1H.12 Apprehension 
1B1T.00 Feeling stressed 
1B1V.00 C/O - Panic attack 
1BK..00 Worried 
1P3..00 Compulsive behaviour 
2253.00 O/E – Distressed 
225J.00 O/E - Panic attack 
225K.00 O/E - Fearful mood 
67J..00 Stress counselling 
8G94.00 Anxiety management training 
8HHp.00 Referral for guided self-help for anxiety 
9N54.00 Encounter for fear 
E200.00 Anxiety states 
E200000 Anxiety state unspecified 
E200100 Panic disorder 
E200111 Panic attack 
E200200 Generalised anxiety disorder 
E200400 Chronic anxiety 
E200500 Recurrent anxiety 
E200z00 Anxiety state NOS 
E202.00 Phobic disorders 
E202.11 Social phobic disorders 
E202.12 Phobic anxiety 
E202000 Phobia unspecified 
E202100 Agoraphobia with panic attacks 
E202200 Agoraphobia without mention of panic attacks 
E202D00 Fear of death 
E203.00 Obsessive-compulsive disorders 
E203.11 Anancastic neurosis 
E203000 Compulsive neurosis 
E203100 Obsessional neurosis 
E203z00 Obsessive-compulsive disorder NOS 
E214.00 Compulsive personality disorders 
E214000 Anankastic personality 
E214100 Obsessional personality 
  Continued on next page 
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Read code Description 
E214z00 Compulsive personality disorder NOS 
E28..00 Acute reaction to stress 
E280.00 Acute panic state due to acute stress reaction 
E281.00 Acute fugue state due to acute stress reaction 
E282.00 Acute stupor state due to acute stress reaction 
E283.00 Other acute stress reactions 
E283z00 Other acute stress reaction NOS 
E284.00 Stress reaction causing mixed disturbance of emotion/conduct 
E28z.00 Acute stress reaction NOS 
Eu05400 [X]Organic anxiety disorder 
Eu4..00 [X]Neurotic, stress - related and somoform disorders 
Eu40.00 [X]Phobic anxiety disorders 
Eu40000 [X]Agoraphobia 
Eu40011 [X]Agoraphobia without history of panic disorder 
Eu40012 [X]Panic disorder with agoraphobia 
Eu40100 [X]Social phobias 
Eu40112 Social neurosis 
Eu41.00 [X]Other anxiety disorders 
Eu41000 [X]Panic disorder [episodic paroxysmal anxiety] 
Eu41011 [X]Panic attack 
Eu41012 [X]Panic state 
Eu41100 [X]Generalized anxiety disorder 
Eu41111 [X]Anxiety neurosis 
Eu41112 [X]Anxiety reaction 
Eu41113 [X]Anxiety state 
Eu41200 [X]Mixed anxiety and depressive disorder 
Eu41y00 [X]Other specified anxiety disorders 
Eu41y11 [X]Anxiety hysteria 
Eu41z00 [X]Anxiety disorder, unspecified 
Eu41z11 [X]Anxiety NOS 
Eu42.00 [X]Obsessive - compulsive disorder 
Eu42.11 [X]Anankastic neurosis 
Eu42.12 [X]Obsessive-compulsive neurosis 
Eu42100 [X]Predominantly compulsive acts [obsessional rituals] 
Eu42y00 [X]Other obsessive-compulsive disorders 
Eu42z00 [X]Obsessive-compulsive disorder, unspecified 
Eu43.00 [X]Reaction to severe stress, and adjustment disorders 
Eu43000 [X]Acute stress reaction 
Eu43012 [X]Acute reaction to stress 
Eu43y00 [X]Other reactions to severe stress 
Eu43z00 [X]Reaction to severe stress, unspecified 
Eu51511 [X]Dream anxiety disorder 
Continued on next page 
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Read code Description 
Eu60511 [X]Compulsive personality disorder 
Eu60513 [X]Obsessive-compulsive personality disorder 
Eu63011 [X]Compulsive gambling 
Z4I7.00 Acknowledging anxiety 
Z4I7100 Recognising anxiety 
Z4I7200 Alleviating anxiety 
Z4I7211 Reducing anxiety 
Z4L1.00 Anxiety counselling 
Z522600 Flooding - obsessional compulsive disorder 
C/O Complaining of; O/E On Examination; NOS Not otherwise specified; [X] Cross 
referenced to specific ICD-10 codes (READ 2 relates to ICD-9) 
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c) Depression 
Read code Description 
13Y3.00 Manic-depression association member 
1465.00 H/O: Depression 
146D.00 H/O: Manic depressive disorder 
1B17.00 Depressed 
1B17.11 C/O - Feeling depressed 
1B1U.00 Symptoms of depression 
1B1U.11 Depressive symptoms 
1BT..00 Depressed mood 
1BT..11 Low mood 
1BT..12 Sad mood 
1JJ..00 Suspected depression 
2257.00 O/E – Depressed 
6659000 Antidepressant drug treatment started 
8BK0.00 Depression management programme 
8CAa.00 Patient given advice about management of depression 
8HHq.00 Referral for guided self-help for depression 
9H90.00 Depression annual review 
9H91.00 Depression medication review 
9H92.00 Depression interim review 
9HA0.00 On depression register 
9hC..00 Exception reporting: depression quality indicators 
9hC0.00 Excepted from depression quality indicators: patient unsuitable 
9hC1.00 Excepted from depression quality indicators: informed dissent 
9k4..00 Depression - enhanced services administration 
9k40.00 Depression - enhanced service completed 
9kQ..00 On full dose long term treatment depression  
9kQ..11 On full dose long term treatment for depression 
9Ov..00 Depression monitoring administration 
9Ov0.00 Depression monitoring first letter 
9Ov1.00 Depression monitoring second letter 
9Ov2.00 Depression monitoring third letter 
9Ov3.00 Depression monitoring verbal invite 
9Ov4.00 Depression monitoring telephone invite 
E001300 Presenile dementia with depression 
E002.00 Senile dementia with depressive or paranoid features 
E002100 Senile dementia with depression 
E002z00 Senile dementia with depressive or paranoid features NOS 
E004300 Arteriosclerotic dementia with depression 
E03y200 Organic affective syndrome 
E11..00 Affective psychoses 
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Read code Description 
E11..11 Bipolar psychoses 
E11..12 Depressive psychoses 
E112.00 Single major depressive episode 
E112.11 Agitated depression 
E112.12 Endogenous depression first episode 
E112.13 Endogenous depression first episode 
E112.14 Endogenous depression 
E112000 Single major depressive episode, unspecified 
E112100 Single major depressive episode, mild 
E112200 Single major depressive episode, moderate 
E112300 Single major depressive episode, severe, without psychosis 
E112400 Single major depressive episode, severe, with psychosis 
E112500 Single major depressive episode, partial or unspecified remission 
E112600 Single major depressive episode, in full remission 
E112z00 Single major depressive episode NOS 
E113.00 Recurrent major depressive episode 
E113.11 Endogenous depression – recurrent 
E113000 Recurrent major depressive episodes, unspecified 
E113100 Recurrent major depressive episodes, mild 
E113200 Recurrent major depressive episodes, moderate 
E113300 Recurrent major depressive episodes, severe, no psychosis 
E113400 Recurrent major depressive episodes, severe, with psychosis 
E113500 Recurrent major depressive episodes, partial/unspecified remission 
E113600 Recurrent major depressive episodes, in full remission 
E113700 Recurrent depression 
E113z00 Recurrent major depressive episode NOS 
E115.00 Bipolar affective disorder, currently depressed 
E115.11 Manic-depressive - now depressed 
E115000 Bipolar affective disorder, currently depressed, unspecified 
E115100 Bipolar affective disorder, currently depressed, mild 
E115200 Bipolar affective disorder, currently depressed, moderate 
E115300 Bipolar affect disorder, now depressed, severe, no psychosis 
E115400 Bipolar affect disorder, now depressed, severe with psychosis 
E115500 Bipolar affect disorder, now depressed, part/unspecified remission 
E115600 Bipolar affective disorder, now depressed, in full remission 
E115z00 Bipolar affective disorder, currently depressed, NOS 
E116.00 Mixed bipolar affective disorder 
E116000 Mixed bipolar affective disorder, unspecified 
E116100 Mixed bipolar affective disorder, mild 
E116200 Mixed bipolar affective disorder, moderate 
E116300 Mixed bipolar affective disorder, severe, without psychosis 
E116400 Mixed bipolar affective disorder, severe, with psychosis 
Continued on next page 
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Read code Description 
E116500 Mixed bipolar affective disorder, partial/unspecified remission 
E116600 Mixed bipolar affective disorder, in full remission 
E116z00 Mixed bipolar affective disorder, NOS 
E117.00 Unspecified bipolar affective disorder 
E117000 Unspecified bipolar affective disorder, unspecified 
E117100 Unspecified bipolar affective disorder, mild 
E117200 Unspecified bipolar affective disorder, moderate 
E117300 Unspecified bipolar affective disorder, severe, no psychosis 
E117400 Unspecified bipolar affective disorder, severe with psychosis 
E117500 Unspecified bipolar affect disorder, partial/unspecified remission 
E117600 Unspecified bipolar affective disorder, in full remission 
E117z00 Unspecified bipolar affective disorder, NOS 
E118.00 Seasonal affective disorder 
E11y.00 Other and unspecified manic-depressive psychoses 
E11y000 Unspecified manic-depressive psychoses 
E11y200 Atypical depressive disorder 
E11y300 Other mixed manic-depressive psychoses 
E11yz00 Other and unspecified manic-depressive psychoses NOS 
E11z.00 Other and unspecified affective psychoses 
E11z000 Unspecified affective psychoses NOS 
E11z100 Rebound mood swings 
E11z200 Masked depression 
E11zz00 Other affective psychosis NOS 
E130.00 Reactive depressive psychosis 
E130.11 Psychotic reactive depression 
E135.00 Agitated depression 
E204.00 Neurotic depression reactive type 
E211.00 Affective personality disorder 
E211000 Unspecified affective personality disorder 
E211200 Depressive personality disorder 
E290.00 Brief depressive reaction 
E290z00 Brief depressive reaction NOS 
E291.00 Prolonged depressive reaction 
E292400 Adjustment reaction with anxious mood 
E2B..00 Depressive disorder NEC 
E2B0.00 Postviral depression 
E2B1.00 Chronic depression 
Eu05300 [X]Organic mood [affective] disorders 
Eu06y11 [X]Right hemispheric organic affective disorder 
Eu20400 [X]Post-schizophrenic depression 
Eu3..00 [X]Mood - affective disorders 
Eu31.00 [X]Bipolar affective disorder 
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Read code Description 
Eu31.11 [X]Manic-depressive illness 
Eu31.12 [X]Manic-depressive psychosis 
Eu31.13 [X]Manic-depressive reaction 
Eu31300 [X]Bipolar affective disorder cur epi mild or moderate depression 
Eu31400 [X]Bipolar affective disorder, current episode sever depress, no 
psychotic symptoms 
Eu31500 [X]Bipolar affective disorder cur epi severe depression with 
psychotic symptoms 
Eu31600 [X]Bipolar affective disorder, current episode mixed 
Eu31700 [X]Bipolar affective disorder, currently in remission 
Eu31800 [X]Bipolar affective disorder type i 
Eu31900 [X]Bipolar affective disorder type ii 
Eu31911 [X]Bipolar ii disorder 
Eu31y00 [X]Other bipolar affective disorders 
Eu31y11 [X]Bipolar ii disorder 
Eu31z00 [X]Bipolar affective disorder, unspecified 
Eu32.00 [X]Depressive episode 
Eu32.11 [X]Single episode of depressive reaction 
Eu32.12 [X]Single episode of psychogenic depression 
Eu32.13 [X]Single episode of reactive depression 
Eu32000 [X]Mild depressive episode 
Eu32100 [X]Moderate depressive episode 
Eu32200 [X]Severe depressive episode without psychotic symptoms 
Eu32211 [X]Single episode agitated depression without psychotic symptoms 
Eu32212 [X]Single episode major depression without psychotic symptoms 
Eu32213 [X]Single episode vital depression without psychotic symptoms 
Eu32300 [X]Severe depressive episode with psychotic symptoms 
Eu32311 [X]Single episode of major depression and psychotic symptoms 
Eu32312 [X]Single episode of psychogenic depressive psychosis 
Eu32313 [X]Single episode of psychotic depression 
Eu32314 [X]Single episode of reactive depressive psychosis 
Eu32400 [X]Mild depression 
Eu32500 [X]Major depression, mild 
Eu32600 [X]Major depression, moderately severe 
Eu32700 [X]Major depression, severe without psychotic symptoms 
Eu32800 [X]Major depression, severe with psychotic symptoms 
Eu32y00 [X]Other depressive episodes 
Eu32y11 [X]Atypical depression 
Eu32y12 [X]Single episode of masked depression NOS 
Eu32z00 [X]Depressive episode, unspecified 
Eu32z11 [X]Depression NOS 
Eu32z12 [X]Depressive disorder NOS 
Continued on next page 
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Read code Description 
Eu32z13 [X]Prolonged single episode of reactive depression 
Eu32z14 [X] Reactive depression NOS 
Eu33.00 [X]Recurrent depressive disorder 
Eu33.11 [X]Recurrent episodes of depressive reaction 
Eu33.12 [X]Recurrent episodes of psychogenic depression 
Eu33.13 [X]Recurrent episodes of reactive depression 
Eu33.14 [X]Seasonal depressive disorder 
Eu33.15 [X]SAD - seasonal affective disorder 
Eu33000 [X]Recurrent depressive disorder, current episode mild 
Eu33100 [X]Recurrent depressive disorder, current episode moderate 
Eu33200 [X]Recurrent depress disorder current episode severe without 
psychotic symptoms 
Eu33211 [X]Endogenous depression without psychotic symptoms 
Eu33212 [X]Major depression, recurrent without psychotic symptoms 
Eu33213 [X]Manic-depress psychosis, depressed, no psychotic symptoms 
Eu33214 [X]Vital depression, recurrent without psychotic symptoms 
Eu33300 [X]Recurrent depress disorder cur epi severe with psychotic 
symptoms 
Eu33311 [X]Endogenous depression with psychotic symptoms 
Eu33312 [X]Manic-depress psychosis, depressed type + psychotic symptoms 
Eu33313 [X]Recurrent severe episodes/major depression + psychotic 
symptom 
Eu33314 [X]Recurrent severe episodes/psychogenic depressive psychosis 
Eu33315 [X]Recurrent severe episodes of psychotic depression 
Eu33316 [X]Recurrent severe episodes/reactive depressive psychosis 
Eu33400 [X]Recurrent depressive disorder, currently in remission 
Eu33y00 [X]Other recurrent depressive disorders 
Eu33z00 [X]Recurrent depressive disorder, unspecified 
Eu33z11 [X]Monopolar depression NOS 
Eu34.00 [X]Persistent mood affective disorders 
Eu34011 [X]Affective personality disorder 
Eu34100 [X]Dysthymia 
Eu34111 [X]Depressive neurosis 
Eu34112 [X]Depressive personality disorder 
Eu34113 [X]Neurotic depression 
Eu34y00 [X]Other persistent mood affective disorders 
Eu34z00 [X]Persistent mood affective disorder, unspecified 
Eu3y.00 [X]Other mood affective disorders 
Eu3y000 [X]Other single mood affective disorders 
Eu3y011 [X]Mixed affective episode 
Eu3y100 [X]Other recurrent mood affective disorders 
Eu3y111 [X]Recurrent brief depressive episodes 
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Read code Description 
Eu3yy00 [X]Other specified mood affective disorders 
Eu3z.00 [X]Unspecified mood affective disorder 
Eu3z.11 [X]Affective psychosis NOS 
Eu92000 [X]Depressive conduct disorder 
ZV11100 [V]Personal history of affective disorder 
ZV11111 [V]Personal history of manic-depressive psychosis 
ZV11112 [V]Personal history of manic-depressive psychosis 
C/O Complaining of; H/O History of; O/E On Examination; NEC Not elsewhere 
classified; NOS Not otherwise specified; SAD Seasonal affective disorder; [V] 
Correspond to the ICD-9 chapter that allows the recording of supplementary 
factors influencing health status or contact with health services other than for 
illness; [X] Cross referenced to specific ICD-10 codes (READ 2 relates to ICD-9) 
 
d) Depression and anxiety 
Read code Description 
E200300 Anxiety with depression 
Eu34114 [X]Persistent anxiety depression 
Eu41200 [X]Mixed anxiety and depressive disorder 
Eu41211 [X]Mild anxiety depression 
[X] Cross referenced to specific ICD-10 codes (READ 2 relates to ICD-9) 
 
e) PTSD 
Read code Description 
E28..11 Combat fatigue 
E29y100 Other post-traumatic stress disorder 
E2A2.11 Post-traumatic brain syndrome 
Eu43013 [X]Combat fatigue 
Eu43100 [X]Post - traumatic stress disorder 
E283100 Acute posttrauma stress state 
[X] Cross referenced to specific ICD-10 codes (READ 2 relates to ICD-9) 
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f) Cognitive impairment 
Read code Description 
1B1A.00 Memory loss – amnesia 
1B1A.11 Amnesia symptom 
1B1A.12 Memory loss symptom 
1B1A.13 Memory disturbance 
1BR..00 Reduced concentration 
1BR0.00 Reduced concentration span 
1BR0.11 Short attention span 
1BW..00 Poor concentration 
1S21.00 Disturbance of memory for order of events 
28E..00 Cognitive decline 
28E0.00 Mild cognitive impairment 
28E1.00 Moderate cognitive impairment 
28E2.00 Severe cognitive impairment 
3A10.00 Memory: own age not known 
3A20.00 Memory: present time not known 
3A30.00 Memory: present place not known 
3A40.00 Memory: present year not known 
3A50.00 Memory: own DOB not known 
3A60.00 Memory: present month not known 
3A70.00 Memory: important event not known 
3A80.00 Memory: important person not known 
3A91.00 Memory: count down unsuccessful 
3AA1.00 Memory: address recall unsuccessful 
3AE1.00 GDS level 2 - very mild cognitive decline 
3AE2.00 GDS level 3 - mild cognitive decline 
3AE3.00 GDS level 4 - moderate cognitive decline 
3AE4.00 GDS level 5 - moderately severe cognitive decline 
3AE5.00 GDS level 6 - severe cognitive decline 
3AE6.00 GDS level 7 - very severe cognitive decline 
Eu80100 [X]Expressive language disorder 
Eu80200 [X]Receptive language disorder 
F481J00 Visual disorientation syndrome 
R00z011 [D]Memory deficit 
R00zX00 [D]Disorientation, unspecified 
Ryu5.00 [X]Symptoms/signs involving cognition, percept, emotion state & 
behaviour 
Ryu5100 [X]Other & unspecified symptom/signs involving cognitive 
function/awareness 
Ryu5700 [X]Disorientation, unspecified 
Z73..00 Cognitive intervention strategies 
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Read code Description 
Z7A1.00 Cognitive skills training 
Z7A1100 Concentration skills training 
Z7A1300 Memory skills training 
Z7A1400 Attention training 
Z7A1500 Memory retraining 
Z7A1600 Orientation training 
Z7A1700 Reality orientation 
Z7A1711 RO - reality orientation 
Z7A1712 Reality orientation approach 
Z7A1A00 Executive functions training 
Z7A2100 Strategy training for cognitive skills 
Z7A2200 Strategy training for perceptual skills 
Z7A2300 Strategy training for executive skills 
Z7C1.00 Impaired cognition 
Z7C2200 Unable to recognise sounds 
Z7C2600 Unable to recognise surroundings 
Z7C2700 Mistakes people's identity 
Z7C2900 Does not recognise self 
Z7C2A00 Does not recognise photographs of self 
Z7C2B00 Does not recognise self in mirror 
Z7C2D00 Unable to recognise parts of own body 
Z7C2F00 Unable to recognise own fingers 
Z7C2H00 Unable to recognise objects 
Z7C2J00 Unable to recognise objects by touch 
Z7C2L00 Unable to recognise objects by sight 
Z7C2L11 Unable to recognise objects visually 
Z7C2N00 Unable to recognise warning sounds 
Z7C2P00 Unable to recognise faces 
Z7C2R00 Unable to recognise faces by sight 
Z7C2T00 Unable to recognise familiar people 
Z7C3200 Unable to reason 
Z7C3300 Difficulty reasoning 
Z7C3500 Unable to use verbal reasoning 
Z7C3600 Difficulty using verbal reasoning 
Z7C3800 Unable to use arithmetic reasoning 
Z7C3900 Difficulty using arithmetic reasoning 
Z7C3B00 Unable to use visuospatial reasoning 
Z7C3C00 Difficulty using visuospatial reasoning 
Z7C4200 Unable to process information 
Z7C4300 Difficulty processing information 
Z7C4600 Unable to process information accurately 
Z7C4700 Difficulty processing information accurately 
Continued on next page 
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Read code Description 
Z7C4900 Unable to process information at normal speed 
Z7C4A00 Difficulty processing information at normal speed 
Z7C4C00 Unable to analyse information 
Z7C4D00 Difficulty analysing information 
Z7C5100 Unable to concentrate 
Z7C5111 Lack of concentration 
Z7C5300 Reduced concentration span 
Z7C5311 Reduced attention span 
Z7C5312 Short attention span 
Z7C5313 Short concentration span 
Z7C6200 Unable to tell the time 
Z7C6300 Difficulty telling the time 
Z7C7200 Unable to write 
Z7C7300 Difficulty writing 
Z7C8200 Unable to read 
Z7C8300 Difficulty reading 
Z7C9200 Unable to perform logical sequencing 
Z7C9300 Difficulty performing logical sequencing 
Z7CC311 Orientation confused 
Z7CC312 Orientation poor 
Z7CC600 Disorientation for person 
Z7CC700 Spatial disorientation 
Z7CC800 Right-left disorientation 
Z7CE400 Memory disturbance (& amnesia (& symptom)) 
Z7CE412 Memory loss symptom 
Z7CE413 Memory loss – amnesia 
Z7CE414 Memory disturbance 
Z7CE415 Loss of memory 
Z7CE611 Memory loss 
Z7CE612 Memory gone 
Z7CE614 Memory loss – amnesia 
Z7CE615 Loss of memory 
Z7CE616 LOM - loss of memory 
Z7CEA11 Impairment of working memory 
Z7CEA13 Impairment of primary memory 
Z7CEB11 Loss of memory for remote events 
Z7CEB12 Poor memory for remote events 
Z7CEC11 Loss of memory for recent events 
Z7CEC12 No memory for recent events 
Z7CEF00 Temporary loss of memory 
Z7CEG00 Transient memory loss 
Z7CEH00 Memory impairment 
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Read code Description 
Z7CEH11 Memory dysfunction 
Z7CEH12 Memory deficit 
Z7CEH13 Bad memory 
Z7CEH14 Memory problem 
Z7CEH15 Poor memory 
Z7CEJ00 Memory lapses 
Z7CEK00 Minor memory lapses 
Z7CEL00 Mild memory disturbance 
Z7CEM00 Distortion of memory 
Z7CEN11 Invents experiences to compensate for loss of memory 
Z7CF800 Poor short-term memory 
Z7CF811 Short-term memory loss 
Z7CFO00 Poor long-term memory 
Z7CFO11 Long-term memory loss 
Z7CFw00 Memory aided by use of diary 
Z7CFx00 Memory aided by use of labels 
Z7CFz00 Memory aided by use of lists 
Z7CGP00 Delayed verbal memory 
Z7CI100 Difficulty making plans 
Z7CI200 Difficulty making decisions 
Z7CI500 Unable to use decision-making strategies 
Z7CI600 Difficulty using decision-making strategies 
Z7CI900 Unable to make considered choices 
Z7CIA00 Difficulty making considered choices 
Z7CJ100 Difficulty solving problems 
DOB Date of birth; GDS Global deterioration scale ; LOM Loss of memory; RO 
Reality orientation; [D] Diagnosis; [X] Cross referenced to specific ICD-10 codes 
(READ 2 relates to ICD-9) 
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Appendix 2: Read codes for (a) transient ischaemic attack (TIA) and (b) stroke. 
a) TIA Read codes 
Read code Description 
G65..00 Transient cerebral ischaemia 
G65..11 Drop attack 
G65..12 Transient ischaemic attack 
G65..13 Vertebro-basilar insufficiency 
G650.00 Basilar artery syndrome 
G650.11 Insufficiency - basilar artery 
G651.00 Vertebral artery syndrome 
G651000 Vertebro-basilar artery syndrome 
G652.00 Subclavian steal syndrome 
G653.00 Carotid artery syndrome hemispheric 
G654.00 Multiple and bilateral precerebral artery syndromes 
G656.00 Vertebrobasilar insufficiency 
G657.00 Carotid territory transient ischaemic attack 
G65y.00 Other transient cerebral ischaemia 
G65z.00 Transient cerebral ischaemia NOS 
G65z000 Impending cerebral ischaemia 
G65z100 Intermittent cerebral ischaemia 
G65zz00 Transient cerebral ischaemia NOS 
Fyu5500 [X]Other transient cerebral ischaemic attacks+related 
syndromes 
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b) Stroke Read codes 
Read code Description 
G60..00 Subarachnoid haemorrhage 
G600.00 Ruptured berry aneurysm 
G601.00 Subarachnoid haemorrhage from carotid siphon and bifurcation 
G602.00 Subarachnoid haemorrhage from middle cerebral artery 
G603.00 Subarachnoid haemorrhage from anterior communicating artery 
G604.00 Subarachnoid haemorrhage from posterior communicating artery 
G605.00 Subarachnoid haemorrhage from basilar artery 
G606.00 Subarachnoid haemorrhage from vertebral artery 
G60X.00 Subarachnoid haemorrhage from intracranial artery, unspecified 
G60z.00 Subarachnoid haemorrhage NOS 
G61..00 Intracerebral haemorrhage 
G61..11 CVA - cerebrovascular accident due to intracerebral haemorrhage 
G61..12 Stroke due to intracerebral haemorrhage 
G610.00 Cortical haemorrhage 
G611.00 Internal capsule haemorrhage 
G612.00 Basal nucleus haemorrhage 
G613.00 Cerebellar haemorrhage 
G614.00 Pontine haemorrhage 
G615.00 Bulbar haemorrhage 
G616.00 External capsule haemorrhage 
G617.00 Intracerebral haemorrhage, intraventricular 
G618.00 Intracerebral haemorrhage, multiple localized 
G61X.00 Intracerebral haemorrhage in hemisphere, unspecified 
G61X000 Left sided intracerebral haemorrhage, unspecified 
G61X100 Right sided intracerebral haemorrhage, unspecified 
G61z.00 Intracerebral haemorrhage NOS 
G62..00 Other and unspecified intracranial haemorrhage 
G62z.00 Intracranial haemorrhage NOS 
G630.00 Basilar artery occlusion 
G631.00 Carotid artery occlusion 
G631.11 Stenosis, carotid artery 
G631.12 Thrombosis, carotid artery 
G632.00 Vertebral artery occlusion 
G63y000 Cerebral infarct due to thrombosis of precerebral arteries 
G63y100 Cerebral infarction due to embolism of precerebral arteries 
G63z.00 Precerebral artery occlusion NOS 
G64..00 Cerebral arterial occlusion 
G64..11 CVA - cerebral artery occlusion 
G64..12 Infarction – cerebral 
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Read code Description 
G64..13 Stroke due to cerebral arterial occlusion 
G640.00 Cerebral thrombosis 
G640000 Cerebral infarction due to thrombosis of cerebral arteries 
G641.00 Cerebral embolism 
G641.11 Cerebral embolus 
G641000 Cerebral infarction due to embolism of cerebral arteries 
G64z.00 Cerebral infarction NOS 
G64z.11 Brainstem infarction NOS 
G64z.12 Cerebellar infarction 
G64z000 Brainstem infarction 
G64z100 Wallenberg syndrome 
G64z111 Lateral medullary syndrome 
G64z200 Left sided cerebral infarction 
G64z300 Right sided cerebral infarction 
G64z400 Infarction of basal ganglia 
G66..00 Stroke and cerebrovascular accident unspecified 
G66..11 CVA unspecified 
G66..12 Stroke unspecified 
G66..13 CVA - Cerebrovascular accident unspecified 
G660.00 Middle cerebral artery syndrome 
G661.00 Anterior cerebral artery syndrome 
G662.00 Posterior cerebral artery syndrome 
G663.00 Brain stem stroke syndrome 
G664.00 Cerebellar stroke syndrome 
G665.00 Pure motor lacunar syndrome 
G666.00 Pure sensory lacunar syndrome 
G667.00 Left sided CVA 
G668.00 Right sided CVA 
G671000 Acute cerebrovascular insufficiency NOS 
G676000 Cerebral infarct due cerebral venous thrombosis, nonpyogenic 
G677000 Occlusion and stenosis of middle cerebral artery 
G677100 Occlusion and stenosis of anterior cerebral artery 
G677200 Occlusion and stenosis of posterior cerebral artery 
G677300 Occlusion and stenosis of cerebellar arteries 
G6W..00 Cerebral infarct due unspecified occlusion/stenosis precerebral 
arteries 
G6X..00 Cerebral infarction due/unspecified occlusion or stenosis/cerebral 
arteries 
Gyu6000 [X]Subarachnoid haemorrhage from other intracranial arteries 
Gyu6100 [X]Other subarachnoid haemorrhage 
Gyu6200 [X]Other intracerebral haemorrhage 
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Read code Description 
Gyu6300 [X]Cerebral infarction due/unspecified occlusion or stenosis/cerebral 
arteries 
Gyu6400 [X]Other cerebral infarction 
Gyu6500 [X]Occlusion and stenosis of other precerebral arteries 
Gyu6600 [X]Occlusion and stenosis of other cerebral arteries 
Gyu6E00 [X]Subarachnoid haemorrhage from intracranial artery, unspecified 
Gyu6F00 [X]Intracerebral haemorrhage in hemisphere, unspecified 
Gyu6G00 [X]Cerebral infarct due unspecified occlusion/stenosis precerebral 
arteries 
Fyu5600 [X]Other lacunar syndromes 
Fyu5700 [X]Other vascular syndromes/brain in cerebrovasculr diseases 
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Appendix 3: Read codes for diagnoses including history of and resolved Read codes 
Diagnosis Read codes 
Atrial fibrillation* G573.% (excluding G5731, G5736)  
Asthma* H33..%, H3120, 173A.  
Cancer* B0... - B32z., B34.. -B6z0. (excluding B677.), Byu.. - Byu41, Byu5. - 
ByuE0, K1323, K01w1  
CHD* G3-G309, G30B-G330z (except G310), G33z-G3401, G342-G365X, 
G38-G3z, Gyu3% (except Gyu31)   
CKD* 1Z12. -1Z16, 1Z1B. – 1Z1L.,  K053. - K055. 
COPD* H3…, H31..% (excluding H3101, H31y0, H3122), H32..%, H36.. - 
H3z.. (excluding H3y0., H3y1.), H5832  
Dementia* Eu02.%, E00..%, Eu01.%, E02y1, E012.%, Eu00.%, E041., Eu041, 
F110. – F112., F116. 
Depression* E0013, E0021, E112.%, E113.%, E118., E11y2, E11z2, E130., E135., 
E2003, E291., E2B.., E2B1., Eu204, Eu251, Eu32.% (excluding 
Eu32A, Eu32B, Eu329), Eu33.%, Eu341, Eu412 
Diabetes mellitus* C10.., C109J, C109K, C10C., C10D., C10E.%, C10F.% (Excluding 
C10F8), C10G.%, C10H.%, C10M.%, C10N.%, PKyP. 
Epilepsy* F25..% (excluding F2501, F2504, F2511, F2516, F256.%, F258. – 
F25A., F25y4, F25G., F25H.), F1321, SC200   
Familial 
hypercholesterolemia 
1W2.., C320.11, C3200, C3201, C3204, C3205 
Heart Failure* G58..%, G1yz1, 662f. – 662i., 585f., G5yy9 
Hypertension* G2..., G20..%, G24.. - G2z.. (Excluding G24z1, G2400, G2410, 
G27..), Gyu2., Gyu20 
Hypothyroidism* C03..%, C04..%  
Learning disabilities* E3…%, Eu7..%, Eu814 – Eu817, Eu81z, 918e 
Osteoporosis* N330.% (Excluding N3308, N3309), N3312, N3313, N3316, N3318 
– N331B, N331H – N331M, NyuB0, NyuB1, NyuB8, N3314, N3315, 
N3746, NyuB2 
PAD* G73.., G73z.% (Excluding G73z1), Gyu74, G734., G73y. 
Palliative care* 1Z01., 2JE.., 8B2a., 8BA2., 8Bae., 8BAP., 8BAS., 8BAT., 8BJ1., 
8CM1.% (excluding 8CM15), 8CM4., 8CMb., 8CME., 8CMQ., 
8CMW3, 8H6A., 8H7g., 8H7L., 8HH7., 8IEE., 9367, 9c0L0, 9c0M., 
9c0N., 9c0P., 9EB5., 9G8.., 9K9.., 9Ng7., 9NgD., 9NNd., 9NNf0, 
ZV57C 
Psychosis, 
schizophrenia, bipolar 
affective disease* 
E10..%, E110.%, E111.%, E1124, E1134, E114. – E117z, E11y.% 
(excluding E11y2), E11z., E11z0, E11zz, E12..%, E13..% (excluding 
E135.), E2122, Eu2..%, Eu30.%, Eu31.%, Eu323, Eu328, Eu333, 
Eu32A, Eu329 
Rheumatoid arthritis* N040.%, N041., N042.% (excluding N0420), N047., N04X., N04y0, 
N04y2, Nyu11, Nyu12, Nyu1G, Nyu10, G5yA., G5y8. 
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Read code Description 
History of Read codes 
Asthma 14B4.00 
Atrial fibrillation 14AN.00 
CHD 14A3.00-14A5.00, 14AH.00, 14AJ.00, 14AL.00, 14AT.00, 14AW.00, 
G32..12 
COPD 14B3.12 
Dementia 1461.00 
Diabetes 1434.00 
Epilepsy 1473.00 
Heart failure 14A6.00, 14AM.00 
Hypothyroidism 1432.00 
Osteoporosis 14GB.00 
Psychosis, 
schizophrenia 
1464.00, 146H.00, ZV11000- ZV11112 
Rheumatoid arthritis 14G1.00 
Resolved Read codes 
Atrial Fibrillation 212R.00 
Asthma 2126200, 212G.00 
Depression 212S.00 
Diabetes 2126300, 212H.00 
Epilepsy 2126000, 212J.00 
Heart failure 2126400 
Hypertension 2126100, 212K.00 
Osteoporosis 2126500 
Psychosis, 
schizophrenia, bipolar 
affective disease 
212T.00-212X.00, E100500, E101500, E102500, E103500, 
E105500, E107500, E110600, E111600, E114600, E115600, 
E116600, E117600, Eu22300, Eu26.00, Eu31700, Eu32900, 
Eu32A00 
 
CHD: Coronary Heart Disease, CKD: Chronic Kidney Disease, COPD: Chronic Obstructive Pulmonary Disease, 
PAD: Peripheral  Arterial Disease 
*QOF business rules version 27 (http://www.pcc-cic.org.uk/article/qof-business-rules-v27) 
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Appendix 7: Residual impairments after 
TIA: Retrospective cohort study results 
A7.1 Supplementary material 
Supplementary Table S1: Values outside clinically plausible ranges which were excluded. 
Variable Cut-off range 
Height (m)    1 - 2.5 
Weight (kg)  35 - 200  
Body mass index (units)   10 - 60  
Systolic blood pressure (mmHg)  60 – 260 
Diastolic blood pressure (mmHg)  40 - 160  
Total cholesterol (mm/L)    1 – 12 
High-density lipoprotein (HDL) cholesterol (mm/L)  0.1 – 12 
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Supplementary Figure S1: Number of incident transient ischaemic attack (TIA) events 
recorded in The Health Improvement Network (THIN) database between 1st January 2000 
and 31st December 2013. 
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Supplementary methods and results 
Exploratory analyses 
Methods 
Sensitivity analyses explored the effect of excluding patients with a record of the outcome 
prior to the index date in matched sub-studies for each impairment. The composite outcome 
psychological impairment was analysed individually for anxiety, depression, and post-
traumatic stress disorder (PTSD). Further exploratory analyses investigated the effects of 
excluding patients with no consultations post-index date or those who consulted for the 
outcomes within the first month of follow-up. 
Results 
Patients with presence of the outcome prior to their index date excluded 
TIA patients had increased risk of consulting for fatigue, psychological and cognitive 
impairment compared to controls when adjusted for patient and demographic variables 
(Table S2-S4). 
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Supplementary Table S2: Adjusted* hazard ratios for the effects of patient and 
demographic characteristics on consultations for fatigue in TIA patients and controls with 
no history of fatigue prior to the index date. 
  
Hazard 
Ratio P value 95% CI 
TIA/ control TIA 1.75 <0.01 1.57 1.94 
Age <45 1.38 0.02 1.06 1.81 
 
45-49 1.02 0.89 0.75 1.39 
 
50-54 0.86 0.26 0.66 1.12 
 
55-59 1.04 0.76 0.82 1.32 
 
60-64 0.93 0.48 0.75 1.15 
 
65-69 0.99 0.95 0.81 1.22 
 
70-74 1.00 
   
 
75-79 1.12 0.19 0.95 1.34 
 
80-84 1.39 <0.01 1.15 1.67 
 
85-89 1.26 0.02 1.04 1.52 
 
≥90 1.13 0.37 0.86 1.49 
Sex Female 1.13 0.02 1.02 1.25 
Impairment prior to index 
date 
Psychological 
impairment 
1.16 0.01 1.04 1.31 
Impairment post index 
date 
Psychological 
impairment 
1.64 <0.01 1.46 1.83 
BMI Healthy 1.00 
   
 
Underweight 1.13 0.49 0.80 1.58 
 
Overweight 1.00 0.95 0.90 1.11 
 
Obese 0.93 0.26 0.82 1.05 
 
Missing 0.71 0.01 0.56 0.90 
Alcohol intake Never 1.00 
   
 
Light 1.31 <0.01 1.11 1.55 
 
Moderate 1.32 0.01 1.09 1.61 
 
Heavy 1.30 <0.01 1.09 1.54 
 
Missing 1.35 <0.01 1.14 1.59 
Comorbidities CKD 0.85 0.03 0.74 0.98 
 
Dementia 0.68 0.01 0.51 0.91 
 
Multimorbidity 1.18 <0.01 1.14 1.23 
Health authority  West Midlands 1.00 
   
 
Yorkshire & Humber 0.87 0.43 0.61 1.24 
 
North West 1.07 0.64 0.81 1.41 
 
East Midlands 1.37 0.14 0.91 2.06 
 
North East 1.18 0.42 0.79 1.78 
 
East of England 1.20 0.20 0.91 1.59 
 
London 0.99 0.95 0.76 1.29 
 
South East Coast 0.89 0.44 0.67 1.19 
Continued on next page 
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Hazard 
Ratio P value 95% CI 
 
South Central 1.18 0.25 0.89 1.58 
 
South West 1.07 0.63 0.81 1.43 
 
Northern Ireland 1.39 0.02 1.05 1.85 
 
Scotland 1.29 0.06 0.99 1.69 
 
Wales 0.98 0.89 0.75 1.29 
BMI: Body Mass Index, CI: Confidence Interval, CKD: Chronic Kidney Disease, TIA: 
Transient Ischaemic Attack 
* Each hazard ratio is adjusted for the other variables in the table 
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Supplementary Table S3: Adjusted* hazard ratios for the effects of patient and 
demographic characteristics on consultations for psychological impairment in TIA patients 
and controls with no history of psychological impairment prior to the index date. 
  
Hazard 
Ratio P value 95% CI 
TIA/ control TIA 1.66 <0.01 1.50 1.84 
Age <45 1.20 0.17 0.93 1.56 
 
45-49 1.27 0.07 0.98 1.65 
 
50-54 1.06 0.64 0.83 1.36 
 
55-59 1.04 0.71 0.86 1.26 
 
60-64 0.98 0.86 0.81 1.19 
 
65-69 1.06 0.48 0.90 1.24 
 
70-74 1.00 
   
 
75-79 1.11 0.17 0.96 1.29 
 
80-84 1.13 0.12 0.97 1.31 
 
85-89 1.23 0.01 1.05 1.45 
 
≥90 1.45 <0.01 1.20 1.75 
Sex Female 1.29 <0.01 1.18 1.41 
Impairment prior to 
index date 
Fatigue 1.43 <0.01 1.29 1.58 
Cognitive impairment 1.63 <0.01 1.37 1.93 
Impairment post 
index date 
Fatigue 1.73 <0.01 1.52 1.97 
Cognitive impairment 1.54 <0.01 1.29 1.86 
Smoking status  Non 1.00 
   
 
Ex 1.16 <0.01 1.06 1.27 
 
Current 1.20 0.01 1.04 1.39 
 
Missing 0.72 <0.01 0.60 0.86 
Deprivation 1 (least deprived) 1.00 
   
 
2 1.00 0.97 0.89 1.12 
 
3 1.08 0.21 0.96 1.21 
 
4 1.10 0.17 0.96 1.25 
 
5 (most deprived) 1.29 <0.01 1.11 1.51 
 
Missing 1.27 0.09 0.97 1.68 
Comorbidities Atrial fibrillation 0.86 0.04 0.75 0.99 
 
Asthma 0.77 <0.01 0.67 0.90 
 
CKD 0.74 <0.01 0.65 0.83 
 
Epilepsy 0.64 0.04 0.42 0.97 
 
Hypertension 0.84 <0.01 0.76 0.93 
 
Hypothyroidism 0.86 0.03 0.74 0.99 
 
PAD 0.77 0.03 0.61 0.97 
 
Multimorbidity 1.26 <0.01 1.20 1.32 
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Hazard 
Ratio P value 95% CI 
Health authority  West Midlands 1.00 
   
 
Yorkshire & Humber 1.73 <0.01 1.25 2.39 
 
North West 1.07 0.51 0.87 1.31 
 
East Midlands 0.82 0.17 0.63 1.09 
 
North East 0.96 0.73 0.78 1.19 
 
East of England 1.22 0.06 0.99 1.49 
 
London 1.00 0.98 0.78 1.27 
 
South East Coast 1.22 0.04 1.01 1.46 
 
South Central 1.24 0.02 1.03 1.49 
 
South West 1.26 0.01 1.07 1.48 
 
Northern Ireland 1.12 0.26 0.92 1.35 
 
Scotland 1.24 0.01 1.05 1.47 
 
Wales 1.07 0.54 0.86 1.32 
CI: Confidence Interval, CKD: Chronic Kidney Disease, PAD: Peripheral Artery Disease, 
TIA: Transient Ischaemic Attack 
* Each hazard ratio is adjusted for the other variables in the table 
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Supplementary Table S4: Adjusted* hazard ratios for the effects of patient and 
demographic characteristics on consultations for cognitive impairment in TIA patients and 
controls with no history of cognitive impairment prior to the index date. 
  
Hazard Ratio P value 95% CI 
TIA/ control TIA 1.54 <0.01 1.35 1.77 
Age <50 0.14 <0.01 0.08 0.26 
 
50-54 0.36 <0.01 0.23 0.56 
 
55-59 0.42 <0.01 0.28 0.62 
 
60-64 0.36 <0.01 0.25 0.52 
 
65-69 0.65 <0.01 0.49 0.86 
 
70-74 1.00 
   
 
75-79 1.67 <0.01 1.34 2.07 
 
80-84 2.26 <0.01 1.83 2.80 
 
85-89 2.43 <0.01 1.95 3.02 
 
≥90 1.99 <0.01 1.49 2.66 
Sex Female 0.94 0.32 0.84 1.06 
Impairment prior 
to index date 
Fatigue 1.45 <0.01 1.26 1.66 
Impairment post 
index date 
Psychological 
impairment 
1.83 <0.01 1.61 2.08 
BMI Healthy 1.00 
   
 
Underweight 1.16 0.41 0.81 1.66 
 
Overweight 0.91 0.15 0.79 1.04 
 
Obese 0.78 0.01 0.65 0.93 
 
Missing 0.63 <0.01 0.49 0.82 
Rurality Urban 1.25 0.01 1.05 1.49 
Comorbidities Dementia 0.55 0.04 0.31 0.98 
 
PAD 0.70 0.03 0.51 0.97 
Health authority  West Midlands 1.00 
   
 
Yorkshire & Humber 0.49 0.08 0.22 1.09 
 
North West 1.18 0.23 0.90 1.54 
 
East Midlands 0.93 0.82 0.49 1.77 
 
North East 1.07 0.60 0.82 1.40 
 
East of England 1.07 0.69 0.78 1.46 
 
London 0.94 0.67 0.70 1.25 
 
South East Coast 0.94 0.63 0.72 1.22 
 
South Central 0.86 0.25 0.66 1.12 
 
South West 1.09 0.55 0.82 1.46 
 
Northern Ireland 1.46 0.04 1.02 2.10 
 
Scotland 1.52 <0.01 1.15 2.03 
 
Wales 0.98 0.94 0.67 1.45 
BMI: Body Mass Index, CI: Confidence Interval, PAD: Peripheral Artery Disease, TIA: Transient 
Ischaemic Attack. †BMI: Healthy (18.5-25.9 kg/m2); Underweight (<18.5 kg/m2); Overweight (26-
30 kg/m2); Obese (>30 kg/m2). * Each hazard ratio is adjusted for the other variables in the table 
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Psychological impairment separated into anxiety, depression and PTSD sub-studies 
Psychological impairment was separated into three matched sub-studies comprised of 
anxiety, depression and PTSD. There were 55,849 patients included in the anxiety sub-study 
(9,379 TIA patients and 46,470 controls); 55,546 in the depression sub-study (9,271 TIA 
patients and 46,275 controls); and 55,930 in the PTSD sub-study (9,419 TIA patients and 
46,511 controls). The K-M curves show that TIA patients consulted more for anxiety, 
depression and PTSD and the difference was statistically different (P<0.01; Figure S2-S4). 
Depression was further separated by time to clinical code for a diagnosis of depression and 
time to prescription for antidepressants to investigate the high failure rate after the index 
date for both TIA patients and controls. Figures S5 and S6 suggest that anti-depressant 
prescriptions account for this trend. 
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Supplementary Figure S2: Kaplan-Meier (K-M) failure estimates for TIA patients and 
controls consulting for anxiety. 
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Supplementary Figure S3: Kaplan-Meier (K-M) failure estimates for TIA patients and 
controls consulting for depression. 
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Supplementary Figure S4: Kaplan-Meier (K-M) failure estimates for TIA patients and 
controls consulting for posttraumatic stress disorder (PTSD). 
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Supplementary Figure S5: Kaplan-Meier (K-M) failure estimates for TIA patients and 
controls consulting for depression with depression defined by prescription for anti-
depressants. 
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Supplementary Figure S6: Kaplan-Meier (K-M) failure estimates for TIA patients and 
controls consulting for depression with depression defined by a clinical code for a 
diagnosis of depression. 
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Patients with consultation for outcome in the first month of follow-up excluded 
Within the first month post-index date, 431 patients consulted for fatigue, 4,803 for 
psychological impairment, and 103 for cognitive impairment. Following the exclusion of 
these patients in exploratory analyses, a significant difference between TIA and control 
patients remained (P<0.0001). 
Patients with no consultations in follow-up excluded 
Number of consultations pre- and post-index date are summarised in Table S5. A significant 
difference remained between TIA patients and controls when patients with no consultations 
in follow-up were excluded for all three sub-studies (P<0.0001). 
Supplementary Table S5: Summary of consultations pre- and post-index date for TIA 
patients and controls. 
Consultations TIA patients Controls 
In the year prior to index 
date (median [IQR]) 
9 [5,14] 6 [3,11] 
In the year post index date 
(median [IQR]) 
10 [6,17] 5 [2,10] 
Number with 0 consolations 
in follow up (frequency) 
80 5,763 
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A7.2 Association between residual impairments post-TIA and stroke 
in follow-up 
 
The second aim of the original protocol was to investigate if patients with TIA and who 
consult in primary care with residual impairments are more likely to experience subsequent 
stroke compared to TIA patients without impairments. Of the 55,930 TIA patients and 
controls included in the study, 440 had a stroke after the index date: 171 TIA patients and 
269 controls.  To test the association between residual impairments in TIA patients and 
subsequent stroke, a Kaplan-Meier (K-M) survivor function analysis was proposed to 
estimate time to stroke for TIA patients with impairment and TIA patients without 
impairment. However, there were unforeseen methodological issues regarding the 
identification of an index date for TIA patients without impairments. Therefore, the analysis 
could not be completed. 
 
 
  
 
 
